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ABSTRACT 
 
Plumeria rubra Linn is locally known in Malaysia as “kemboja” and belongs to family 
Apocynaceae. It has been used traditionally in Southeast Asia for the treatment of malaria, 
diabetes, analgesic to relieve fever and alleviate arthritis. The Thin Layer 
Chromatography (TLC) profile of PR ̶ HE, PR ̶ CE, PR ̶ ME and PR ̶ WE extracts of 
showed the presence of essential oils, phenols, flavonoids and terpenoids. The analysis 
red flowers extracts with LCMS/MS displayed that it contains 3 ̶  caffeyolquinic acid, 5 ̶ 
caffeoquinic acid, 1,3 ̶ dicaffeoquinic acid, chlorogenic acid, citric acid, 3,3 ̶ di ̶ O  ̶
methylellagic acid, kaempferol ̶ 3 ̶ O ̶ glucoside, kaempferol ̶ 3 ̶ rutinoside, kaempferol, 
quercetin 3 ̶ O ̶  α ̶ L ̶ arabinopyranoside, quercetin, quinic acid and rutin. The TPC and 
TFC contents were highest in PR-ME extract at 184.632 mg GAE/g and 203.2.2 mg QE/g, 
respectively. In the six different antioxidant activity assays, PR ̶ ME extract exhibited the 
best DPPH scavenging activity at IC50 value at 59.385 µg/ml, highest reducing power 
toward ferric ions which was 4.950 mmol Fe2+/g extract, highest metal chelating activity 
at IC50 value at 185.559 µg/mL, highest in hydrogen peroxide scavenging activity at IC50 
value at 248.376µg/mL, highest in nitric oxide scavenging activity at IC50 value at 62.096 
µg/mL and also highest in superoxide radical scavenging activity at IC50 value at 54.773 
µg/mL. The result of XO inhibitory activity in vitro assay revealed that the PR ̶ ME extract 
possesses highest inhibition effects with the IC50 value was 23.91 µg/mL. The acute 
toxicity test among the males and females rats demonstrated the PR ̶ ME extract were safe 
up to a maximum dose of 4000 mg/kg body weight due to no mortality and sign of toxicity 
occurred within two weeks of experiment. Administration of PR ̶ ME extract at doses of 
400 and 200 mg/kg to the rats significantly reduced serum uric acid level by 67.5 % and 
28.9 %, respectively when compared to gout control group. Furthermore, the significant 
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inhibitory actions on the XO activity in serum were showed at doses at 400 and 200 mg/kg 
in which were 7.18 mU/mL by 43.77 % and 8.73 mU/mL by 31.64 %, respectively. The 
result of in vivo study indicated that serum XO activity was correlated with liver XO 
activity. XO activity in liver was significantly inhibited by PR ̶ ME extract at doses of 
400 and 200 mg/kg, which were 7.76 mU/mL by 31.64 % and 9.88 mU/ml by 16.06 %, 
respectively. However, PR ̶ ME extract did not show any XO inhibition effects in normal 
rats. Moreover, no significant difference of body weight between treated rats and non-
treated rats within 7 days of extract administration. In conclusion, PR ̶ ME extract from 
P. rubra red flower contained active phytochemical compounds as detected in LCMS/MS 
has contributed to inhibition of XO activity in in vitro and in vivo which also had partly 
mediated to the urate lowering effects in serum as well as the potential to scavenged free 
radical intermediates and superoxide byproducts. 
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ABSTRAK 
 
Plumeria rubra Linn dikenali di Malaysia sebagai “kemboja” dan terdiri dari keluarga 
Apocynacea. Ia digunakan secara tradisional di Asia Tenggara dalam rawatan malaria, 
kencing manis, sebagai analgesik untuk meredakan demam dan arthritis. Kromatografi 
lapisan nipis (TLC) dari ekstrak PR ̶ HE, PR ̶ CE, PR ̶ ME dan PR ̶ WE menunjukkan 
kehadiran minyak pati, phenols, flavonoid dan terpenoids. Analisis ekstrak bunga merah 
dari P. rubra melalui LCMS/MS mempamerkan kehadiran 3 ̶ O ̶ caffeyolquinic acid, 5  ̶
O ̶ caffeoquinic acid, 1,3 ̶ dicaffeoquinic acid, chlorogenic acid, citric acid, 3,3 ̶ di ̶ O ̶ 
methylellagic acid, kaempferol ̶ 3 ̶ O ̶ glucoside, kaempferol ̶ 3 ̶ rutinoside, kaempferol, 
quercetin 3 ̶ O ̶ α  ̶ L ̶ arabinopyranoside, quercetin, quinic acid dan rutin. Jumlah 
kandungan TPC dan TFC yang tertinggi dikesan dalam PR ̶ ME iaitu masing-masing 
sebanyak 184.632 mg GAE/g dan 203.2.2 1 mg QE/g. Dalam enam cerakin aktiviti 
antioksidan yang berbeza, PR ̶ ME menunjukkan aktiviti pemerangkapan DPPH tertinggi 
dengan nilai IC50 sebanyak 59.385 µg/mL, nilai tertinggi dalam keupayaan 
mengurangkan kuasa ke arah ion ferric iaitu 4.950 extract/g mmol Fe2+, aktiviti 
pengkelatan logam yang tertinggi dengan nilai IC50 sebanyak 185.559 µg/mL, nilai 
tertinggi dalam pemerangkapan radikal hidrogen peroksida dengan nilai IC50 sebanyak 
248.376 µg/mL, nilai tertinggi dalam pemerangkapan radikal nitrik oksida dengan nilai 
IC50 sebanyak 62.096 µg/mL dan juga nilai tertinggi dalam pemerangkapan radikal 
superoksida dengan nilai IC50 sebanyak 54.773 µg/mL. Aktivity perencatan enzim XO 
secara in vitro mendedahkan PR ̶ ME mempunyai kesan perencatan yang tertinggi dengan 
nilai IC50 sebanyak 23.91 µg/mL. Ujian ketoksikan akut menunjukkan PR ̶ ME didapati 
selamat diberikan kepada haiwan sehingga dos maksimum 4000 mg/kg berat tikus, 
berdasarkan tiada kematian dan ciri- ciri ketoksikan yang berlaku pada tikus sepanjang 
dua minggu eksperimen. Kedua- dua dos PR ̶ ME iaitu 400 dan 200 mg/kg  telah 
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menurunkan kadar asid urik dalam serum tikus secara ketara iaitu masing-masing 
sebanyak 67.5 % dan 28.9 %, jika dibandingkan dengan kumpulan tikus dalam kawalan 
gout. Tambahan pula, berlaku perencatan secara ketara terhadap aktiviti enzim XO di 
dalam serum  melalui pemberian dos 400 dan 200 mg/kg PR ̶ ME, di mana masing- 
masing memberi nilai aktiviti sebanyak 7.182 mU/mL iaitu peratus perencatan adalah 
43.77 % dan 8.731 mU/ml iaitu peratus perencatan adalah 31.64 %. Kajian aktiviti XO 
secara in vivo mendapati aktiviti enzim XO dalam serum mempunyai korelasi dengan 
activiti enzim XO dalam hati. Aktiviti perencatan enzim XO dalam hati berlaku secara 
ketara oleh dos 400 mg/kg iaitu sebanyak 7.76 mU/mL dan peratus perencatan ialah 34.07 
% manakala dos 200 mg/kg memberi nilai aktiviti sebanyak 9.88 mU/mL dan peratus 
perencatan ialah 16.06 %. Namun begitu, tiada kesan perencatan XO ditunjukan oleh PR ̶ 
ME kepada kumpulan tikus kawalan normal. Malahan, tiada perubahan yang ketara 
didapati pada berat badan tikus dalam kumpulan rawatan dan dalam kumpulan kawalan 
sepanjang 7 hari eksperimen. Kesimpulannya, PR ̶ ME dari ekstrak bunga merah P.rubra 
mengandungi sebatian fitokimia aktif yang dikesan melalui analisis LCMS/MS didapati 
telah menyumbang terhadap aktiviti perencatan enzim XO secara in vitro dan in vivo, 
menjadi pengantara kepada sebahagian mekanisme penurunan urate di dalam serum dan 
berupaya menyingkirkan  pengantara radikal bebas dan produk superoksida. 
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CHAPTER 1 
INTRODUCTION 
 
   Gout is one of diseases that has been investigated for decades. According 
to epidemiological studies from different countries revealed that rising of the prevalence 
and incidence of gout has been resulting to a substantial economic burden (Roddy et al. 
2007; Wu et al. 2008). It is most prevalent form of inflammatory arthritis and is associated 
with impaired quality of life. The development of gout is derived from the key predictor, 
hyperuricemia, which is elevated uric acid above super ̶ saturation concentrations (6.8 
mg/dl at physiological pH and temperature) leading to formation monosodium urate 
(MSU) crystals within joints and subcutaneous tissues associated to development of 
painful attacks of gouty arthritis (Dalbeth  et al. 2008).  
   Xanthine oxidase (XO) which is present in significant concentration in 
liver and intestines, has been considered as major contributor to gout disease. The 
formation of uric acid occur from the final biosynthesis in purine catabolic pathway which 
it responsible to catalyzes the oxidation process of hypoxanthine to xanthine and further, 
xanthine to uric acid. The overproduction and/or underexcretion of this uric acid lead to 
the major contributor of incidence of gout which is hyperuricemia (Rasaratnam & 
Christophidis, 1995). Moreover, during the reoxidation of this enzyme, molecular oxygen 
acts as electron acceptor leads to reactive oxygen species production including superoxide 
radical and hydrogen peroxide. Consequently, elevated oxidative stress has been reported 
in gouty patient (Urano et al. 2002). Therefore, (XO) is gaining interest among 
researchers in worldwide due to its important biological source of oxygen ̶ derived free 
radicals which contribute to oxidative damage to living tissues involved in many 
pathological processes including the inflammation, atherosclerosis, cancer, aging and 
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gout (Chiang et al. 1994; Cos et al. 1998; Pacher et al. 2006). In ̶ vitro bioassays is pre-
requisite in order to basis screening sample for XO inhibition, as inhibitors of XO may 
be potentially useful for new medicament of gout or other XO induced diseases 
(Goodman Gilman et al. 2006). Therefore, the capability of bioactive compounds to 
inhibit the activity of XO might be able to decreased uric acid level and also in ROS 
production, so that this phytochemical compound may alleviate inflammation, then; it 
serves as anti-hyperuricemic and antioxidative effects. 
   The ultimate formation of uric acid in man depends on the activity of 
enzyme, XO, on hypoxanthine and xanthine. This concerns the common treatment of gout 
is allopurinol or (4 ̶ hydroxypyrazolo [3, 4 ̶ d] pyrimidine) (Hak & Choi, 2008). 
Allopurinol is the kind of XO inhibitors class of drugs, which is most commonly approach 
in order to lower urate levels in serum and urine. In addition, allopurinol is effective in 
decreasing flares and tophi, particularly among patients in whom target urate levels are 
achieved. Allopurinol is slowly oxidized to its active metabolite; oxypurinol  as a xanthine 
analogues, act as more potent XO inhibitor in order to impairs the conversion of 
hypoxanthine to xanthine and then conversion of xanthine to uric acid. It showed 
beneficial effects in the treatment of hyperuricemia both in experimental animal models 
and in small-scale human clinical trials. Although allopurinol has been successfully used 
as urate- lowering therapy, but it is not the appropriate choice in treating acute gouty 
athritis (Dubchak & Falasca, 2010). Instead, allopurinol generates superoxide (Berry & 
Hare, 2004) and some people develop rash as they are allergic to allopurinol (Kong et al. 
2000). Severe reactions also occur including liver function abnormalities (Fields et al. 
1996), a fatal complication known as “allopurinol hypersensitivity syndrome” (Kelso & 
Keating, 1996; Kong et al. 2000) and adverse drug reactions such as Toxic Epidermal 
Necrolysis syndrome (TENS) (Pacher et al. 2006). Furthermore, safety of using 
allopurinol in children and during pregnancy has not been established (Borges et al. 
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2002). Non- steroidal anti ̶ inflammatory drug (NSAID) such as indomethacin are often 
used as first ̶ line therapy to treat acute inflammation in gout.  
 In addition, this drug also contributed to adverse effects including 
gastrointestinal toxicity, renal toxicity or gastrointestinal bleeding (Sabina et al. 2010) 
.Therefore, many research to develop an alternative medicine which for hyperuricemia 
and gout has focused on the screening of natural substances due to the adverse side effects 
of allopurinol, which so far, remains the only prescription for the disease. Understanding 
these facts, has motivated the recent studies which focus on biological activities such as 
new anti ̶ inflammatory and hypouricemic effect, including xanthine oxidase inhibitors, 
from natural sources which could be useful in gout treatment (Zhu et al. 2004; Mo et al. 
2007; Ahmad et al. 2008; Liu et al. 2008; Haidari et al. 2008, 2009; Sabina et al. 2010; 
Huang et al. 2011).  
   Use of plants for health improvement was practiced in Chinese medicine 
since 4000–6000 years ago (Farkas et al. 1986). Flavonoids belong to a group of natural 
substances with variable phenolic structures and are found in fruit, vegetables, grains, 
bark, roots, stems and flowers. Their contribution to physiological functions such as seed 
maturation and dormancy has already been established. Flavonoids have probably existed 
in the plant kingdom for over one billion years. Therefore, this long interaction between 
flavonoids compound and humans with its benefits has encouraged much interest of many 
researchers over the world to study the biochemical and physiological activities of these 
phytochemical. Researches on flavonoids have suggested these compounds might act as 
active inhibitors for XO (Cos et al. 1998). Flavonoids also are widely distributed 
polyphenolic compounds which acts as free radical scavengers by fast donation of 
hydrogen atoms to free radicals. Plant has been used as experimental material in this 
study, since medicinal plants have always been significant for pharmacological research 
and drug development. The flavonoids contents in Plumeria rubra red flowers would 
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become the new alternatives to allopurinol with increased therapeutic activity and fewer 
side effects. The aim of this study is, therefore, to investigate the potential of 
phytochemical bioactive compounds from P.rubra flower as XO inhibitor for gout 
treatment in vitro assay as well as in vivo model using experimental gout model. 
    The selected ornamental plant, P.rubra is currently gaining interest by the 
scientific researchers due to its therapeutic value. In the present study, the Indian 
medicinal plant, P.rubra flowers was selected based on ethnomedicinal use in gout and 
arthritis (Burkill, 1966), inflammation, constipation (Hamburger et al. 1991; Gupta et al. 
2006) and hypolipidemic (Merina et al. 2010). Despite the widely popular use of P.rubra 
flowers, the available scientific information about the potential effects of P.rubra flowers 
in animal models of gout study is limited. Although there are many studies demonstrated 
XO inhibitory effects from various medicinal plants and also phytochemical bioactive 
compounds, there is no previous research has been reported on XO inhibitory activity 
from P.rubra. Thus, the inhibitory effects of bioactive compounds from the red flower of 
P.rubra on XO activity are worth to be evaluated. Therefore, the present study was 
conducted to identify and evaluate the phytochemical bioactive compounds, in red 
flowers of P.rubra as a XO inhibitors and as a potential of alternative drugs of plant origin 
for gout treatment.  
 
1.1 General Objective 
   The general objective of this study is to investigate the potential of 
bioactive compounds in P.rubra red flower in inhibition of XO activity in in vitro and in 
vivo model. 
 
 
 
 5 
 
 
1.2 Specific Objectives 
i. To detect and identify the phytochemical bioactive compounds in extracts using 
Thin Layer Chromatography (TLC) and LCMS. 
ii. To evaluate the antioxidant activity of extracts. 
iii. To evaluate xanthine oxidase (XO) inhibitory activity of extracts in in vitro 
model. 
iv. To evaluate xanthine oxidase (XO) inhibitory activity of extracts in in vivo model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
 
 
CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Gout: Global scenario and Background  
   Gout is known as inflammatory disorder caused by the deposition of 
monosodium urate (MSU) crystals in articular and periarticular tissues (Choi, 2005). In 
addition, gout is a common biochemical abnormality with an estimated prevalence of 8.4 
cases per 1,000 persons (Hwang & Saag, 2013) and is associated with painful arthritis 
attacks and the development of metabolic syndromes (Choi et al. 2007) and nephropathy 
(Avram and Krishnan, 2008). These crystals cause an acute inflammatory response and 
can induce a permanent tissue damage which is characterized by the appearance of 
ulceration of the joint cartilage, marginal osteophytosis, geodic and erosive lesions and 
chronic inflammation of synovial membrane (Dalbeth, 2005; Corrado et al. 2006).  
   Gout is already became a common medical problem which occurred in up 
to 1 % of individuals in Western countries. Estimations from the Third National Health 
and Nutrition Examination Survey (NHANES III) indicate that 0.5 % of the total 
population from US has suffered from a gout attack. Gout is currently considered to be 
the most common form of inflammatory arthritis in men over 40 years old exceeding 
rheumatoid arthritis (Weaver, 2008). Moreover, the epidemiological studies showed the 
prevalence of gout is increasing not only in elderly but also is higher among men than 
among women, with a ratio of 4 to 1 overall. However, this sex disparity decreases at 
older ages, at least in part because of declining levels of estrogen, which has uricosuric 
effects in women (Wallace et al. 2004: Miao et al. 2008: Doherty, 2009: Zhu et al. 2011). 
Evidently, it represents the most frequent chronic inflammatory arthritis in men and an 
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increasing cause of arthritis in women (Roddy & Doherty, 2010: Zhu et al. 2011). The 
rising of incidence gout is closely associated with unhealthy life-style choices, including 
of increased intake of high purine diets which particularly meats and seafoods, alcohol 
which particularly beer and spirits, and fructose ̶ sweetened drinks that caused metabolic 
syndrome with obesity, longevity, insulin resistance and hyperlipidemia (Choi et al. 2004; 
Choi et al. 2007; Choi et al. 2008: Wu et al. 2008; Neogi, 2011; Singh et al. 2011) and 
also the number of age ̶ related risk factors including an increase in the prevalence of renal 
failure and diuretic ̶ treated hypertension (Choi et al. 2004). Gout is strongly associated 
with obesity and metabolic syndrome. Adiposity and weight gain are important risk 
factors for development of gout, while weight loss is protective (Choi, 2005). Besides 
this, recipients of organ transplants also have an increased risk of gout due to use of 
cyclosporine and other antirejection drugs (Baroletti et al. 2004). 
 
2.2 Uric acid 
   Uric acid is the final product of purine metabolism and these catabolic 
steps are catalyzed mainly by XO enzyme in human. Instead, in most mammals, uric acid 
is degraded by uricase to allantoin which is highly soluble and carbon dioxide, then 
readily excreted in the urine with no obvious adverse effects. Uricase is inactive in human 
due to evolution which including diverse mutations, probably environmentally driven 
gave place to a non-functional gene. During the Miocene period, two parallel mutations 
occurred in early hominids and humans that disabled uricase gene, resulting in higher 
serum uric acid concentrations. The parallel mutation suggests the inactivating uricase 
gene was confer some advantageous to early hominids and humans, possibly due to one, 
or a combination of the antioxidant activity of uric acid compensating for vitamin C 
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deficiency; the ability of uric acid to maintain blood pressure under low- salt dietary 
condition; the adjuvant activity of uric acid (Wu et al.1992; Dalbeth et al. 2008).  
 
2.2.1 Chemistry of Uric acid 
   Uric acid or IUPAC name as 2, 6, 8 ̶ trioxypurine (Figure 2.1) is a weak 
acid with 2 ionization constants (pKa1= 5.75 and pKa2=10.3). The solubility product of 
monosodium urate increases with increasing ionic strength. At pH 7.7 such as in serum 
or synovial fluids, about 98 % of uric acid is ionized as monosodium urate whereas at 
lower pH such in the urine, it exists mostly in free form. The chemical properties of uric 
acid is significant to the development of gout disease which involved its capability to 
form crystals and its relative insolubility in non-alkaline solutions (Seegmiller et al. 
1963). 
 
Figure 2.1. Chemical structure of uric acid 
Adapted from Seegmiller et al. 1963 
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2.2.2 Formation of Uric acid 
 Uric acid, produced mostly in the liver, and the end product of exogenous 
and endogenous purine metabolism. The exogenous sources for uric acid are the purine 
and purine precursors from the diets. A diet rich in animal proteins contributes 
significantly to the purine pool and subsequent uric acid formation by a series of 
enzymatic reactions involving xanthine oxidase as the final step. The endogenous 
production of uric acid from de novo purine synthesis, and tissue catabolism breakdown 
of nucleic acids and nucleotides (salvage synthesis) under normal circumstances 
(Newcombe, 1975). 
 In normal circumstances salvage predominates over synthesis, but 
synthesis is particularly active in tissues with a high rate of cell turnover such as in gut 
epithelium, skin, bone marrow and etc (Stone & Simmonds, 1991). Ribose-5-phosphate, 
derived from glycidic metabolism, is converted to phosphoribosyl pyrophosphate (PRPP) 
via the PRPP synthetase and then to inosine monophosphate (Cammalleri & 
Malaguarnera, 2007). This intermediate compound yields adenosine monophosphate 
(AMP) and guanosine monophosphate, the purinic nucleotides used in DNA and RNA 
synthesis, as well as inosine. The latter is converted by the purine nucleoside 
phosphorylase to hypoxanthine. Xanthine oxidase (XO), an enzyme inhibited by 
allopurinol, converts hypoxanthine to xanthine and subsequently xanthine to uric acid 
(Figure 2.2). Hypoxanthine and guanine may enter a salvage pathway through the activity 
of hypoxanthine ̶ guanine phosphoribosyltransferase (HGPRT), an enzyme that 
reconverts these purine bases into their respective nucleotides. Key enzymes that cause 
abnormal uric acid levels include: PRPP synthetase, purine nucleoside phosphorylase, 
XO and HGPRT (Wilcox, 1996). 
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Figure 2.2. Pathway of purine metabolism. A schematic diagram of purine 
metabolism including the enzymes involved in uric acid synthesis and degradation. 
Key enzymes include PRPP synthetase, purine nucleoside phosphorylase, XO and 
HGPRT. PRPP Phosphoribosyl pyrophosphate, ATP Adenosine triphosphate, 
AMP Adenosine monophosphate, IMP Inosine monophosphate, GMP Guanosine 
monophosphate, APRT Adenine phosphoribosyltransferase, HGPRT 
Hypoxanthine-guanine phosphoribosyltransferase, XO Xanthine oxidase       
Adapted from Fathallah-Shaykh  & Cramer, (2014). 
 
2.2.3 Excretion of Uric acid 
   The homeostasis of blood urate levels is maintained by the balance 
between purine biosynthesis pathway and excretion. Primary regulation of uric acid 
excretion is by renal-handling which acts as uric acid clearance and accounting for two-
thirds of its elimination. The remaining one-third of uric acid excretion are occurs in 
intestine skin, hair and nails account. In the intestine bacteria catabolize uric acid into 
carbon dioxide and ammonia, which are then eliminated as intestinal air or absorbed and 
excreted in the urine. 
   Renal handling of uric acid is complex whereby 95 % of plasma uric acid 
is filtered through glomerulus as uric acid. In humans, net reabsorption of uric acid into 
the blood predominates owing to less excretion of uric acid than is filtered at the 
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glomerulus. Passive back diffusion of secreted uric acid occurs with the result only with 
only 10 % of that filtered is finally excreted in the urine. This renal exchange is mediated 
by specialized molecule expressed in renal proximal tubule cells (Dalbeth & Merriman, 
2008) (Figure 2.3). The identified molecule are included the fructose transporter SLC2A9 
(GLUT9), urate ransporter 1 (URAT1), organic anion transporter 1, 3, 4 (OAT1, OAT3, 
OAT4), multi-drug resistant protein 4 (MRP4), sodium coupled monocarboxyl 
transporters SMCT1, 2 and human ATP ̶ binding cassete, subfamily G, (ABCG2) 
(Enomoto et al. 2002; Caulfield et al. 2008; Woodward et al. 2009). URAT1 and SLC2A9 
(GLUT9) are members of the organic acid transporter (OAT) family and have 
predominant effects on serum urate level. SLC2A9 gene is glucose transporter 9 
(GLUT9) which transports the sugars glucose and fructose from the proximal tubule 
lumen across the apical and basolateral membranes, which may be pertinent to the dietary 
influences of these compounds on hyperuricemia and gout. SLC2A9 is inhibited by the 
uricosuric agent, benzbromarone but not by the commonly used uricosuric agent 
probenecid. URAT1 is highly specific for urate and mediates solute concentration-
dependent bidirectional exchange of urate for a variety of endogenous and drug anions 
known to affect renal uric acid transport. URAT1 also inhibited by the uricosuric agent, 
benzbromarone and probenecid. OAT4 is a low-affinity assymetric urate transporter that 
facilitates diuretic associated hyperuricemia, also inhibited by benzbromarone and 
probenecid. MRP4 is control ATP ̶ dependent urate extrusion from the cells into the tubule 
lumen and thus contribute to urate excretion. ABCG2 is a secretory urate transporter in 
the proximal tubule, which the activity of uricosuric agent on ABCG2 still not known. In 
other words, these uric acid transportasome have been associated with hyperuricemia and 
gout (Enomoto et al. 2002; Caulfield et al. 2008; Woodward et al. 2009; Vitart et al. 
2008). Taniguchi et al. (2005) reported that the main cause of the renal impairment of 
urate excretion is due to the genetic defects. 
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Figure 2.3. The uric acid transportasome. Monocarboxylates accumulate in the 
tubular cell through sodium-dependent monocarboxylate transporters SLC5A8 
and SLC5A12, and dicarboxylates through SLC13A3. Uric acid enters the cell in 
exchange for monocarboxylatevia apical URAT1 and for dicarboxylate via apical 
OAT4. Apical SLC2A9v2 plays a significant role in uric acid reabsorption, the 
reabsorbed uric acid exiting the cell through basolateral SLC2A9v1                
Adapted from Merriman & Dalbeth, (2011). 
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2.3 Gout and Hyperuricemia  
   Hyperuricemia is prerequisite of gout and identified when serum uric 
acid/urate (sUA) levels are above 7 mg/dl (0.42 mmol/l) in men and 6.5 mg/dl (0.387 
mmol/l) in women, approximately the saturation point for urate solubility at physiologic 
temperature and pH.  Gout may appeared in varying duration depends on the degree of 
hyperuricemia and other factors (Mikuls et al. 2005)   Many studies had evident the close 
relationship of serum uric acid with an increased risk of gout episodes (Cleland et al. 
1995; Shoji et al. 2004). Asymptomatic hyperuricemia is considered in patients with 
hyperuricemia but without clinical signs of gout or lithiasis (Vazquez-Mellado et al. 
2004; Choi, 2005). Ruilope and Garcia-Puig (2001) stated that blood uric acid level of 
more than 9 mg/dL considered as a severely hyperuricemic condition. 
    Hyperuricemia results from overproduction or underexcretion of uric acid. 
About 80 to 90 % of the patients with hyperuricemia or gout are underexcretors of uric 
acid. According to analysis of (NHANES III) hyperuricemia could be resulted from urate 
over-production due to acquired factors such as high purine diet, fructose ingestion, 
alcohol intake and decrease with high dairy intake. Fructose ingestion increases urate 
production by increasing hepatic ATP degradation to AMP to become a urate precursor 
and rapidly degrade to uric acid (Choi et al. 2004 & 2005). In addition, a strong 
relationship between the ingestion of fructose ̶ containing beverages and both 
hyperuricemia and gout had been found from several studies (Choi & Curhan, 2008; Gao 
et al. 2007). However, although historically the condition was linked to men's excessive 
rich foods and alcohol intake, food actually contains only little urate, which is mainly 
produced in the liver and, to a lesser extent, in the small intestine (Richette & Bardin, 
2010). Genetic factors can be the principal contributor to the high prevalence of 
hyperuricemia in some ethnic groups such as hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) deficiency and PRPP synthetase superactivity 
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(Vazquez ̶ Mellado et al. 2004).The other contributor factor of increasing serum uric acid 
concentration are age, sex, body weight, body surface area, body mass and socioeconomic 
status of an individual (Puig et al. 1986). Indeed, hyperuricemia prevalence seems to be 
increasing worldwide, probably due to longer survival, increased prevalence of 
hypertension and the usage of certain drugs such as salicylate and pyrazinamide (Kim et 
al. 2003; Vazquez ̶ Mellado et al. 2004).  
   Both metabolic syndrome and type 2 diabetes are more common in 
patients with gout (Choi et al. 2007 & 2008). Furthermore, the hyperuricemia is rises with 
the occurring of metabolic syndrome and incidence such as hypercholesterolemia, 
hypertension, obesity, atherosclerosis and impaired carbohydrate metabolism are occurs. 
The relationship between gout and metabolic syndrome is thought to be mediated by 
hyperuricaemia whereby serum urate concentrations correlate with the degree of central 
adiposity and measures of insulin resistance, and insulin inhibits renal tubular uric acid 
excretion (Facchini et al. 1991). In addition, gout and hyperuricemia are also associated 
with psoriasis and psoriatic arthritis, other emerging factors of cardiovascular risk (Punzi 
et al. 2007; Ramonda et al. 2011).  
   Classically, hyperuricemia is a major risk factor for gout and lithiasis. In 
addition, it also has been linked to other human diseases such as pre-eclampsia, renal 
dysfunction, stroke, cardiovascular diseases, hypertension, hyperlipidemia, cancer, 
diabetes and metabolic syndrome (Vazquez ̶ Mellado et al. 2004: Nakagawa et al. 2005: 
Heinig & Johnson, 2006; Choi et al. 2007). Further, with an apparent reciprocal 
relationship between these comorbidities and gout, because their presence may increase 
the gout flares (Primatesta et al. 2011). Generally, hyperuricemia is classified as primary 
or idiopathic/ genetic and secondary or known as acquired. Both of these types of 
hyperuricemia occur as a result of increased uric acid production, impaired renal uric acid 
 15 
 
 
excretion or a combination of these mechanisms. For instance, alcohol consumption and 
obesity are not only associated with increased urate formation but also with reduced renal 
excretion (Facchini et al. 1991). The other condition such as acute or chronic renal failure, 
less urate is filtered in the glomeruli cause increase of urate levels. Besides this, an 
enhanced purine turnover rate in Tumor Lysis syndrome which this disease is caused by 
lymphomas, hematologic malignancies, solid tumors and cytolytic therapy, hemolysis, 
and psoriasis also can dramatically increase the urate levels (Kalemkerian et al. 1997). 
Nevertheless, the risk of gout and these linked complications are varying depending on 
the degree of hyperuricemia (Roddy & Doherty, 2010). On the other words, uric acid is 
sparingly soluble in extracellular body fluids and slight changes in its concentrations may 
cause supersaturation and precipitation of urate crystals in synovial fluid which leads to 
attacks of painful acute arthritis (Agudelo, 1989). For this reason, the goal treatment for 
gout disease is to maintain sustained serum uric acid levels below 6.5 mg/dl in order to 
prevent acute attacks, tophi and also probably deterioration in renal function. Finally, the 
control of uric acid level in blood still be considered in the prevention and treatment of 
gout. 
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2.4 Pathogenesis of Gout 
2.4.1 Clinical Features 
   Gout is a chronic disease are summarized in three stages: (i) acute arthritis; 
(ii) intercritical gout; and (iii) chronic tophaceous gout. Acute gouty flare presents with 
an abrupt onset of severe monoarthritis often at night, red, with extreme pain, warmth, 
swelling, erythaema that crescendo to maximal intensity over 8 ̶ 12 hours, fever and, in 
the elderly, delirium may even be a feature (Michet et al. 1995). At first attacks, 90 % are 
monoarticular, half of which usually involve one joint in the lower limbs, the first 
metatarsophalangeal joint (podagra). Common sites of acute flares are the feet, ankles, 
knees and, less commonly, elbows, wrists and fingers. Untreated initial attacks typically 
subside over 3–10 days but often there are other attacks within 6 months to 2 years. As 
the inflammation recedes, the overlying skin may exfoliate (Teng et al. 2006). 
   An asymptomatic phase between attacks is called intercritical gout. 
Despite clinical quiescence, the disease may continue to advance, with variable 
shortening of intercritical segments as the body urate stores accumulate. 
   Advanced gout is characterized by chronic destructive arthritis with 
secondary degenerative changes, bony erosions and development of tophi. Chronic 
polyarticular gout may be confused with rheumatoid arthritis because of the non ̶ remitting 
pain, inflammation and deformities associated with tophi, which can be mistaken for 
rheumatoid nodules. Tophi development is a function of early age of onset, long duration 
of untreated disease and high serum urate levels. However, tophies are found most 
commonly in the finger pads, wrists, pinnae, knees and olecranon bursae, and over 
pressure points, such as extensor aspect of the forearm and Achilles’ tendon. In some 
patients, chronic tophaceous gout may develop with progressive joint destruction and 
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disability or destructive arthropathy (Choi et al. 2005; Nuki & Simkin, 2006; Richette & 
Bardin, 2010: Marson & Pasero, 2012). 
 
2.4.2   Pathophysiology of Acute Inflammation Gout, Chronic Tophaceous Gout 
            and Resolution Phase 
   The presence of monosodium urate crystals (MSU) in synovial fluid or 
tophi is main criterion for diagnosis of gout (Weselman & Agudelo, 2001). It could be 
said that a number of endogenous substances and physicochemical conditions affect 
crystal precipitation, growth and even dissolution, regulating not only MSU crystal 
metabolism but also their inflammatory activity (Oliviero et al. 2011). Besides that, the 
presence of certain protein including, immunoglobulin (particularly IgM) and insoluble 
collagen associate with the accumulation of debris within the synovial cavity may provide 
a nucleus for crystal development (Kanevets et al. 2009).  
   The sequel of formation of monosodium urate (MSU) crystals resulting 
from regulation of innate immunity response is summarized in Figure 2.4. Phagocytosis 
of MSU crystals is greatly promoted by opsonization by IgG or complement components 
(Dalbeth, 2005).  MSU crystals cause a massive of neutrophil influx into the synovium 
and joint fluid, where they phagocytise crystals actively (Haskard & Landis, 2002). The 
consequences of neutrophil interaction with MSU crystals and phagocytosis caused the 
release of a large variety of mediators that promote the vasodilatation, erythema and pain 
associated with the acute gout attack. These include reactive oxygen species such as 
superoxide, hydrogen peroxide and singlet oxygen, nitric oxide, leukotriene B4, 
prostaglandin E2, anti-microbial peptides, enzymes, IL ̶ 1, and chemokines such as 
S100A8, S100A9 and IL ̶  8 (Dalbeth, 2005).  MSU that have undergone phagocytosis 
activate the NLRP3 inflammasome, leading to secretion of interleukin ̶ 1β while 
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neutrophil ingress by crystals is therefore crucial to the induction and perpetuation of the 
inflammatory response. 
   The interaction of innate immunity response in acute gouty inflammation 
was reinforced by activation of cytoplasmic NACHT ̶ LRRPYD-containing protein ̶ 3 
(NALP3), also known as cryopyrin, inflammasoma complex is crucial for acute MSU 
crystal-induced inflamamation. In fact, the releasing of mature interleukin, IL ̶ 1β, by 
stimulation of MSU crystals requires activation of NLRP3 inflammasome: an 
intracellular protein complex composed of a member of the NALP protein family and the 
adaptor protein ASC that connects the NALPs with caspase ̶ 1. Triggering of NLRP3 
leads to activation of caspase ̶ 1, which cleaves pro-IL ̶ 1β to the active secreted product 
(Figure 2.5). Furthermore, macrophages are prerequisite for components of the NLRP3 
inflammasome able to secrete active IL ̶ 1β following triggering with MSU crystals 
(Martinon et al. 2006). 
   In addition, caspase ̶ 1 activation, IL ̶ 1ß processing and release and 
triggering of inflammation are driven by link TLR (TLR2 and TLR4 adaptor molecule)  ̶ 
mediated recognition events from CD4 for MSU crystals with intracellular engagement 
of the crystal by the NALP3 inflammasome (Scott et al. 2006). The other component such 
as leucine-rich repeat (LRR) domain of cryopyrin also required for MSU crystal ̶ induced 
inflammatory response (Hoffman et al. 2010). Despite the role of biological cellular 
pathways in acute gout attack, IL ̶ 1β is a crucial mediator for gout and MSU crystal ̶ 
induced inflammation. (Terkeltaub et al. 2009). 
   Chiefly, the acute gouty arthritis involved high levels of cytokines such as 
IL ̶ 1β, IL ̶ 6, TNF ̶ α and chemokines such as IL ̶ 8 and CCL2 in synovial fluid 
(McNearney et al. 2004; Scanu et al. 2012). As shown in Figure 2.5, phagolysosomes, 
are produced when crystals initially lie within phagosomes once received the hydrolases 
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by degranulation of lysosomes. The substances coating the urate crystals are then digested 
by the hydrolases, and the crystals come in direct contact with the phagolysosomal 
membrane and form hydrogen bonds. The phagolysosomal membrane is damaged and 
the contents, including the hydrolases, leak out into the free cytoplasm and to the 
extracellular media injuring the host cell and eventually lead to cell disruption (Hoffstein 
& Weissmann, 1975). The MSU crystals thus released are again ingested by other cells 
which in turn degranulate and die, thus possibly recycling the above series of events. 
   Figure 2.5 showed that after pro-IL ̶ 1β stimulated by MSU crystals, the 
other components also contribute in modulating the process of IL ̶ 1β maturation and 
released which could be mediated by a second signal such as extracellular ATP through 
its receptor P2X7 and potassium (K+) efflux or reactive oxygen species (ROS) (Piccini et 
al. & Cassel et al. 2008). 
   In chronic gout, the presence of prolong hyperuricemia cause some 
patients develop tophi within joints and soft tissues. These lesions response depict a 
foreign body granulomatous response to MSU crystals and may invade bone caused bone 
erosion and joint damage with low-grade synovitis and frequently recurring or non-
resolving flares, these inflammatory processes are probably ongoing with potentially 
continued release of inflammatory mediators, including interleukin ̶ 1β, in the presence 
of persistent monosodium urate crystals (Neogi, 2011). 
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Figure 2.4. Sequel of formation of monosodium urate crystals (MSU) in gout in 
innate immunity. Adapted from Neogi, (2011). 
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Figure 2.5. Inflammasome activation induced by monosodium urate crystals. MSU 
crystals, once recognized and phagocytosed by cells, interact with the innate 
immunity receptor NALP3 leading to its activation. Consequently, caspase-1 
cleaves the inactive pro ̶ IL ̶ 1ß to the active IL ̶ 1ß. ATP accumulation and reactive 
oxygen species (ROS) production induced by crystals, also contribute to NALP3 
activation. Adapted from Punzi et al. (2012). 
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2.4.3. Treatment 
   The primary goal of gout management is to reduce serum urate to target 
levels < 6 mg/dl through lifestyle modification and use of pharmacologic urate ̶ lowering 
therapies (ULT) including xanthine oxidase inhibitors, uricosuric agents, and uricase 
agent. Unfortunately, ULT may increase the risk of gout flares and, gout management 
guidelines recommend concomitant used of colchicine and non-steroidal anti-
inflammatory drugs (NSAID) for prophylaxis of ULT ̶  associated gout flares (Khanna et 
al. 2012). However, these prophylactic agents are associated with well-recognized side 
effects, and the presence of the specific comorbid conditions, especially in an older 
population, and those with heart failure, renal insufficiency, hepatic dysfunction, or 
known gastrointestinal symptoms which these contraindications may pose barriers to their 
use (Spieker et al. 2002; Hoskison & Wortmann, 2007; Keenan et al. 2011; Neogi, 2011).  
   The interaction between the gout attack and the comorbid conditions make 
the management and treatment of gout more complex, and suggest the need for alternative 
medicine which derived from natural source that have a more favorable safety and 
tolerability profile in patients. Xanthine oxidase (XO) inhibitors, including allopurinol 
and febuxostat block the synthesis of uric acid and can be used regardless of whether 
there is overproduction of urate. At present, allopurinol is the type of XO inhibitor drug 
that commonly used in clinical application of hyperuricemia or particularly among 
patients in whom target urate levels are achieved and gout which is effective in decreasing 
flares and tophi (Becker et al. 2005; Becker et al. 2010). The other class which is 
uricosuric drugs including probenecid, block renal tubular urate reabsorption. Although 
these drugs can be used in patients with underexcretion of urate which is predisposing for 
up to 90 % of patients with gout, they are used less frequently than XO inhibitors or 
allopurinol and are contraindicated in patients with a history of nephrolithiasis (Reinders 
et al. 2009). Uricase including pegloticase, converts uric acid into soluble allantoin. This 
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class of drug is use for chronic gout in adults whose disease is refractory to conventional 
therapy; e.g., lack of normalization of serum urate, inadequate control of signs and 
symptoms with the use of a XO inhibitor at maximum medically appropriate dose, or 
other contraindication. The other consideration of this drug is a risk of infusion reactions 
(26 %, vs. 5 % in placebo group) even with premedication, particularly in patients without 
a therapeutic response (in whom serum urate levels increase to above 6 mg per deciliter, 
particularly on two consecutive occasions) or with antibodies against pegloticase. 
Anaphylaxis occurs in 5 % of patients (vs. 0 % in placebo group).In addition, cost is 
higher than for other drugs (Sundy, 2008). 
   Understanding all the mentioned of contributed factors and the 
complicated mechanism pathway for gout will help us in identifying what type of gout 
we are targeting for the treatment as the treatment of this disease depends on the type of 
attack. NSAIDs and colchicine are first-line agents for acute gouty attacks. Meanwhile, 
controlling the uric acid level in the blood is still the main therapy particularly in the 
management of the chronic gout attacks especially allopurinol (Mandell, 2002). 
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2.5 Reactive Oxygen Species and Gout 
   ROS are defined as an atoms or small molecules that have unpaired 
valence shell electrons. They readily accept another electron or transfer their unpaired 
electron to another molecule. ROS are formed as by-products of basal cellular metabolism 
as shown in Figure 2.6. Under normal conditions, approximately 95 % of molecular 
oxygen in biological systems undergoes controlled reduction through the addition of four 
electrons (tetravalent) in the mitochondrial cytochrome oxidase system to form water. 
The remaining molecular oxygen undergoes sequential, univalent reduction to produce 
partially reduced oxygen free radical intermediates, superoxide anion, hydrogen peroxide 
and the highly reactive hydroxyl radical. However, alterations in the amount and the 
nature of released of ROS occurs in various disease state (Halliwell & Gutteridge, 1990).  
 
Figure 2.6. Pathways for the production and removal of reactive oxygen species.                   
GSH, glutathione; GSSG, oxidized glutathione; GSR, glutathione reductase; XO, 
xanthine oxidase. Adapted from Afonso et al. (2007). 
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   Reactivity varies widely from one ROS to another’s. Among ROS 
produced by living cells, superoxide anion, O2
˙ˉ is a proinflammatory compound that 
damages cells and the ECM. Figure 2.7 shown the subsidiary product of superoxide anion, 
O2˙ˉ in living organism. O2˙ˉ capable to damages endothelial cells and increasing the 
permeability of the microvasculature then promoting the migration of neutrophils to foci 
of inflammation. O2˙ˉ can be converted to other, more aggressive, ROS such as the 
hydroxyl radical HO·, which is produced when O2˙ˉ interacts with free iron or copper 
ions. These ions are normally present in tiny amounts in healthy individuals, as they are 
sequestered by specialized proteins such as ferritin, so that virtually no HO· is produced. 
O2˙ˉ also can combine with NO to produce peroxynitrite (ONOOˉ), thereby modifying 
the bioavailability of NO. Hydrogen peroxide (H2O2) can diffuse in the cytoplasm and 
cross cell membranes. Some ROS act as mediators that regulate cell functions such as 
proliferation and apoptosis, by influencing intracellular signaling pathways via effects on 
gene expression (Haddad, 2002).  
  
Figure 2.7. Superoxide anion (O2·ˉ) and its derivatives. Adapted from Afonso et al. 
(2007). 
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   From the Figure 2.6, endothelial xanthine oxidase could contributed to 
ROS production. Xanthine Oxidase, (XO) is main sources of ROS during purine 
biosynthesis pathway which attributable to production of uric acid and thus, become a 
target of therapeutic drugs against hyperuricemia or gout (Elion, 1989). XO, an isoform 
of xanthine oxidorreductase (XOR), an enzyme that catalyses the final steps in the purines 
metabolism (Parks & Granger, 1986). XOR exists in two interconvertible forms, either as 
xanthine dehydrogenase (XDH), which predominates in healthy tissues, and as XO, 
which appears to have an important role in cell and tissue injuries (Harrison, 2002). Both 
forms catalyse the conversion of hypoxanthine to xanthine and then to uric acid, which is 
final reactions in the metabolism of purine bases however, the XDH can reduce either 
oxygen or NAD+ and generates the reduced β ̶ nicotinamide adenine dinucleotide 
(NADH), whereas XO reduces molecular oxygen, leading to the production of ROS, such 
as hydrogen peroxide (H2O2) and superoxide anion (Berry & Hare 2004). The dual role 
of XO means that it is an important regulator of cellular redox state (Elahi et al. 2009). 
The accumulation of uric acid in the body is responsible for several diseases and thus it 
plays a vital role in hyperuricemia and gout. This, mechanism yielding superoxide 
radicals and raises the oxidative level in an organism. During the reoxidation of xanthine 
oxidase, molecular oxygen acts as electron acceptor, producing superoxide radical and 
hydrogen peroxide. Hydroxylation takes place at the molybdopterin center (Mo ̶ pt) via 
Mo–OH oxygen which forms a bond with a carbon atom of the substrate such that the 
oxygen atom is derived from water rather than molecular oxygen (Okamoto et al., 2004). 
Thus, treatment with XO inhibitor are found to prevent the development of various 
disease including endothelial dysfunction, atherosclerosis, gout and given during 
initiation of chemotherapy in myeloproliferative malignancies, in order to prevent the 
harmful effects of high production of uric acid (Schroder et al. 2006).  
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2.6 Xanthine Oxidase  
   Xanthine oxidoreductase (XOR), or also known as Xanthine Oxidase 
(XO) a member of the molybdenum hydroxylase flavoprotein family which also a 
complex enzyme long known to be present in the bovine milk fat globule membrane 
(Patton & Keenan, 1975). XO is the most well documented biological source of reactive 
oxygen species and has been detected in a large number of bacteria which comprising of 
at least eight phyla and innumerable classes of the animal kingdom. The highest xanthine 
oxidase activity had been found at liver and small intestine from the mammalian tissue 
studied, (Parks & Granger, 1986). In humans, apart from liver and intestine, most tissues 
show little XO activity (Sarnesto et al., 1996). XO was purified and characterized 
sucesfully from various species including the human breast in 1986 (Krenitsky et al. 
1986). Regulation of XO activity is important during inflammation (Nakai et al. 2006). 
XO has high amino acids sequence homology among the mouse, rat, bovine and human 
enzymes with about 90 % identity, and consisting of about 1,330 amino acids (Nishino, 
1994; Borges et al. 2002; Godber et al. 2005). Studies showed the existence of similar 
physicochemical properties of XO between human and bovine milk, but it has only 
approximately 5 % of the activity of the bovine milk enzyme towards xanthine and related 
substrates proposing that the low activity is due to grossly deficient of molybdenum 
(Abadeh et al. 1992). 
   The crystal structure is a homodimer of 150 kDa subunits (Enroth et al. 
2000). Each of the subunits is composed of three domains, as shown in homodimer 
structure in Figure 2.8. The right side is cofactor arrangement of XO. The N-terminal (in 
red), the C-terminal (in blue) and the intermediate (in yellow) domains contain the iron-
sulfur centers, the molybdopterin and the FAD centers. The largest domain contains the 
molybdenum center (molybdenum cofactor; molybdopterin), the intermediate contains 
flavin adenine dinucleotide (FAD) cofactor and the smallest contains the two iron sulfur 
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centers ([2Fe ̶ ̶ 2S] type). The redox reaction centers are almost linearly positioned in the 
order of molybdopterin, two [2Fe ̶ 2S] type iron sulfur centers and FAD. The iron sulfur 
centers are called Fe/S I and Fe/S II, based on their redox potentials and EPR signals 
(Iwasaki et al. 2000; Caldeira et al. 2000). Fe/S II has the higher redox potential. Electrons 
that are passed to the molybdenum during the hydroxylation reaction are transferred to 
FAD via the iron sulfur centers. Finally, NAD+ or oxygen molecule, which is the final 
electron acceptor, is reduced (Okamoto et al., 2013). Arrows in Figure 2.8 show the 
directions of electron flow during catalysis. The reduced FAD reacts with either NAD+ 
or oxygen to produce NADH or hydrogen peroxide (H2O2) or superoxide (O2
-). FADH2 
reacts with O2 to produce H2O2, while FADH produces O2. 
 
Figure 2.8. Crystal structure of bovine milk from Protein Data Bank (entry code 
1F4Q). Adapted from Nishino & Okamoto, (2015) 
 
The crystal structures of bovine milk XO as shown in Figure 2.8, suggests that 
hypoxanthine and xanthine bind to the C ̶ terminal domain of the XO, close to the 
molybdopterin cofactor. During substrate oxidation, the molybdenum center (Mo centre) 
is first reduced by electron received from the substrate and subsequently re ̶ oxidized, as 
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the electron passes first to the iron- sulfur centres and then to the FAD centre, and are 
finally donated to NAD+ or O2 (Ratnam, 1995; Kisker et al. 1998; McMaster & Enemark, 
1998). Salicylate was crystallised with XO as a competitive inhibitor, and it bound to the 
Mo active site. Although salicylate itself does not bind to the Mo ̶ pt cofactor, it blocks 
the approach of substrates toward the metal complex. Several amino acid residues, 
including Arg 880, Phe 914, Phe 1009, Thr 1010, and Glu 1261 (Figure 2.9) contributed 
important hydrogen and electostatic interactions between salicylate and the binding site. 
The salicylate molecule is kept in place by several hydrogen bonds and electrostatic 
interactions.  
 
Figure 2.9. Amino acid residues involved in the catalytic reaction in the Mo-pt 
active site of XO. Adapted from Yamaguchi et al. (2007). 
 
Two catalytic reactions are involved in mechanism of XO; reductive half and the 
oxidative half reaction. The reductive half reaction is takes place in the molybdenum 
center of the enzyme while Mo(VI) is converted to its reduced form Mo(IV) which 
contributed to conversion of xanthine to uric acid. While the oxidative half reaction takes 
place at the FAD center, and oxidize Mo(IV) to Mo(VI) by molecular oxygen with the 
formation of (O•2 
- ) or H2O 2 (Huber et al. 1996). 
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   The oxidative part of the reaction involves the binding of molecular 
oxygen to the FAD centre of the reduced form of XO. This will lead to the transfer of 
electrons from the reduced form, to achieve enzyme oxidation (Harris & Massey, 1997) 
as shown in Scheme 2.1. Slow and fast phase in this reaction have been observed, and six 
electrons are transferred throughout the reaction (Mondal et al. 2000) as shown in Scheme 
2.2. The fast phase involves in the transfer of five electrons and the formation of hydrogen 
peroxide (H2O2) and superoxide (O2
. - ). Whereas the slow phase includes the oxidation 
of one electron and the formation of superoxide only (Mondal & Mitra, 1996) as given in 
Scheme 2.3. The mechanism of the formation of xanthine and uric acid is considered as 
the reductive half reaction (Scheme 2.4) (Kim et al. 1996). 
 
Scheme 2.1 
 
 
Scheme 2.2 
 
 
 
 
Scheme 2.3 
 
 
                                                                        Scheme 2.4 
Scheme 2.4 
 
(XO)reduced + O2 (XO)reduced O2                      (XO)oxidized  + H2O2 
XO(6e)           XO(4e)         XO(2e)            XO(1e)              XO(0e)     
Fast phase:  
XO(6e) + O·2                      XO(6e)· O2                     XO(1e) + O2·- + H2O2 
Slow phase: 
XO(1e) + O2                 XO(0e) + O2 ·- 
 
 
(XO)oxidized + Xanthine Xanthine  ̶  (XO)oxidized 
 
(XO)reduced + Uric acid 
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2.7 Role of medicinal plants and natural products in gout  
   Natural products have been contributed extensively towards the 
development of modern medicine, and continuously play a significant role in drug 
discovery. South-east Asian countries like Malaysia, Thailand and Borneo have a long 
history of using medicinal plant that offer considerable pharmaceutical potential. 
Malaysia houses more than 8,000 species of flowering plants, including shrubs, herbs, 
lianas, and epiphytes holds great promise for the discovery of novel biologically-active 
compound (Aziz et al. 2011). Out of the total flowering plants reported from the world, 
more than 50,000 are used for medicinal purposes (Teklehaymanot & Giday, 2007). 
   Natural products discovered from medicinal plants have provided 
numerous clinical useful medicines and can be predicted to remain an essential 
component in the search for new medicines (Balunas & Kinghorn, 2005). Because current 
treatments for gout result in undesirable side effects and tend to be expensive, natural 
products devoid of such disadvantages offer a great opportunity. Since ancient times, 
plant-based medicines which in form of dispensed in the form of extracts, tinctures, 
powders or poultices have been used for the alleviation of pain and other inflammatory 
conditions including gout. In India and Pakistan, healers use Coccinia grandis, Datura 
metel, Stychnosnux vomica, Pistacia integerrima and Vitex negundo. Anti ̶ inflammatory 
and gout therapy is dominated by opioids and non-steroidal anti ̶ inflammatory drugs 
(NSAIDs) but both classes of drugs produce serious side effects. The search for 
pharmacological agents to overcome these shortcomings has become a major goal in pain 
research. Recently, their XO ̶ inhibitory effects have been elucidated as the mechanism 
for their anti-gout effects (Umamaheswari et al. 2007; Ahmad et al. 2008). Scientists have 
turned to explore the potent XO inhibitor from a wide variety of traditional folk 
medicines. Natural XO inhibitors from in vitro studies were reported from a variety of 
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plants used as traditional herbal medicines in different countries in the world such as 
Coccinia grandis and Vitex negundo in India (Umamaheswari et al. 2007), 
Chrysanthemum sinense and Tetracera scandens in Vietnam (Nguyen et al. 2004), 
Cleodendrum floribundum, Eremophila maculata and Stemodia grossa in Australia 
(Sweeney et al. 2001), Cinnamomum cassia, Chrysanthemum indicum and Lycopus 
europaeus and Polygonum cuspidatum in China (Kong et al. 2000a), Larix laricina in 
North America (Owen & Johns, 1999), Hyptis obtusiflora and Hyptis lantanaefolia in 
Panama (Gonzalez et al. 1995) and Hexachlamys edulis and Eugenia punicifolia in 
Paraguay (Theduloz et al. 1988) and Polynesian traditional fruit, Morinda citrifolia (Palu 
et al. 2009). In general, the methanol extracts were found to be more active than the 
methanol-water or water extracts (Kong et al. 2000a; Nguyen et al. 2004).  
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2.8 Studied Plant- Plumeria rubra Linn 
2.8.1 Taxonomy of Plumeria rubra Linn. 
 
                                                                                    
 
 
 
 
 
 
Figure 2.10. Plumeria rubra tree 
             
                           
 
 
Kingdom- Plantae  
Class- Magnoliopsida
Subclass- Asteridae 
Order- Gentianales  
Family- Apocynaceae  
Genus- Plumeria  
Species- rubra 
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Plumeria rubra Linn which belong to family Apocynaceae is kind of shrub tree which 
growing in tropical and sub-tropical regions of the world and distributed from Southern 
Mexico to Southest Asia (Ye et al. 2009). In Malaysia this famous garden plant is 
commonly known as 'kemboja,' and several other names such as 'pokok kubur' and 'bunga 
kubur’ (Comer, 1997).  
  The tree is deciduous and has very thick, stout branches with milky 
latex.  The leaves are spirally arranged near the ends of the swollen branches. They are 
recognized as excellent ornamental plants and often seen in the graveyards. It grows as a 
spreading tree with crooked trunk and rough bark, swollen branches leafy at the tips, 
elongated alternate leaves (Pino et al. 1994).  The shape of the leaf can be described as 
elliptical, oblanceolate and rarely lanceolate, while the tip is described as acuminate, acute 
or obtuse (Chinn, 1986). The flowers are generally large, waxy and very fragrant, in 
terminal or lateral stalked clusters (Burkill, 1966). This gorgeous tropical tree consist of 
reddish blooms and spiral ̶ shaped which appears at the branch tips is commonly used in 
decoration such as leis and wreaths (Ye et al. 2009). Plumeria plants are famous for their 
attractiveness and fragrant flower due to delightful aroma which is most intense during 
the early part of the day.  
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Figure 2.11. Plumeria rubra (A) Leaves (B) Flowers 
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2.8.2 Traditional and Medicinal Used of Plumeria rubra Linnn 
  There are numerous reports on the ethnomedical uses of plants 
belonging to the pantropic genus Plumeria (Hamburger et al. 1991). Traditionally, the 
decoction of the bark is used as a purgative. emmenagogue, febrifuge or diuretic, and to 
cure gonorrhea, dropsy and dysuria due to venereal disease, while the decoction of the 
leaves is used as a lotion for cracks and eruptions on the soles of the feet (Lim, 2011). 
The leaves of P.rubra L. are used in ulcers, leprosy, inflammations and rubefacient 
(Bobbarala et al. 2009; Gupta et al. 2006). Wiart, (2002) reported that the decoction of 
the bark and roots of P.rubra L. is traditionally used to treat asthma, ease constipation, 
promote menstruation and reduce fever whereas the latex is used to soothe irritation. The 
fruit is reported to be eaten in West Indies. In India, however, it has been used as an 
abortifacient (Zaheer et al. 2010). In Indonesia, the plant is cultivated as an ornamental 
species and decoctions prepared from the bark is used to treat venereal diseases (Burkill, 
1966). The roots and rhizomes of this plant are also used against snakebite (Houghton & 
Osibogun, 1993). The essential oils from the flowers are used for perfumery and 
aromatherapy purposes (Wiart, 2002). The Siamese use an infusion of the flowers in 
cosmetics, applied after bathing (Burkill, 1966). The flowers are aromatic and widely 
used in pectoral syrups. The flowers decoction of P. rubra was reported to be used in 
Mexico for control of diabetes mellitus (Bobbarala et al. 2009). In addition, P.rubra L. 
flowers are known to contain potent cardioactive glycosides that have positive inotropic 
effects on the heart (Frishman et al. 2009). Furthermore, P.rubra L. is also has been 
reported that among the traditional plants claimed to exhibit anti-tumoural, antimicrobial 
and cytotoxic activities and is also effective against parasitic infestations, such as scabies 
and pediculosis (Monzon, 1995; Nargis et al. 1994). 
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2.8.3 Chemical Constituents of Plumeria rubra Linn 
   Phytochemical studies of the flowers of P. rubra L., are found to contain 
tannins, flavonoids, terpenoids, reducing sugars and alkaloids.  
Table 2.1 Chemical Compounds found in P.rubra L. 
 
 
 
Phytochemical compounds Chemical Structure 
 
Myristic acid 
 
Tohar et al. 2006 
 
 
Linoleic acid 
 
Tohar et al. 2006 
 
Lauric acid 
 
Tohar et al. 2006 
 
Palmitic acid 
 
Tohar et al. 2006 
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Plumericidine 
 
Ye et al. 2009 
Anthocyanin  
 
1. cyaniding ̶ 3 ̶ O ̶ β ̶ (2” ̶ 
glucopyranosyl ̶ O ̶ β ̶ 
galactopyranoside) 
 
2.cyanidin ̶ 3 ̶ O ̶ β ̶ 
galactopyranoside 
 
 
Byamukama et al. 2011 
Rubranonoside (=7 ̶ O ̶ α ̶ L ̶ 
rhamnopyranosyl ̶ 4’ ̶ O ̶ β ̶ 
D ̶ 
glucopyranosylnaringenin 
 
 
Akhtar et al. 2013 
Rubranin             (new 
flavanone glycoside) 
 
 
Akhtar et al. 2013 
Rubradoid (plumieridine ̶ 
1 ̶ O ̶ β ̶ D ̶ 
galactopyranoside) 
 
Akhtar et al. 2013 
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Rubrajaleelol (new iridoid 
galactoside) 
  
 
Akhtar et al. 2013 
Rubrajaleelic acid 
 
Akhtar et al. 2013 
1 ̶ α ̶ plumieride (two new 
nor ̶ terpenoids with known 
iridoids) 
 
Akhtar et al. 2013 
Plumieride                                
p ̶ z ̶ coumarate 
 
Akhtar et al. 2013 
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2.9. Phytochemical Compounds with Xanthine Oxidase Inhibitor 
   Some of herbal plants and their phytochemicals are worth to be explored 
as potential xanthine oxidase inhibitor as they are already used as food or food 
supplements for many years and found to be safe for human bodies (Azmi et al. 2012). 
More often, plant based-natural products provide lead structures which are starting points 
for chemical modification to derive an optimal drug (Bezerra et al. 2013). In the past two 
decades, the potential of free radical scavenging and XO inhibitors were explored from a 
wide variety of traditionally used herbal plants (Montoro et al. 2005). Thus, most research 
on medicinal plants focused on their active chemical constituents currently used and those 
with the potential to be developed as anti ̶ gout medications in the future.  
   The anti ̶ gout effects of these medicinal plants include three mechanisms 
which including (i) the decrease of uric acid production, (ii) uricosuric effects and (iii) 
anti-inflammatory activities. Under the three main mechanisms of pathogenesis, 
medicinal plants that can be potent in the treatment of gout are collected and described, 
together with their active phytochemicals. Ten classes of compounds derived from plants 
with anti-gout potential had been identified. Flavonoid which are very potent anti-gout 
mediators due to their multiple effects correlated with different mechanisms, including 
genistein, astilbin, apigenin, quercetin, myricetin, liquiritigenin, isoliquiritigenin, rutin, 
procyanidin, luteolin and apigenin ̶ 4’ ̶ O ̶ (2 ̶ O ̶ p ̶ coumaroyl) ̶ d ̶ glucopyranoside. 
Flavonoid exhibit in vitro, in vivo, or both of the two XO inhibitory effect even with 
different inhibition modes (Gariboldi et al. 1998; Kong et al. 2000; Jiao et al. 2006; 
Cimanga et al. 2010; Chen et al. 2011; Huang et al. 2011). Morin, rutin and quercetin 
revealed both XO inhibitory activity and uricosuric action (Yu et al. 2006; Shi et al. 
2012). Luteolin and apigenin give anti-inflammtory effect (de Souza et al. 2012). Caffeic 
acid, luteolin, eriodictyol and 1, 5 ̶ di-O ̶ caffeoylquinic acid from Chrysanthemum sinense 
have demonstrated significant XO inhibition (Nguyen et al. 2004). The other studies 
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which also revealed good XO inhibitory activity were including water –soluble phenolics 
and tannin (Owen & Johns, 1999), resveratrol (Chen et al. 2011) and melanoxetin and 
okanin (Tung & Chang, 2010). Both resveratrol and lithospermic acid give not only XO 
inhibitory activity but also anti ̶ inflammatory effects (Soung et al. 2003; Aggarwal et al. 
2004; Shishodia & Aggarwal, 2006; Liu et al. 2008). Recently, chlorogenic acid, which 
is the one of the most abundant polyphenols in the Chinese medicines, has been reported 
to have an anti ̶ gout effect. As less literature reported that chlorogenic acid was known 
phytochemical that acts as XO inhibitors but surprisingly Meng et al. (2014) has been 
found that chlorogenic acid could decreased the serum uric acid level by inhibiting the 
xanthine oxidase (XOD) activity but not increasing the urinary uric acid level in 
potassium oxonate (PO) ̶ induced hyperuricemia of mice model. In addition, chlorogenic 
acid also exhibited the effect of suppressing paw swelling of MSU crystal-induced 
inflammation in rat.  Tannin compounds like geraniin, corilagin and gallic acid which 
isolated from Geranium sibiricum Linn had elicited uricosuric action (Wu et al. 2010) 
while ellagic acid which isolated from longan had suppressed XO activity (Hou et al. 
2012). Berberine is a potent XO inhibitor (Kong et al. 2004), while other alkaloids, 
colchicine and piperine give very good anti-inflammatory activity (Ahern et al. 1987; 
Sabina et al. 2011). Of note, colchicine is a classical anti-gout drug with effects of both 
pain relief and inflammation resistance. Additionally, the crude extract of Jatropha 
isabellei that is rich of alkaloids also presents antinociceptive and anti-inflammatory 
effects (Silva et al. 2013). An essential oil component, cinnamaldehyde, shows dual urate 
lowering effects, XO inhibitory and uricosuric action (Wang et al. 2008). The later effect 
is hypouricemic action activating the blocked urate transporter (UAT) activity induced 
by oxonate in the hyperuricemia model of mice (Zhao et al. 2006). An iridoid glucoside, 
specioside and two coumarins, fraxetin and esculetin reveal XO inhibitory (Kong et al. 
2000; Kumar et al. 2005). Lupeol, a triterpenoid, exerst anti-inflammatory effects (de 
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Souza et al. 2012). The lignans, arctigenin from Arctium lappa L., exert anti-
inflammatory activities through inhibition of the iNOS pathway (Zhao et al. 2009), other 
three lignans, phyllanthin, hypophyllanthin and phyltetralin of Phyllanthus niruri exhibit 
both XO inhibitory and uricosuric action (Murugaiyah & Chan 2009). The only 
phytochemical compound isolated from phycophyta in this review is fucoxanthin, a kind 
of xanthophyll, possesses potential anti-inflammatory activity (Heo et al. 2010). 
    Studies by Vivot et al. (2001); Kumar et al. (2005); Boumerfeg et al. 
(2009); Wu et al. (2010) revealed that the plants which give antioxidant activities should 
be highly potent in the management of gout because they often share XO inhibitory 
effects. Furthermore, it is generally believed that plants with higher phenolic content 
show good antioxidant activity. In other words, there is a direct correlation between total 
phenol contents and antioxidant activity (Brighente et al. 2007; Biglari et al. 2008; 
Salazar et al. 2008). Thus it can be stated that the phenolic content of the plant may be a 
good indicator of its antioxidant capacity (Chanda & Nagani, 2010), and even of its 
potential to be used in anti-gout treatment. 
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CHAPTER 3 
 METHODOLOGY 
 
3.1 Plant Materials 
 
   The red flowers of P.rubra were collected in February, 2014 in area of 
Faculty Science, University of Malaya. The materials were identified by Prof. Dr Ong 
Hean Choi from Institute Biological Science, University of Malaya. A voucher specimen; 
reference no: KLU 48177 was deposited in the Rimba Ilmu herbarium, University 
Malaya.  
 
3.2 Instruments and Chemical & Reagents 
   ELISA microplate reader Tecan Sunrise (Austria), LCMS  Flexar FX ̶ 15 
UHPLC, USA, Spectrophotometry UV ̶ 1700 Shimadzu, Japan, 2,2diphenyl ̶ 1 ̶ 
picrylhydrazyl (DPPH), 2,4,6 ̶ tripyridyl ̶ s ̶ triazine (TPTZ), gallic acid monohydrate, 
ferrozine, sodium nitroferricyanide(III)dehydrate, hydrogen peroxide, sodium hydroxide, 
aluminium chloride, sodium nitrite, Griess reagent, curcumin, sodium phosphate 
monobasic and dibasic, tris base and quercetin dihydrate were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). Ascorbic acid, acetic acid glacial, hydrochloric acid, 
sodium chloride, dimethyl sulfoxide (DMSO), ferrous sulfate (FeSO4), nitro blue 
tetrazolium, nicotinamide adenine dinucleotide, phenazine methosulphate, ferric chloride 
hexahydrate (FeCl3⋅6H2O), ethylenediaminetetraacetic acid disodium dehydrate 
(EDTANa2⋅2H2O), Folin-Ciocalteu phenol reagent, and sodium carbonate were 
purchased from Merck Chemical Co. (Malaysia). Allopurinol, xanthine, xanthine oxidase 
(bovinemilk) also potassium oxonate were purchased from Sigma-Aldrich Chemicals (St. 
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Louis, MO, USA). All chemicals used are of analytical grade and were used without 
further purifications. 
 
3.3 Preparation of Flower Extract 
 
  The red flowers of P. rubra were cleaned and cut into small pieces for efficient 
drying process. The red  flowers were dried in the shaded at room temperature before 
grounded into fine powder by using domestic blender and store in the freezer prior the 
extraction process. The extracts of hexane, chloroform and methanol were prepared by 
using Soxhlet apparatus.  
  The ground flowers (22 g) was placed in a thimble-holder, and extracted with 
250 ml of solvent in boiling flask at 40 °C for 20 hours. When extraction solvent reach 
the boiling point, the vapors condensed through the condenser and the solvent drips into 
the thimble contained grind sample. Extractions were repeated using with different 
polarity starting with lowest polarity to more polar solvent. The solvent from the filtrate 
was removed using rotary vacuum evaporator at more than 40 °C to yield hexane, 
chloroform and methanol extract. 
  The ground flowers (22 g) was soaked in distilled water with the ratio of 1:10 
and at room temperature approximately for 3 days. The extraction was carried out without 
adding any heat to avoid compound destruction. Following extraction, the water extracts 
was filtered and the residue was then re ̶extracted under the same conditions twice. The 
filtrates were combines and freeze ̶ dried. Water extract of P. rubra was extracted 
accordingly to the method described by Handa, (2008). The dried powder were weighed 
and kept in sample bottle at -20 ºC until further used.  
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3.4 Detection of Phytochemical Compounds 
a) Thin Layer Chromatography (TLC) 
   The separation of phytochemical compounds in red flower of P. rubra 
extract was carried out using Thin Layer Chromatography (TLC) according to method 
described by Harbone, (1984). The polar stationary phase was more strongly attracted 
polar molecules. 
   1 cm was measured from the base of the TLC plate, marked with a pencil 
and labelled. Capillary tube was used to spot the plates with the extract. Small quantities 
of the concentrated solutions were collected with capillary tube by dipping it in the 
solution. They were then used to spot the plates on Silica gel 60 F254 ̶ precoated TLC 
plates, size 20 cm x 20 cm. The plates were placed in a chromatography tank and covered, 
ensuring that the solvent was just below the spots. Solvent was poured into the TLC 
chamber to a depth of just less than 0.5 cm and must be covered with watch glass. The 
following solvent system are used: toluene: hexane (3:7) for hexane extract P.rubra (PR ̶ 
HE), chloroform: methanol (9:1) for chloroform extract P.rubra (PR ̶ CE), butanol: acetic 
acid: water (4:5:1) for methanol extract P.rubra (PR ̶ ME) and water extract P.rubra (PR ̶ 
WE). Apparatus was placed on a level surface for the solvent to rise. The plate was 
removed after about two hours when the solvent had risen close to the top edge, the 
distance travelled by solvent with a pencil was marked immediately. It was then dried at 
room temperature and viewed under UV ̶ 254 nm and 366 nm.  
   The distances moved by the solvents and the spots were measured, in 
centimetres, with a rule. The retardation factors (Rf) of the samples were then determined. 
The Rf value was the distance of compound moved in chromatography relative to the 
solvent front, (Figure 3.1) following the formula: 
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Figure 3.1 Diagram of determination of Retardation factor (Rf) value on TLC 
plate. 
 
 
 
   The detection of chemical compound of TLC plates was carried out by 
observing under visible light and UV light for any colour presence and then TLC plate 
were dried in fume cupboard prior to spraying with different chemical reagents. Reagents 
were prepared according to published procedure described by Wagner & Bladt, (2001). 
 
i. Visible light 
   Under visible light, the coloured spots can be seen clearly on the dried 
TLC plate. The dried TLC plates are examined initially in visible light for pigments which 
appear as coloured spots. Available coloured spots on the plate were marked lightly with 
a pencil and Rf value were measured. The coloured spots were analyzed in order to detect 
 
Rf value = Distance travelled by chemical compound (B) 
         Distance traveled by solvent front (A) 
 
 47 
 
 
which phytochemical compound and pigments such as chlorophyll, xanthophyll or 
betalains. 
 
ii. Ultra Violet (UV) light 
   Those spots which could not be seen under visible light need to be further 
visualized with ultra violet light. TLC chromatograms were observed under ultra violet 
light in the dark room by using shortwave UV lamp at 254 nm and long wave UV lamp 
with 366 nm to detect the fluorescence spots then marked with a pencil and Rf value was 
measured. TLC plate were  observed whether included native florescence  which appeared 
as bright zone on a dark background under long wave at 366 nm or included florescence 
indicator compounds that can quench the fluorescence and show up as a dark spots or 
other colours such as purple or blue on a green background under short wave at 254 nm 
(Harbone, 1984).  
 
iii. Dragendroff’s Reagent 
   The mixture of 0.8 g of bismuth nitrate (BiONO3) in 10 mL of glacial 
acetic acid (HAc) was diluted with distilled water in order to obtained solution A.  
Solution B was prepared by dissolving 20 g Potassium iodide (KI) powder to 50 mL 
distilled water in brown volumetric flask. 100 mL dragendroff reagent was prepared 
according to Jia and Tia, (2009) by mixtures of 5 mL solution A and 5 mL solution B in 
100 mL brown volumetric flask, and mixtures was diluted until 100 mL solution. 
Dragendroff reagent was stored in covered brown bottle.   
   TLC plates which had been removed from TLC chamber were placed in 
the fume cupboard in order to allow the solvent to evaporatate before they were sprayed 
with dragendroff reagent. The reagent reacted to alkaloids and choline produced orange 
spots.Orange spots were marked with a pencil and Rf value were measured. 
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iv. Vanilin ̶ Sulphuric acid reagent 
   Fresh vanillin ̶ sulphuric acid (H2SO4) reagent was prepared by dissolving 
1 g of vanillin in 100 mL of ethanol and water (40:10) .TLC plates which had been 
removed from TLC chamber were placed in the fume cupboard in order to allow the 
solvent to evaporatate before they were sprayed with vanillin ̶ H2SO4 reagent. Then, the 
plates were heated on hot plate at 100 °C. The formation of purple spot indicate presence 
of terpenoid compounds while red and pink spots indicates presence of phenolic 
compounds 
 
v. Anisaldehyde – Sulphuric Acid reagent 
   A mixture of 0.5 mL of anisaldehyde, 80 mL methanol, 30 mL of glacial 
acetic acid (HAc) and 5 mL of H2SO4. TLC plates which had been removed from TLC 
chamber were placed in the fume cupboard in order to allow the solvent to evaporatate 
before they were sprayed with anisaldehyde ̶ H2SO4 and heated at 100 °C. The formation 
of red spot indicates the presence of flavonoids, purple spot indicates the presence of 
terpenoids while blue and black spot indicate the presence of saponins. 
 
b) Liquid Chromatography Mass Spectrometry (LCMS) 
   The PR ̶ ME and PR ̶ WE extracts from red flower of P.rubra was analyzed 
with Liquid Chromatography Mass Spectrophotometry (LCMS) to determine the 
chemical compounds present. Extracts was screened with AB Sciex 3200QTrap 
LCMS/MS and fully scan with MS/MS data collection with negative ionization mode. 
Phenomenex Aqua C18 (50 mm x 2.0 mm x 5 µM) was used a column in a rapid screening 
at 15 min run time. Water with 0.1 % formic acid (HCO2H) and 5 mM ammonium formate 
(NH4HCO2) was used as buffer A and a mixture of acetonitrile (CH3CN) with 0.1 % 
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HCO2H and 5 mM ammonium formatted as buffer B. Sample were run with gradient 
mode; 10 % A to 90 % B from 0.01 min to 8.0 min and were held for 3 min and back to 
10 % A in 0.1 min and re ̶ equilibrated for 4 min. Pre- run equilibration time was 1.0 min. 
1 mL of concentrated sample of PR ̶ ME and PR ̶ WE extracts was diluted 5 times with 
methanol and filtered with 0.2 µM nylon filter prior to being analyzed. Injection volume 
for both samples were 20 µL.  
 
3.5   Determination of Total Phenolic Content 
Total phenolics were determined using Folin ̶ Ciocalteu (FC) reagent according to the 
method described by Muller et al (2010) with slight modification.  
 
3.5.1 Preparation of Folin ̶ Ciocalteu (FC) Reagent 
FC reagent was prepared by mixing 20 mL of the folin ̶ ciocalteu reagent with 200 mL 
distilled water. 
 
3.5.2 Preparation of 7.5 % Sodium Carbonate (Na2CO3) 
 Na2CO3 was prepared by dissolving 7.5 g of Na2CO3 stock in 100 mLdistilled water. 
 
3.5.3 Preparation of Gallic Acid 1mg/mL Standard solution 
Gallic acid was prepared by dissolving 0.01 g of gallic acid in 10 mL distilled water used 
as positive control. 
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3.5.4 Total Phenolic Assay 
    Briefly, twenty microliters of red flower from P. rubra extracts was mixed 
with 100 𝜇L of FC reagent (diluted 10-fold with distilled water) in a 96 ̶ well microplate, 
incubated for 5 min, and 75 𝜇L of Na2CO3 solution (7.5 %) was added. After 2 hours of 
incubation period in darkness at room temperature, the absorbance was measured at 740 
nm using microplate reader (Tecan Sunrise, Austria).  Gallic acid (1 mg/1mL) was used 
as standard for calibration and construction of a linear regression line and DMSO 3 % 
was used as a blank. The total phenolic content of the extract was calculated as mg gallic 
acid equivalent (GAE) mg /g of dry weight extract and were done in triplicate. 
 
 
3.6   Determination of Total Flavonoid Content 
The total flavonoid content was determined according to the method described by Zhishen 
et al. (1999) with slight modification. 
 
3.6.1 Preparation of 5 % Sodium nitrite (NaNO2) solution 
5 % of NaNO2 was prepared by dissolving 5 g NaNO2 in 100 mL distilled water. 
 
3.6.2 Preparation of 10 % Aluminium Chloride (AlCl3) 
10 % AlCl3 was prepared by dissolving 10 g AlCl3 in 100 mL distilled water. 
 
3.6.3 Preparation of 1M Sodium hydroxide (NaOH) solution 
1M NaOH solution was prepared by dissolving 1.599 g NaOH in 60 mL distilled water. 
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3.6.4 Total Flavonoid Assay 
   Briefly, fifty microliters of extracts were added with 70 𝜇L of distilled 
water and 15 𝜇L of 5 % NaNO2 solution in a 96 ̶ well microplate. The solutions were well 
mixed and incubated for 5 min at room temperature. Then, 15 𝜇L of 10 % AlCl3 solution 
was added into the mixture. After 6 min of incubation, 100 𝜇L of 1M NaOH solution was 
added, and the absorbance was measured at 510 nm with a microplate reader (Tecan 
Sunrise, Austria). Methanol was used as blank. The final absorbance of each extracts was 
compared with a standard curve plotted of quercetin. The total flavonoid content of the 
extracts was expressed in mg quercetin equivalent (QAE) mg /g of dry weight extract. 
 
3.7   Determination of Antioxidant Activity 
3.7.1   2, 2 ̶ diphenyl ̶ 1 ̶ picrylhydrazyl (DPPH) Scavenging Activity Assay 
Quantitative measurements of radical scavenging assay were carried out according to the 
method as described by Marghitas et al. (2009) with a slight modification.  
 
a. Preparation of 50 𝜇M DPPH solution in methanol  
0.00197 g of DPPH was dissolved in 100 mL methanol. The solution was kept in flask 
wrapped with aluminium foil. This reagent is stable when stored in a refrigerator at 4 °C 
for several days. 
 
b. DPPH Scavenging Assay 
 The scavenging activity of red flowers from P. rubra extracts and ascorbic acid were 
tested at various concentrations range of 15.63, 31.25, 62.5, 125 and 250 𝜇g/mL. Reaction 
mixtures containing DPPH and extracts or ascorbic acid were prepared according to Table 
3.1. 
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Table 3.1 Preparation of Reaction Mixtures of Extracts or Ascorbic acid and 
DPPH reagent for DPPH Scavenging Assay 
 
Concentrations of ascorbic 
acid or extracts (𝜇g/mL) 
Volume of ascorbic acid or 
extracts (µL) 
Volume of DPPH reagent 
(µL) 
250 40 200 
125 40. 200 
62.5 40 200 
31.25 40 200 
15.63 40 200 
 
   Briefly, 40 𝜇L of extracts of each concentrations (15.63 to 250 µg/mL) 
were mixed with 200 𝜇L of 50 𝜇M DPPH solution in methanol. The mixture was 
immediately shaken and incubated for 15 min in the dark at room temperature. The 
absorbance reading was measured at 517 nm using ELISA microplate reader (Tecan 
Sunrise, Austria). Ascorbic acid (15.63 ̶ 250 𝜇g/mL) served as a standard positive control 
and the negative control was methanol.  
 
   The percentage of scavenging activity of the P. rubra flowers extracts was 
calculated according to the following equation: 
 
DPPH scavenging activity (%) =  
 
 
 
 
 
 
   The concentration of extracts required to scavenge 50 % of DPPH radical 
was estimated from the graph plotted against the percentage inhibition and compared with 
the standard. All the tests were performed in triplicate, and the results were expressed as 
𝜇/mL. 
 
Absorbance of control – Absorbance of sample / standard   x 100% 
             Absorbance of control 
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3.7.2 Ferric Reducing Anti-oxidant Power (FRAP) 
The FRAP assay was carried out as described according to Benzie & Strain (1996) with 
slightly modification in 96 ̶ well microplates. 
 
a. Preparation of Acetate Buffer 0.3M 
16 mL of glacial acetic acid was added to 3.1 g sodium acetate trihydrate. Then, solution 
was made up to 1 L using distilled water. The pH of the solution was adjusted using pH 
meter.  
 
b.  Preparation of 2,4,6 ̶ Tripyridyl ̶ s ̶ Triazine (TPTZ) solution  
0.031 g of TPTZ was added to 10 mL of 40 mM HCl and dissolved at 50 °C in water 
bath. TPTZ solution was freshly prepared each time the assay was performed. 
 
c. Preparation of Ferric chloride solution (FeCl3) 
0.054 g of FeCl3 was dissolved in 10 mL of distilled water. FeCl3 solution was freshly 
prepared each time the assay was performed.  
 
d. Ferric Reducing Anti-oxidant Power (FRAP) assay 
   Twenty microliters of red flowers of P. rubra extracts in ethanol were 
mixed with 200 𝜇L of daily prepared FRAP reagent, which contained 5 mL 10 mM TPTZ 
in 40 mM HCl, 5 mL of 20 mM FeCl3, and 50 mL of 0.3M acetate buffer (pH3.6) in 96 ̶ 
well microplate. After 8 min of incubation time, the formation of the TPTZ ̶ Fe2+ complex 
in the presence of antioxidant compounds in the extract was measured at 595 nm with a 
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microplate reader (Tecan Sunrise, Austria). Methanol was used as a blank. Ferrous sulfate 
(FeSO4) solution (0.2 mM to 1 mM) was used for standard calibration curve. The FRAP 
value was evaluated according to the linear regression between standard solutions and 
absorbance at 595 nm and the results were estimated as mmol Fe2+/ g of dry extract from 
triplicate tests. 
 
3.7.3 Metal Chelating Activity Assay 
The ferrous ion chelating activity of the red flowers from P. rubra extracts was 
determined according to the procedure by Srivastava et al. (2012) by measuring the 
formation of the Fe2+ ̶ Ferrozine complex. The assay performed to measure chelating 
ability of ferrous ion was based on the chelation of ion Fe2+ with ferrozine to form ferrous-
ferrozine complex which can be detected at 562 nm. 
 
a. Preparation of 5 mM of Ferrozine (FZ) 
A stock of 0.0246 g of FZ was dissolved in 10 mL deionized water. The stock solution 
was kept in centrifuge tube and wrapped with aluminium foil. 
 
b. Preparation of 2 mM Ferum Chloride (FeCl2)  
A stock of 0.0025 g of FeCl2 was dissolved in 10ml deinonized water. The stock solution 
was kept in centrifuge tube and wrapped with aluminium foil. 
 
c. Metal Chelating Assay 
   EDTA was used as positive reference standard in metal chelating assay. 
The metal chelating activity of red flowers P. rubra extracts and EDTA were tested at 
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various concentrations of 15.63, 31.25, 62.5, 125 and 250 𝜇g/mL. Reaction mixtures 
containing ferrozine, ferric chloride in Ethylenediaminetetraacetic acid (EDTA) or 
extracts were prepared according to Table 3.2. 
 
Table 3.2 Preparation of Reaction Mixtures of Extracts or EDTA Containig 
Ferrozine, Ferric Chloride and Distilled Water. 
 
Concentration of 
EDTA or extract 
(µg/mL) 
Volume of 
Ferrozine (FZ) 
(µL) 
Volume of 
Ferric Chloride 
(FeCl3) (µL) 
Volume of 
EDTA or 
extracts 
Volume of 
distilled 
water (µL) 
250 20 10 100 120 
125 20 10 100 120 
62.5 20 10 100 120 
31.25 20 10 100 120 
15.63 20 10 100 120 
 
   Briefly, 100 𝜇L of extracts from each concentrations (15.63 ̶ 250 𝜇g/mL) 
were mixed with 120 𝜇L distilled water and 10 𝜇L FeCl2 (2 mM) in a 96 ̶ well microplate. 
FZ (5 mM, 20 𝜇L) was added to the mixture to initiate the reaction. The reaction mixture 
was incubated at room temperature for 20 min and absorbance at 562 nm. EDTA was 
served as positive control (15.63 ̶ 250 µg/mL) while 0.05 % DMSO was used as a negative 
control; blank was without ferrozine (20 𝜇L of distilled water instead of FZ). The percent 
inhibition of Fe 2+ ̶ FZ complex formation was calculated. The concentration of extracts 
required to chelate 50 % of the Fe2+ ion (IC50) was calculated from the graph against the 
percentage of inhibition. 
 
    The percent inhibition of Fe2+- ̶ FZ complex formation was calculated 
according to the following formula: 
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Ferrous ion chelating activity =      
 
 
 
 
3.7.4 Hydrogen peroxide Scavenging Activity Assay  
The scavenging capacity for hydrogen peroxide was measured according to the method 
as described by Sroka & Cisowski, (2003) with a slight modification.  
 
a. Preparation of 50mM Phosphate buffer  
Phosphate buffer was prepared according to phosphate buffered saline system, are 
comprising the following reagents: potassium phosphate (monobasic) (KH2PO4), 
potassium phosphate (dibasic) (K2HPO4) and sodium chloride (NaCl) 
Solution A : 1.36 g KH2PO4 (monobasic) was dissolved in 10 mL distilled water.  
Solution B : 8.70 g K2HPO4 (dibasic) was dissolved in 50 mL distilled water 
Solution C : 2.93 g NaCl was dissolved in 50 mL distilled water. 
6.3 mL of solution A, 43.7 mL of solution B and 30 mL of solution C were mixed and 
diluted with one liter of distilled water, then, the pH of buffer was adjusted to 7.4. 
 
b. Preparation of 2 mM Hydrogen peroxide (H2O2) solution  
100 mL of 2 mM H2O2 was prepared with the mixtures of 20 mL of hydrogen peroxide 
solution and 80 mL phosphate buffer. 
 
 
 
Absorbance control – (Absorbance sample or standard)   x   100 
Absorbance control 
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c. Hydrogen peroxide Scavenging Assay  
   The scavenging activity of both red flowers from P. rubra extracts and 
ascorbic acid were tested at various concentrations of 15.63, 31.25, 62.5, 125 and 250 
𝜇g/mL. Reaction mixtures containing H2O2 solutions in phosphate buffer (50 mM) and 
extracts or ascorbic acid were prepared according to Table 3.3. 
 
Table 3.3 Preparation of Reaction Mixtures of Extracts or ascorbic acid and 
hydrogen peroxide solution 
Concentration of ascorbic 
acid or extracts (𝜇g/mL) 
Volume of ascorbic acid or 
extracts (mL) 
Volume of Hydrogen 
Peroxide (H2O2) solution 
(mL) 
250 0.1 0.6 
125 0.1 0.6 
62.5 0.1 0.6 
31.25 0.1 0.6 
15.63 0.1 0.6 
 
   
   A solution of H2O2 (2 mM) was prepared in 50 mM phosphate buffer (pH 
7.4). H2O2 concentration was determined spectrophotometrically at 230 nm absorption 
using the molar extinction coefficient for H2O2 of 81 mol-
1cm-1. 0.1 mL of each 
concentrations of extracts and ascorbic acid (16.63 ̶ 250 μg/mL in respective solvents), 
was transferred into the test tubes and their volumes were made up to 0.4 mL with 50 mM 
phosphate buffer (pH 7.4) or solvent (methanol). After addition of 0.6 mL H2O2 solution, 
tubes were vortexed and absorbance was measured at 230 nm was determined after 10 
min, against a blank. 50 mM phosphate buffer without H2O2 was used as blank.   
 
   Hydrogen peroxide scavenging ability (in triplicate) was calculated by the 
formula: 
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Hydrogen peroxide scavenging activity =   
 
 
 
 
3.7.5 Nitric Oxide Scavenging Activity Assay 
The nitric oxide scavenging activity of the red flowers from P. rubra extracts was 
determined according to the procedure by Srivastava et al. (2012) by measuring the 
formation of the nitrite ions in the reaction mixture that can be detected by Griess reagent 
which can be detected at 546 nm. 
 
a. Preparation of 20mM Phosphate Buffered Saline (pH 7.4) 
0.1 M Phosphate buffer was prepared according to phosphate buffered saline system, are 
comprising the following reagents: potassium phosphate (monobasic) (KH2PO4), 
potassium phosphate (dibasic) (K2HPO4) and Sodium Chloride (NaCl). 
Solution A : 27.6 g of KH2PO4 (monobasic) was dissolved in 19 mL distilled water.  
Solution B : 28.4 g K2HPO4 (dibasic) was dissolved in 81 mL distilled water 
Solution C : 4.68 g NaCl was dissolved in 80 mL distilled water 
Solution A, Solution B and Solution C were mixed and diluted with 100 mL of distilled 
water, then, the pH of buffer was adjusted to 7.4. 
20 mM phosphate buffer was prepared by diluted 10 mL 0.1 M phosphate buffer with 40 
mL distilled water. The pH of buffer was adjusted to 7.4. 
 
b. Preparation of 10 mM of sodium nitroferricyanide (Na2[Fe(CN)5NO] · 2H2O) 
A stock of 0.149 g sodium nitroferricyanide was dissolved in 50 mL phosphate buffer. 
Absorbance control – (Absorbance sample/ standard)   x 100 
   Absorbance Control 
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c.    Preparation of Griess reagent 
0.2 % naphthylethylenediamine dihydrochloride and 2 % sulphanilamide in 5 % 
phosphoric acid were prepared separately in an amber colored bottle label it and store it 
in 4 °C. The equal volume of both solutions were mixed before assay estimation. 
 
d. Nitric Oxide Radical Scavenging Assay 
   Curcumin was used as positive reference standard in metal chelating 
assay. The nitric oxide radical scavenging activity of each P. rubra flowers extracts and 
curcumin were tested at various concentrations of 15.63, 31.25, 62.5, 125 and 250 𝜇g/mL. 
Reaction mixtures containing sodium nitroferricyanide (Na2[Fe(CN)5NO] · 2H2O) and 
Griess reagent with curcumin or extracts were prepared according to Table 3.4. 
 
Table 3.4: Preparation of Reaction Mixtures of Extracts or Curcumin Containing 
Sodium ferrocyanide and Griess Reagent 
Concentration of 
Curcumin or 
extract (µg/mL) 
Volume of 
Sodium 
ferricyanide 
(Na2[Fe(CN)5NO] 
· 2H2O 
(µL) 
Volume of 
Griess reagent 
(µL) 
Volume of 
Curcumin or 
extracts (µL) 
250 50 125 50 
125 50 125 50 
62.5 50 125 50 
31.25 50 125 50 
15.63 50 125 50 
 
 
   Briefly, fifty microliters of extracts at each concentrations (15.63 ̶ 250 
𝜇g/mL) and an equal amount of sodium nitroferricyanide (Na2[Fe(CN)5NO]·2H2O) (10 
mM) in phosphate-buffered saline (20 mM, pH 7.4) were mixed well in a 96 ̶ well 
microplate. The mixture was incubated at room temperature for 150 min and 125 𝜇L of 
Griess reagent was added. After 10 min, the absorbance was measured at 546 nm with a 
microplate reader (Tecan Sunrise, Austria). Curcumin (15.63 ̶ 250 𝜇g/mL) and ethanol 
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were used as a standard and control. The reaction mixture without Griess reagent was 
served as blank.  
 
   The percent inhibition of nitric oxide was calculated using the formula: 
 
 
 
 
   The concentration of extracts needed to scavenge 50 % of the nitric oxide 
(IC50) was estimated from the graph against the percentage of inhibition. All the tests 
were performed in triplicate, and the results were expressed as 𝜇g/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Absorbance control – (Absorbance sample or standard)     x 100% 
                                      Absorbance control 
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3.7.6 Superoxide Scavenging Activity Assay 
The superoxide scavenging activity was determined by PMS ̶ NADH with slightly 
modifications as described by Shukla et al. (2012). Superoxide radicals are generated in 
phenazine methosulphate-nicotinamide adenine (PMS ̶ NADH) systems by the oxidation 
of NADH and assayed by the reduction of NBT which can be measured at 570 nm. 
 
a. Preparation of 0.1M Tris-HCl Buffer 
The stock solution buffer was prepared 121.11 g Tris base was dissolved in 800 mL 
distilled water. The desired pH was adjusted with concentrated 1M HCl. The volume was 
adjusted to 1 L with distilled water. 0.1M was prepared by dilution of 5 mL of 1M Tris ̶ 
HCl buffer with 45 mL of distilled water. The desired pH (pH 8) was adjusted with 
concentrated 1M HCl. 
 
b. Preparation of 0.2 mM Nitro blue tetrazolium (NBT) solution 
The stock of 0.0016 g NBT was dissolved in 10 mL distilled water. 
 
c. Preparation of 0.5 mM Nicotinamide adenine dinucleotide (NADH) solution 
The stock of 0.0038 g NADH was dissolved in 10 mL Tris ̶ HCl buffer. 
 
d. Preparation of 25 µM phenazine methosulphate (PMS) solution 
The stock of 0.0007 g PMS was dissolved in 10 mL Tris ̶ HCl buffer. 
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e. Superoxide Radical Scavenging Assay  
   Quercetin and ascorbic acid were used as positive reference standard in 
superoxide radical scavenging activity assay. The red flowers of P. rubra extracts as well 
as standards, quercetin and ascorbic acid were tested at various concentrations of 15.63, 
31.25, 62.5, 125 and 250 𝜇g/mL. Reaction mixtures containing with PMS, NADH and 
NBT reaction system with quercetin, ascorbic acid or extracts were prepared according 
to Table 3.5. 
Table 3.5: Preparation of Reaction Mixtures for Superoxide Radical Scavenging 
Assay  
Concentration 
of Quercetin or 
Ascorbic acid 
or extracts 
(µg/mL) 
Volume of 
Quercetin or 
Ascorbic acid or 
extracts (µL) 
Volume of 
Nitro blue 
tetrazolium 
(NBT) 
(µL) 
Volume of 
Nicotinamide 
adenine 
dinucleotide 
(NADH)   (µL) 
Volume of 
Phenazine 
methosulphate 
(PMS) (µL) 
250 100 50 50 50 
125 100 50 50 50 
62.5 100 50 50 50 
31.25 100 50 50 50 
15.63 100 50 50 50 
 
   Briefly, fifty microlitre of NBT solution (0.2 mM in distilled water) with 
50 μL of NADH solution (0.5 mmol/L in 0.1 M Tris ̶ HCl, pH 8.0) and 100 μL of extract 
at each concentrations (15.63 ̶ 250 µg/mL) were mixed and treated with 50 μL of PMS 
solution (25 μM PMS in distilled water). The reaction mixture was incubated at room 
temperature for 10 min, and the absorbance at 570 nm was measured. Quercetin and 
ascorbic acid were used as positive control.  
 
   The percentage of scavenging was calculated by the formula: 
 
 
                                                              
  A1-A0     x 100% 
    A1 
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   The A1 was the absorbance of control (PMS ̶ NADH ̶ NBT reaction system 
without sample) at 517. A0 was the absorbance at 570 nm with sample at different 
concentrations with PMS ̶ NADH ̶ NBT reaction system. 
   The concentration of extracts needed to scavenge 50 % of the nitric oxide 
(IC50) was estimated from the graph against the percentage of inhibition. All the tests 
were performed in triplicate, and the results were expressed as 𝜇g/mL. 
 
3.8   Xanthine Oxidase Inhibitory Activity  
 
3.8.1   In vitro Model 
The XO inhibitory assay of the extracts from P. rubra red flowers was determined 
according to the procedure by Owen & Johns, (1999) and all these extracts from P.rubra 
flower were asayed spectrophotometrically under aerobic conditions. 
 
a. Preparation of 50 mM Phosphate buffer  
Phosphate buffer was prepared according to phosphate buffered saline system, are 
comprising the following reagents: potassium phosphate (monobasic) (KH2PO4), 
potassium phosphate (dibasic) (K2HPO4) and sodium Chloride (NaCl) 
Solution A : 1.36 g KH2PO4 (monobasic) was dissolved in 10 mL distilled water.  
Solution B : 8,70 g K2HPO4 (dibasic) was dissolved in 50 mL distilled water 
Solution C : 2.93 g NaCl was dissolved in 50 mL distilled water. 
6.3 mL of solution A, 43.7 mL of solution B and 30 mL of solution C were mixed and 
diluted with one liter of distilled water, then, the pH of buffer was adjusted to 7.5. 
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b. Preparation of Xanthine Oxidase (XO) enzyme solution  
5 mL Phosphate buffer was mixed w ith 1 unit/mL XO to produced 0.1 unit/mL stock of 
XO enzyme solution. 
1 mL from stock enzyme solution was mixed with 9 mL Phosphate buffer to produced 
0.01 unit/mL of XO enzyme solution. 
 
c. Preparation of Xanthine substrate (150mM) solution 
150 mM of xanthine was prepared by dissolving 0.456 g of xanthine in 20 mL phosphate 
buffer.  
 
d. Preparation of 1N of Hydrochloric acid (HCl) 
1N of HCl was prepared by mixed 82.898 mL HCl with 917.102 mL distilled water. 
 
e. Xanthine Oxidase Inhibition Activity in vitro Assay 
   Briefly, 1 ml of extracts at each concentration (62.5 to 500 µg/mL) was 
added to 2.9 mL of phosphate buffer, and 0.1 mL of enzyme solution (0.01 units/ mL in 
phosphate buffer, pH 7.5) which was prepared immediately before use. After pre ̶ 
incubation at 25°C for 15 min, the reaction was initiated by the addition of 2 mL of 150 
mM xanthine solution in the same buffer which acts as a substrate and this reaction 
mixture were incubated at 25 °C for 30 min. The reaction was stopped by addition of 1 
mL of 1N of HCl and the absorbance was measured at 290 nm by using UV 
spectrophotometer. Blank was prepared in the same way, but the enzyme solution added 
to the assay mixture after adding 1N HCl. The assay was done in triplicate. One unit of 
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XO is defined as the amount of enzyme required to produce 1 mmol of uric acid per min 
at 25 ̊ C.  
 
   XOI activity was evaluated as the percentage of inhibition of XO in this 
assay system calculated as: 
 
   Percentage of XO inhibitory activity = 
 
 
 
    
   Where A is the activity of the enzyme without test extract, B the control 
of A without test extract and enzyme, C and D are the activities of the test extract with 
and without XO, respectively. 
   The extracts were dissolved initially in DMSO followed by dilution with 
the buffer and the final concentration of DMSO was less than 0.5 %. Allopurinol, a known 
inhibitor of XO, was used as a positive control. 
 
 
 
 
 
 
 
 
 
(A – B)      x 100% 
(C – D) 
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3.8.2   In Vivo Model 
a. Rat For In Vivo Study 
   Male Sprague–Dawley (SD) rats (200 ± 30 g) were purchased from the 
University of Malaya Animal Experimental Unit. Rats were allowed to adapt to their 
environment before being used for experiments for at least 1 week.  They were maintained 
in a room controlled at 22–24 ºC with a relative humidity of 60 ± 5 % and a 12 hours 
light/ dark cycle (6:00 a.m– 6:00 p.m.). They were given standard chow and water ad 
libitum for the duration of the experiment. All experimental protocols described in this 
study were approved by Ethics Committee on Animal Experiment of University of 
Malaya Animal Care and Use Committee. (Ethic No ISB/12/09/2014/SSPMI (R)) 
 
b. Acute Toxicity Study 
   Acute toxicity study of PR ̶ ME extract of red flower P.rubra was 
performed in healthy adults Sprague Dawley (SD) rats according to OECD guidelines 
423 (Organization of Economic Cooperation and Development in 2001. A 6 of healthy 
adult male and female of SD rats were kept overnight fasted (16 hours) but had been 
allowed to free access to water prior to extract administration using an intragastric tube. 
After the administration of the extract, food but not water is withheld for further 3 to 4 
hours. The group of acute toxicity study of the present study were divided into two groups. 
Group 1 was treated orally with extract 2 g/kg body weight. Group 2 was treated orally 
with extract 4 g/kg body weight. The rats were observed at least once during the first 24 
hours which the special attention to first 4 hours and also daily thereafter for a period of 
14 days. Observations of first 4 hours should include changes in skin, fur, eyes and 
mucous membranes, and also respiratory, autonomic including defecation and urination, 
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the central nervous systems including spontaneous reaction, reactivity, touch response, 
pain response, and the behavior pattern including alertness, restlessness and irritability. 
Mortality, if any, is determined over a period of 2 weeks. The LD50 of the extract as per 
OECD guidelines falls under class four values with no sign of acute toxicity at 4 g/kg. 
The biological evaluation is carried out at 1/10th of maximum tolerated dose i.e. 400 
mg/kg body weight if no toxic signs observed in rats. 
 
c. In Vivo Study of Hyperuricemic Rats 
  The hypouricemic effect of PR ̶ ME extract from red flower P. rubra was 
examined by the methods reported previously by Liu et al. (2014) with slight 
modification. The hyperuricemic rat model was prepared by intraperitoneal (i.p) 
administration of potassium oxonate (PO) (280 mg/kg single dose) 1 hour before the final 
drug administration according to the method described by Carroll et al. (1971). PO for 
administration was suspended in 0.9 % NaCl solution and was given at day 1, 3, 5 and 7. 
Allopurinol solution, extract solutions and PO suspension were prepared according to the 
body weight measured immediately prior to drug administration. Reaction of allopurinol 
and P. rubra flower doses as hyporuricemic activity were determined based on 
conversion from human clinical practice. P. rubra extract and allopurinol were 
solubilized in 0.5 % carboxymethylcellulose (CMC) prior to drug administration. All 
drug and extract solution were given orally once daily at 11.00 ̶ 12.00 hour within seven 
consecutive days.  
   Briefly, the eight groups of SD rats are assigned to this experiment (n=6 
per group). Generally group 1, 2 and 3 are normal control groups which are not induced 
by PO. Then, hypouricemic and xanthine oxidase (XO) activity of methanol extract of P. 
rubra red flower extract was determined. Group 1 served as a baseline which do not 
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received any solvent vehicle and treatment within seven days of experiment. Group 2 
served as a vehicle control group of normal rat which only orally administered with 0.5 
% CMC solution for seven consecutive days. In group 3, the rats only receive test extract 
of P.rubra in high dose (400 mg/kg body weight) whereas in group 4 also only received 
test extract but in low dose (100 mg/kg body weight). Group 5 is hyperuricemia group 
served as gout control which intraperitoneally administered PO in a dose of 280 mg/kg 
without received any treatment. Group 6 and 7 received the oral gavage of anti- gout 
treatment with extract solution which high dose (400 mg/kg body weight) and low dose 
(200 mg/kg body weight), respectively. Group 8 is a standard drug control which received 
allopurinol (10 mg/kg body weight). The treatment for group 6, 7 and 8 were given after 
1 hour induced with PO. At the seventh day, two hours after PO ̶ induced action, the rats 
were anaesthetized with ketamine and xylazine (100 and 20 mg/kg, respectively), via 
intraperitoneal injection and whole blood samples will be collected by cardiac puncture 
1 hour later after final drug administration. The blood will be allowed to clot for 1 hour 
at ambient temperature and then centrifuge at 3500 rpm for 5 min to obtain the serum. 
The serum was stored at -40 ̊ C until assayed. 
Table 3.6. Summary of Classification Group of Rats and their Treatment in Seven 
Days of In Vivo Study  
Number of groups Classification  Treatment 
1 Baseline (N) No solvent vehicle, standard 
allopurinol and P.rubra 
extracts administration 
Non-induced with PO 
2 Vehicle Control (0.5 % 
CMC) 
0.5 % of CMC 
administration  
Non-induced with PO 
3 High Dose Control Group of 
P.rubra extracts (HC) 
400 mg/kg body weight of 
P.rubra extracts 
administration 
Non-induced with PO 
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4 Low Dose Control Group of 
P.rubra extracts (LC) 
200 mg/kg body weight of 
P.rubra extracts 
Non- induced with PO 
5 Hyperuricemic Gout Control 
Group (HGC) 
Intraperitoneally 
administration of PO in  dose 
of 280 mg/kg at day 1, 3, 5 
and 7 
No administration of P.rubra 
extracts and standard 
allopurinol 
6 High Dose Treatment Group 
of P.rubra Extracts (HPRT) 
Intraperitoneally 
administration of PO in  dose 
of 280 mg/kg at day 1, 3, 5 
and 7 
400 mg/kg body weight of 
P.rubra extracts 
administration 
7 Low Dose Treatment Group 
of P.rubra extracts (LPRT) 
Intraperitoneally 
administration of PO in  dose 
of 280 mg/kg at day 1, 3, 5 
and 7 
200 mg/kg body weight of 
P.rubra extracts 
administration 
8 Standard Drug Group 
Allopurinol (AP) 
Intraperitoneally 
administration of PO in  dose 
of 280 mg/kg at day 1, 3, 5 
and 7 
10 mg/kg body weight of 
standard drug allopurinol 
administration 
 
3.9 Body Weight Measurement of Rats 
   Fasting body weight (BW) of rats were monitored for every 2 days until 
final administration of drugs which held on day 0, day 1, day 3, day 5 and day 7. The in 
vivo studies were carried out in 16 hours fasted rats. 
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 3.10 Determination of Uric Acid Assay 
   Serum uric acid concentration was determined by enzymatic colorimetric 
method, using a standard diagnostic kit purchased from Sigma ̶ Aldrich (MAK077) 
according to manufacturer’s instructions. 
 
3.11 Determination of Xanthine Oxidase Assay in In Vivo Model 
   Rats livers were excised immediately after blood collection, washed in 0.9 
% cold saline and rapidly stored at - 80 °C until further experiment. Briefly, livers were 
homogenized in 4 mL of 80 mM sodium phosphate buffer (pH 7.4) and, then, the 
homogenate was centrifuged at 3500 g for 10 min at 4 °C. Lipid layer was carefully 
removed, and supernatant was further centrifuged at 10,000 g for 60 min at 4 °C. The 
final supernatant was used for xanthine oxidase enzyme activity assays. Xanthine oxidase 
activity was determined spectrophotometrically using standard kit purchased from 
Sigma- Aldrich (MAK078).  
 
3.12 Statistical Analysis 
   Results were expressed as the mean ± standard error (SEM) for the three 
independent experiments. Differences between extracts were analyzed by one way 
ANOVA followed by Duncan and Dunnett’s post hoc multiple comparison test at the 5 
% level (p < 0.05). The statistical program (SPSS 22.0 version, Chicago, IL, USA) was 
performed in the entire test. 
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CHAPTER 4 
RESULTS 
 
 4.1 Extraction Yields of Plumeria rubra flowers extracts 
   Dry powdered of red P. rubra flowers (22 g) was extracted with hexane, 
chloroform and methanol using a Soxhlet apparatus for 20 hours and the filtrate were 
evaporated under reduced pressure using rotary evaporator to remove the solvent.  From 
the extraction process, a variety of extraction yield of P. rubra flower extract from 
different solvents were obtained. The hexane (PR ̶ HE) extract was oily yellowish green 
with 3.27 % of yield, chloroform (PR ̶ CE) extract is a greenish brown with 3.03 % yield 
and methanol (PR ̶ ME) extract is dark purple powder with 10.76 % yield.  
   The water (PR ̶ WE) extract of P. rubra flowers was prepared by 
incubating the powder in water bath at 40 °C for 8 hours. The yield obtained after 
lyophilization was a dark red powder with 7.35 % yield. The extraction yields, in 
descending order, were: PR ̶ ME > PR ̶ WE > PR ̶ CE > PR ̶ HE. The yields of each 
extracts were summarized and presented in Table 4.1. 
Table 4.1 Yields of P. rubra flower extracts 
Extract Yield (%) 
PR-HE 3.27 
PR-CE 3.03 
PR-ME 10.76 
PR-WE 7.35 
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4.2 Detection of Phytochemical compounds from P.rubra Flowers 
a. Thin Layer Chromatography 
   The extracts of red P. rubra flowers was subjected to TLC method by 
using TLC aluminium silica gel 60 F254 sheets. The presence of chemical compound was 
detected by spraying sheets with specific visualization reagents such as dragendroff 
reagents, folin, vanilin- sulphuric acid and anisaldehyde-sulphuric acid. 30 % ethyl 
acetate in toluene (ethyl acetate: toluene / 3:7) was used as solvent system in TLC to 
separated one labelled compound in PR ̶ HE extract; PR ̶ HE1; three labelled compounds 
in PR ̶ CE extract; PR ̶ CE1, PR ̶ CE2 and PR ̶ CE3, seven labelled compounds in PR ̶ ME 
extract; PR ̶ ME1, PR ̶ ME2, PR ̶ ME3, PR ̶ ME4, PR ̶ ME5, PR ̶ ME6 and PR ̶ ME7;two 
labeled compound from PR ̶ WE extract; PR ̶ WE1 and PR ̶ WE2.  
   According to table 4.2 ̶ 4.5, the appearance of spots in the visible lights 
showed the presence of the pigments carotenoids which gave the colour of yellow, green 
and red as well as the flavonoids which gave the colour of red to purple. While the 
appearance of yellow to green spots under UV light showed the presence of the 
phytochemical with compound with native florescence which including polycyclic 
aromatic hydrocarbons, phenols and quinine.
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Table 4.2 TLC Profile of PR ̶ HE extract of P. rubra Red flowers using Solvent System (ethyl acetate: toluene / 3:7) 
 
 
 
 
 
 
 
  
 
 
 
Indication for Intensity of colour: 
+++ = Strong 
++ = Moderate 
+ = Weak 
-  = No colour observed 
 
 
 
 
 
 
 
 
Label 
Compounds 
 
 
 
Rf 
value 
x 100 
Observation Comment 
Colour 
under 
visible 
light 
Color 
under 
UV 
light 
 
Reagent 
Dragendorff’s 
Reagent 
Folin 
Reagent 
Vanilin ̶ 
H2SO4 
Reagent 
Anisaldehyde ̶ 
H2SO4 
PR ̶ HE1 69 - Yellow 
(++) 
- Blue (+) Blue (+) Blue (+) Phenol 
Essential 
oil 
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Table 4.3 TLC Profile of PR ̶ CE extract of P. rubra Red flowers using Solvent System (chloroform: methanol /9:1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indication for Intensity of colour: 
+++ = Strong 
++ = Moderate 
+ = Weak 
-  = No colour observed 
 
 
 
 
 
Label 
Compounds 
Rf 
Value 
x 100 
Observation Comment 
Visible 
light 
UV 
light 
Reagent 
Dragendorff’s 
Reagent 
Folin 
Reagent 
Vanilin ̶ 
H2SO4 
Reagent 
Anisaldehyde ̶ 
H2SO4 
PR ̶ CE1 64 Green 
(++) 
Yellow 
(++) 
- Blue 
(+++) 
Blue 
(++) 
Yellow (+) Phenol 
PR-CE2 58 Green 
(++) 
- - Blue 
(++) 
Red (+) - Phenol 
PR-CE3 54 Yellow 
(+) 
- - Blue (+) Red(+) Red (+) Phenol, 
Flavonoid 
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Table 4.4 TLC Profile of PR ̶ ME extract of P. rubra Red flowers using Solvent System (butanol: acetic acid: water / 
4:5:1) 
 
 
           Indication for Intensity of colour: 
+++ = Strong 
++ = Moderate 
+ = Weak 
- = No colour observed 
 
Label 
Compounds 
Rf 
Value 
x 100 
Observation Comment 
Visible 
light 
UV 
light 
Reagent 
Dragendorff’s 
Reagent 
Folin 
Reagent 
Vanilin ̶ 
H2SO4 
Reagent 
Anisaldehyde  ̶ H2SO4 
PR ̶ ME1 62 Red 
(++) 
Green 
(++) 
- Blue 
(+++) 
Blue (++) - Phenol 
PR ̶ ME2 58.1 - Yellow 
(+) 
- Blue (+) Green (+) - Phenol 
PR ̶ ME3 50.9 Yellow 
(++) 
Green 
(+) 
- Blue (++) Green 
(+++) 
Red (+++) Phenol, 
Flavonoid 
PR ̶ ME4 42.7 Red 
(+++) 
Yellow 
(+++) 
- Blue (++) Green 
(++) 
Yellow (+) Phenol 
PR ̶ ME5 32 Purple  
(+) 
Green 
(+) 
- Blue 
(+++) 
Green 
(++) 
Red (+) Phenol 
Flavonoid 
PR ̶ ME6 24.5 Green 
(+) 
- - Blue (++) Purple (+) - Phenol 
Terpenoid 
PR ̶ ME7 16.4 Yellow 
(+) 
- - Blue (+) Blue (+) - Phenol 
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Table 4.5 TLC Profile of PR ̶ WE extract of P. rubra Red flowers using Solvent System (butanol : acetic acid:water / 
3:1:1) 
 
 
 
 
 
 
 
 
 
 
 
Indication for Intensity of colour: 
+++            =        Strong 
++              =        Moderate 
+                =        Weak 
-                 =         No colour observed
Label 
Compounds 
Rf 
Value 
x 100 
Observation Comment 
Visible 
light 
UV 
light 
Reagent 
Dragendorff’s 
Reagent 
Folin 
Vanilin ̶ 
H2SO4 
Anisaldehyde ̶ 
H2SO4 
PR ̶ WE1 83 - Green 
(++) 
- Blue (+) Green 
(+) 
- Phenol 
PR ̶ WE2 58 - Yellow 
(+) 
- Blue (+) Red (+) - Phenol 
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 The thin layer chromatography of extracts from P. rubra flower (Table 
4.2 ̶ 4.5), showed the presence of essential oils, phenols, flavonoids and terpenoids. The 
detection of these compounds was carried out using chemical reagents. The formation of 
blue spot with Folin–Ciocalteu reagent indicated the presence of phenols. The labeled 
compounds; PR ̶ HE1 from the red flowers of PR ̶ HE extract P. rubra using ethyl acetate 
: toluene (3: 7, v/v) as a solvent system (Table 4.2), PR ̶ CE1 and PR ̶ CE2 from the red 
flowers of PR ̶ CE extract P. rubra by using methanol: chloroform (1: 9, v/v) as a solvent 
system (Table 4.3), the labeled compounds; PR ̶ ME1, PR ̶ ME2, PR ̶ ME3, PR ̶ ME4, 
PR ̶ ME5, PR ̶ ME6 and PR ̶ ME7 from the red flowers of PR ̶ ME extract P. rubra by 
using butanol: acetic acid: water (4: 5: 1, v/v) as a solvent system (Table 4.4), the labeled 
compounds PR ̶ WE1 and PR ̶ WE2 from the red flowers of PR ̶ WE extract P. rubra by 
using butanol: acetic acid: water (3: 1: 1, v/v) as a solvent system (Table 4.5) were 
detected as phenol.  
 The presence of terpenoids was carried out using vanillin ̶ sulphuric acid 
reagent with the formation of purple spot whereas the formation of red spots or other 
colour indicated the presence of phenols and flavonoids The labeled compound; PR ̶ HE1 
from the red flowers of PR ̶ HE extract P. rubra by using toluene: ethyl acetate (7: 3, v/v) 
as a solvent system (Table 4.2), the labeled compound; PR ̶ CE1 PR ̶ CE2 and PR ̶ CE3 
from the red flowers of PR-CE extract P. rubra by using methanol: chloroform (1: 9, v/v) 
as a solvent system (Table 4.3), the labeled compounds; PR ̶ ME1, PR ̶ ME2, PR ̶ ME3, 
PR ̶ ME4, PR ̶ ME5 and PR ̶ ME7 from the red flowers of PR ̶ ME extract P. rubra by 
using butanol: acetic acid: water (4: 5: 1, v/v) as a solvent system (Table 4.4) showed the 
presence of phenols and flavonoid whereas PR ̶ ME6 showed the presence of terpenoids. 
The labeled compounds PR ̶ WE1 and PR ̶ WE2 from the red flowers of PR ̶ WE extract 
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P. rubra by using using butanol: acetic acid: water (3: 1: 1, v/v) as a solvent system (Table 
4.5) were detected as phenol and flavonoids.  
 Anisaldehyde ̶ sulphuric acid reagent was carried out to all extracts of P. 
rubra red flower and the result showed the formation of blue spot indicated the presence 
of essential oils, whereas the red colour spots indicated the presence of flavonoid 
compound. The labeled compound; PR ̶ HE1 from the red flowers of PR ̶ HE extract P. 
rubra by using toluene: ethyl acetate (7: 3, v/v) as a solvent system (Table 4.2) was 
detected as essential oil, the labeled compound; PR ̶ CE3 from the red flowers of PR ̶ CE 
extract P. rubra by using methanol: chloroform (1: 9, v/v) as a solvent system (Table 4.3) 
and the labeled compounds; PR ̶ ME3, PR ̶ ME4, PR ̶ ME5, and PR ̶ ME7 from the red 
flowers of PR ̶ ME extract P. rubra by using butanol: acetic acid: water (4: 5: 1, v/v) as a 
solvent system (Table 4.4),) were detected as flavonoid.  
 Dragendroff reagent was carried out to all extracts of P.rubra red flower 
and the TLC profile indicated no formation of orange spots which could be describde that 
there are no alkaloids in the red flower of P.rubra. 
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b. Liquid Chromatography Mass Spectrometry combined with Mass Spectrometry  
(LCMS/MS) 
   Liquid Chromatography Mass Spectrometry combined with Mass 
Spectrometry (LCMS/MS) was used to determine the chemical compounds present in 
extract of red flowers of P.rubra. The methanol (PR ̶ ME) and water (PR ̶ WE) extracts 
have been fully screen with AB Sciex 3200QTrap LCMS/MS and fully scan with MS/MS 
data collection.  
i. PR ̶ ME extract  
Figure 4.1. LCMS/MS Full Chromatogram of PR ̶ ME extract from red flower of 
P. rubra 
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   Full LCMS chromatogram of PR ̶ ME shows 11 peaks separated at 
different time of 1.85’, 2.09’, 3.28’, 3.83’, 4.29’, 6.04’, 6.71’, 7.93’, 8.37’, 9.48’, and 
10.67’ (Figure 4.1). 11 phytochemical compounds were detected in PR ̶ ME extract of red 
flower P.rubra by LCMS/MS which comprised of 3 ̶ O ̶ caffeoylquinic acid, 5 ̶ O ̶ 
caffeoylquinic acid, chlorogenic acid, citric acid, kaempferol ̶ 3 ̶ O ̶ glucoside, kaempferol ̶ 
3 ̶ rutinoside, kaempferol, quercetin 3 ̶ O ̶ α ̶ L ̶ arabinopyranside, quercetin, quinic acid 
and rutin.  
   Table 4.6 showed the chemical structure of phytochemical compounds 
which had been detected by LCMS/MS in PR ̶ ME and these compounds were including 
of phenols and flavonoids. 
Table 4.6. Chemical Structures of Phytochemical Compounds in PR ̶ ME from Red 
flower of P.rubra Detected by LCMS/MS 
 
Phytochemical Compound Structure Group 
3 ̶ O ̶ caffeoylquinic acid 
 
Phenolic 
acid 
5 ̶ O ̶ caffeoylquinic acid 
 
Phenolic 
acid 
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Chlorogenic acid 
 
Phenolic 
acid 
Citric acid 
 
Organic 
acid 
Kaempferol  ̶ 3 ̶ O ̶ glucoside 
(Astragalin) 
 
Flavonoid 
Kaempferol ̶ 3 ̶ rutinoside 
(Nicotiflorin) 
 
Flavonoid 
Kaempferol 
 
Flavonoid 
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Quercetin 3 ̶ O ̶ α ̶ L ̶ 
arabinopyranoside 
 
Flavonoid 
Quercetin 
 
Flavonoid 
Quinic acid 
 
Phenolic 
acid 
Rutin 
 
Flavonoid 
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ii. PR ̶ WE extract 
 
Figure 4.2. LCMS/MS Full Chromatogram of PR ̶ WE extract from red flower of 
P.rubra 
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   Full LCMS chromatogram of water extract (PR ̶ WE) shows 8 peaks 
separated at different time of 1.86’, 2.73’, 3.28’, 3.94’, 5.38’, 6.04’, 6.70’ and 10.34’ 
(Figure 4.2). 7 phytochemical compounds were detected in water extract from red flower 
P.rubra by LCMS/MS which comprised of 1, 3 ̶   dicaffeoquinic acid, 3, 3 ̶ di ̶ O ̶ methyl 
ellagic acid, 3 ̶ O ̶ caffeyolquinic acid, kaempferol  ̶ 3 ̶ O ̶  glucoside, kaempferol ̶ 3 ̶ 
rutinoside, quercetin and quinic acid.   
   Table 4.7 showed the chemical structure of phytochemical compounds 
which had beed detected by LCMS/MS in PR ̶ WE and these compounds were including 
of phenols and flavonoids. 
Table 4.7. Chemical Structures of Phytochemical Compounds in PR ̶ WE from 
Red flower of P.rubra Detected by LCMS/MS 
Phytochemical 
Compound 
Structure Group 
1,3 ̶ dicaffeoquinic 
acid 
 
Phenolic acid 
3,3 ̶ di ̶ O ̶ 
methylellagic acid 
 
Phenolic acid 
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3 ̶ O ̶ Caffeoylquinic 
acid 
 
Phenolic acid 
Kaempferol ̶ 3 ̶ O ̶ 
glucoside (Astragalin) 
 
Flavonoid 
Kaempferol ̶ 3 ̶ 
rutinoside 
(Nicotiflorin) 
 
Flavonoid 
Quercetin 
 
Flavonoid 
Quinic acid 
 
Phenolic acid 
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Table 4.8 Summary of LCMS/MS Profile of P. rubra Red flowers extracts   
Extract of      P. 
rubra 
Tentative ID Reference Figure 
(Refer to 
Appendices) 
Retention Time 
PR ̶ ME 3 ̶ Caffeyolquinic acid Figure 8.01 2.09’ 
 5 ̶ Caffeoquinic acid Figure 8.02 Between 2.09’ and 
3.28’ 
 Chlorogenic acid Figure 8.03 Between 3.28’ and 
3.83’ 
 Citric acid Figure 8.04 Between 2.09’ and 
3.28’ 
 Kaempferol ̶ 3 ̶ O ̶ 
glucoside 
Figure 8.05 Between 4.29’ and 
6.04’ 
 Kaempferol ̶ 3 ̶ rutinoside Figure 8.06 Between 4.29’ and 
6.04’ 
 Kaempferol Figure 8.07 6.71’ 
 Quercetin 3 ̶ O ̶ α ̶ L ̶ 
arabinopyranoside 
Figure 8.08 Between 3.83’ and 
4.29’ 
 Quercetin Figure 8.09 6.04’ 
 Quinic acid Figure 8.10 1.85’ 
 Rutin Figure 8.11 4.29’ 
PR ̶ WE 1,3 ̶  Dicaffeoquinic acid Figure 8.12 Between 3.94’ and 
5.38’ 
 3,3 ̶ di ̶ O ̶ methylellagic 
acid 
Figure 8.13 6.70’ 
 3 ̶ Caffeoylquinic acid Figure 8.14 Between 3.28’ and 
3.94’ 
 Kaempferol ̶ 3 ̶ O ̶ 
glucoside 
Figure 8.15 Between 3.94’ and 
5.38’ 
 Kaempferol ̶ 3 ̶ rutinoside Figure 8.16 Between 3.94’ and 
5.38 
 Quercetin Figure 8.17 6.04’ 
 Quinic acid Figure 8.18 1.86’ 
 
 
 
 
 
 
 
 
 87 
 
4.3 Determination of Total Phenolic Contents from P. rubra flower extract 
 Total Phenolic Content (TPC) in different extracts of P. rubra flower were 
determined by Folin-Ciocalteu (FC) method using gallic acid as the standard. The 
absorbance values obtained at different concentrations of gallic acid was used for the 
construction of standard curve. TPC of the extracts was calculated from the regression 
equation of calibration curve (y=0.0019x + 0.0255, r2=0.9906) and expressed as mg gallic 
acid equivalents (GAE) per gram of sample in dry weight (mg/g) (Figure 4.3).  The values 
of TPC in hexane (PR ̶ HE), chloroform (PR ̶ CE), methanol (PR ̶ ME) and water (PR ̶ 
WE) extracts of P. rubra flower are presented in Table 4.9. The TPC range from 2.210 ± 
0.764 to 184.632± 0.765 mg equivalent gallic acid/g dry extract. The highest TPC have 
been detected in methanol (PR ̶ ME) extract which is 184.63 ± 0.77 mg equivalent gallic 
acid /g dry extract. 
 
 
 
Figure 4.3. Standard curve of gallic acid 
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4.4 Determination of Total Flavonoid Contents from P. rubra flower extracts 
 The Total Flavonoid Content (TFC) in different extracts were measured 
by using aluminium chloride method and used quercetin as standard equivalent. The 
result was expressed as mg quercetin equivalents (QAE) per gram of sample in dry weight 
(mg/g). The standard curve equation was obtained was y=0.0005x + 0.0294, r2=0.9819) 
as presented in Figure 4.4. The values of TFC in hexane (PR ̶ HE), chloroform (PR ̶ CE), 
methanol (PR ̶ ME) and water (PR ̶ WE) extracts of P. rubra flower are presented in Table 
4.9. The TFC range from 1.2± 1.16 to 203.2 ± 1.76 mg equivalent quercetin/g dry extract. 
The highest TFC have been detected in PR ̶ ME extract which is 203.20 ± 1.76 mg 
equivalent quercetin /g dry extract. 
 
Figure 4.4. Standard curve of quercetin 
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TABLE 4.9. TPC and TFC Values of P. rubra flower extracts. Each values is 
represented as mean ± SE (n = 3). The means with different lower case letters (a, b, 
c, and d) in the same column are significantly different at P < 0.05 (ANOVA, 
followed by Duncan’s multiple comparison test). 
Extracts of P. 
rubra 
Total Phenolic Content 
(mg GAE)/g dry extract 
Total Flavonoid Content 
(mg QE)/ g dry extract 
PR-HE 2.21 ± 0.76a 1.20 ± 1.16a 
PR-CE 66.21 ± 1.27b 119.20 ± 2.40b 
PR-ME 184.63± 0.77c 203.20 ± 1.76c 
PR-WE 110.79 ± 1.07d 163.20 ± 1.33d 
 
 
4.5 Antioxidant Activity Assay 
The purpose of this study was to evaluate the potential of P. rubra red flower extracts by 
using six different assays. 
4.5.1 2, 2 ̶ diphenyl ̶ 1 ̶ picrylhydrazyl (DPPH) Radical Scavenging Activity Assay 
   The potential antioxidant activity of PR ̶ HE, PR ̶ CE, PR ̶ ME and PR ̶ 
WE extracts of P. rubra flowers were determined on the basis of scavenging activity 
against the 2, 2 ̶ diphenyl ̶ 1 ̶ picrylhydrazyl (DPPH) radicals. The radicals were 
characterized by a typical deep purple colour and maximum absorbance in the range of 
515 ̶ 520 nm.  
   Ascorbic acid was chosen in this study since it is a powerful antioxidant 
and the synthetic antioxidants, such as butylated hydroxyanisole (BHA) and butylated 
hydroxytolune (BHT), have restricted use in foods as these synthetic antioxidants are 
suspected to be carcinogenic (Madhavi et al. 1996). 
    The scavenging effect of the ascorbic acid on DPPH radicals was 
presented in Table 4.10. 
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Table 4.10. Percentage of Inhibition of DPPH radical by standard reference, 
ascorbic acid. Percentage of inhibition are expressed as mean ± SE, (n=3) 
Concentration of Ascorbic acid  
(µg/mL) 
 Percentage of DPPH inhibition  
(%) 
 
15.63 36.23 ±0.003 
 
31.25 
 
52.79 ± 0.002 
 
62.5 
 
72.62 ± 0.002 
 
125 
 
80.66 ±0.004 
 
250 
 
85.57 ± 0.003 
 
   The radical scavenging activity of ascorbic acid increased with increasing 
concentrations. The percentage of inhibition of ascorbic acid ranged between 36.23 % at 
15.63 µg/mL to 85.57 % at 250 µg/mL. The percentage of inhibition of ascorbic acid at 
concentration 31.25, 62.5 and 125 µg/mL were 52.79 %, 72.62 % and 80.66 %, 
respectively. 
   The result of DPPH radical scavenging assay for PR ̶ HE, PR ̶ CE, PR ̶ ME 
and PR ̶ WE extracts of P. rubra red flower at concentration 15.63, 31.25, 62.5, 125 and 
250 µg/mL are shown in Table 4.11. 
Table 4.11. Radical scavenging activity of the hexane (PR ̶ HE), chloroform PR ̶ 
CE), methanol (PR ̶ ME) and water (PR ̶ WE) extracts of P. rubra flower in DPPH 
Radical Scavenging assay. Percentage of Inhibition (%) of extracts are expressed 
as mean ± SE, (n=3) 
Concentration of 
Sample Extracts 
(µg/mL) 
Percentage of DPPH Inhibition (%) 
 PR ̶ HE 
extract 
PR ̶ CE extract PR ̶ ME 
extract 
PR ̶ WE 
extract 
15.63 10.16 ± 0.002 14.26 ± 0.002 22.62 ± 0.001 18.53 ± 0.003 
31.25 16.89 ± 0.002 18.85± 0.002 35.25 ± 0.002 24.43 ± 0.002 
62.5 20.16± 0.002 23.77 ±0.003 52.62 ± 0.003 32.95 ± 0.004 
125 22.62 ± 0.002 24.43 ± 0.01 63.44 ± 0.001 44.26 ± 0.004 
250 29.34 ± 0.007 42.46 ± 0.002 70.98 ± 0.003 54.10 ± 0.002 
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   The percentage of inhibition of DPPH radical scavenging activity of PR ̶ 
HE, PR ̶ CE, PR ̶ ME and PR ̶ WE extracts of P. rubra flowers increased with increasing 
concentration of the extracts. Among the four extracts, PR ̶ ME extract exhibited the 
highest inhibition of DPPH scavenging activity with 70.98 % inhibition at the highest 
concentration tested, 250 µg/mL,   followed by PR ̶ WE, PR ̶ CE and PR ̶ HE extracts 
with 54.10 %, 42.46 % and 29.34 % inhibition of DPPH scavenging activity at the same 
concentration, respectively. 
   Figure 4.5 illustrated the dose response curve of DPPH radical scavenging 
activity of reference standard ascorbic acid, PR ̶ HE, PR ̶ CE, PR ̶ ME and PR ̶ WE extracts 
of P. rubra flower. 
 
Figure 4.5 DPPH radical scavenging capacity of flowers extracts from P. rubra. All 
analyses were performed in triplicate. Results expressed as mean ±SE (n=3) 
 
   In comparison with the positive reference standard ascorbic acid, the 
percentage inhibition of DPPH radical activity of the PR ̶ ME extract was approximately 
1.3 fold lesser compared to the ascorbic acid. From the Table 4.20, the IC50 of PR ̶ ME 
extract is 59.39 µg/mL while the IC50 standard ascorbic acid is 29.6 µg/mL. Nevertheless, 
there are no significant difference of DPPH scavenging activity between PR ̶ ME extract 
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and standard ascorbic acid (p<0.05). On the other hand, PR ̶ WE extract showed moderate 
scavenging activity at highest concentration tested which the IC50 value was 231.06 
µg/mL but show no significant difference with PR ̶ CE extract (p<0.05). The IC50 of PR ̶ 
HE and PR ̶ CE extract could not be determined at the concentration evaluated due to 
inhibition percentage of DPPH radical did not reach 50 % even at the highest 
concentration tested. The order of DPPH radical scavenging activity of extracts from P. 
rubra flowers was ascorbic acid > PR ̶ ME> PR ̶ WE> PR ̶ CE>PR ̶ HE. 
 
4.5.2 Ferric Reducing Anti ̶ Oxidant Power Assay 
The purpose of reducing power assay is to evaluate the ability of P. rubra red flower 
extracts to reduce Fe 3+ to Fe2+. 
   The FRAP assay is based on the reduction, at low pH, of a colorless ferric 
complex (Fe3+-tripyridyltriazine) to a blue-colored ferrous complex (Fe2+ ̶ 
tripyridyltriazine) by the action of electron-donating antioxidants. The reduction is 
monitored by measuring the change of absorbance at 595 nm. Ferrous sulphate (Fe2SO4) 
was used as the reference standard. The FRAP value was evaluated according to the linear 
regression between reference standard solutions and absorbance at 595 nm and the results 
were estimated as mmol Fe2+ /g of dry extract. Standards of known Fe (II) concentrations 
(FeSO4·7H2O) were run in triplicate using several concentrations between 200 and 1000 
μg/mL (200, 400, 600, 800 and 1000 μg/mL).   Figure 4.6 showed the linear regression 
of standard reference. In this assay, the reducing capacity of the extracts of P.rubra flower 
was calculated with reference to the reaction signal given by a Fe2+ solution. 
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Figure 4.6. Standard curve of ferrous sulphate as a standard in the FRAP assay. 
 
   The ferric reducing power assay for PR ̶ HE, PR ̶ CE, PR ̶ ME and PR ̶ WE 
extracts of P. rubra red flower at concentrations 0.1 mg/mL and 1 mg/mL are shown in 
Figure 4.7. The result as depicted in Figure 4.7 and Table 4.20, were expressed as milimol 
ferrous iron equivalents per g of sample. 
   The reducing power of all four extracts increased with increasing 
concentrations. The order of FRAP value was PR ̶ ME extract > PR ̶ WE extract > PR ̶ 
CE extract > PR ̶ HE extract. In accordance with DPPH radical scavenging ability (Table 
4.20), the highest FRAP value was detected in PR ̶ ME extract of P. rubra flower with 
4.95 ± 0.004 (mmol Fe2+ /g of dry extracts) followed by PR ̶ WE extract of with 3.49 ± 
0.03 (mmol Fe2+ /g of dry extracts) in P. rubra flower. The reducing ability of PR ̶ HE 
with 0.22 ± 0.003 mmol Fe2+ /g of dry extracts was almost negligible. The moderate 
reducing power was detected in the medium polar solvent PR ̶ CE extract with 0.97 ± 
0.004 mmol Fe2+/g of dry extracts. 
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Figure 4.7 Ferric Reducing power of the P. rubra extracts 
 
 
4.5.3 Metal Chelating Activity Assay 
The purpose of metal chelating assay is to evaluate the ability of P. rubra red flower 
extracts to chelate ferrous ion and preventing the formation of ferrozine ̶ Fe2+ complex. 
   EDTA (Ethy lenediaminetetra acetic acid) was used as the reference 
standard in the metal chelating assay. Table 4.12 shows the percentage of inhibition of 
Ferrozine ̶ Fe2+ complex formation by standard EDTA at concentration of 15.63, 31.25, 
62.5, 125 and 250 µg/mL. 
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Table 4.12. The Percentage of inhibition Ferrozine ̶ Fe2+ complex formation by 
EDTA in metal chelating assay 
Concentration of EDTA  
(µg/mL) 
Percentage of Inhibition Ferrozine – 
Ferum2+ complex (%) 
 
15.63 28.45 ± 0.004 
31.25 45.19 ±0.002 
62.5 55.65 ±0.005 
125 71.97 ±0.009 
250 92.89 ±0.003 
 
   The percentage of inhibition of Ferrozine ̶ Fe2+ complex formation by 
EDTA increased with increasing concentrations. Very strong chelating activity was 
observed at highest concentration 250 µg/mL with 92.89 % chelating activity. The 
percentage of chelating activity at concentration of 15.63, 31.25, 62.5 and 125 µg/mL 
were 28.45 %, 45.12 %, 55.65 % and 71.97 %, respectively. 
   The result of metal chelating assay for PR ̶ HE, PR ̶ CE, PR ̶ ME and PR ̶ 
WE extracts of P.rubra red flower are shown in Table 4.13 and were obtained at 
concentrations 15.63, 31.25  62.5, 125 and 250 µg/mL. 
Table 4.13. Metal chelating activities by hexane (PR ̶ HE), chloroform (PR ̶ CE), 
methanol (PR ̶ ME) and water (PR ̶ WE) extracts of P.rubra flower in metal 
chelating assay. All percentage of inhibition (%) are expressed as mean ± SE, (n=3) 
Concentration 
of Extracts 
(µg/mL) 
Percentage Inhibition of metal chelating (%) 
 PR ̶ HE 
Extract 
PR ̶ CE 
 Extract 
 PR ̶ ME 
Extract 
 PR ̶ WE 
Extract 
15.63 4.60 ±0.004 7.53±0.007 14.64±0.01 7.11±0.01 
31.25 13.81±0.004 8.79±0.008 23.01±0.004 14.64±0.003 
62.5 18.83 ±0.001 21.76±0.0003 33.05±0.01 27.20±0.002 
125 21.34±0.007 33.89±0.01 46.03±0.001 35.15±0.01 
250 35.57±0.001 43.10±0.0003 67.36±0.01 50.21±0.003 
 
   The PR ̶ ME extract was the highest metal chelator compared to other 
extracts with percentage of inhibition of 67.36 %, 46.03 %, 22.05 % and 23.01 % and 
14.64 % at 250, 125, 62.5, 31.25 and 15.63 µg/mL, respectively. The metal chelating 
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activities of PR ̶ WE extracts showed moderate activity with metal chelating activity 
inhibition of 50.21 % at highest concentration of 250 µg/mL then followed with PR ̶ CE 
extract with metal chelating activity at 43.10 % at the same concentration. The PR ̶ HE 
extract exhibited the weak metal chelating activity with only 35.57 % at concentration of 
250 µg/mL. 
   Figure 4.8 illustrated the dose ̶ response curves presenting the metal 
chelating activities of all four extracts of P. rubra flower and EDTA as a positive 
standard. 
 
Figure 4.8. Metal chelating activity of P. rubra flower extracts and standard 
EDTA. 
 
   The percentage of inhibition of ferrozine –Fe2+ complex by all extracts and 
also including reference standard, EDTA were increased with increasing concentrations. 
EDTA possess the excellent of inhibition of Ferrozine ̶  Fe2+ as it showed the best IC50 
value which was 56.16 µg/mL. The IC50 value of PR ̶ ME extract was 185.56 µg/mL 
while the IC50 value of PR ̶ WE extract was 248.96 µg/mL as shown in Table 4.20. 
Moreover, the PR ̶ ME extract possess highest significantly of metal chelating activity 
compared to other three extracts of flowers from P.rubra (p<0.05). The IC50 of PR ̶ HE 
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and PR ̶ CE extract could not be determined at the concentration evaluated due to 
inhibition percentage of metal chelating activity did not reach 50 % even at the highest 
concentration tested. The order of metal chelating activity of extracts from P. rubra 
flowers was EDTA> PR ̶ ME> PR ̶ WE> PR ̶ CE>PR ̶ HE. 
 
4.5.4 Hydrogen Peroxide Radical Scavenging Activity Assay 
The purpose of hydrogen peroxide scavenging assay is to evaluate the ability of extracts 
from P.rubra red flowers to scavenge hydrogen peroxide radical. 
   Ascorbic acid was used as the reference standard in the hydrogen peroxide 
radical scavenging assay. Table 4.14 shows the percentage of inhibition of hydrogen 
peroxide radical by standard ascorbic acid at concentration of 15.63, 31.25, 62.5, 125 and 
250 µg/mL. 
Table 4.14. The Percentage of inhibition hydrogen peroxide radical by ascorbic 
acid in hydrogen peroxide radical scavenging assay. 
Concentration of Ascorbic acid 
 (µg/mL) 
Percentage of Inhibition of Hydrogen peroxide  
(%) 
15.63 26.94±0.03 
31.25 41.82±0.01 
62.5 49.21±0.04 
 125 60.06±0.01 
250 70.63±0.007 
 
   The radical scavenging activity of ascorbic acid increased with increasing 
concentrations. The percentage of inhibition of ascorbic acid ranged between 26.94 % at 
15.63 µg/mL to 70.63 % at 250 µg/mL. The percentage of inhibition of ascorbic acid at 
concentration 31.25, 62.5 and 125 µg/mL were 41.82 %, 49.21 % and 60.06 %, 
respectively. 
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   The result of hydrogen peroxide radical scavenging assay for PR ̶ HE, PR ̶ 
CE, PR ̶ ME and PR ̶ WE extracts of P.rubra red flower at concentration 15.63, 31.25, 
62.5, 125 and 250 µg/mL are shown in Table 4.15. 
Table 4.15. Radical scavenging activity of the hexane (PR ̶ HE), chloroform (PR ̶ 
CE), methanol (PR ̶ ME) and water (PR ̶ WE) extracts of P. rubra flower in 
Hydrogen peroxide Radical Scavenging assay. Percentage of Inhibition (%) of 
extracts are expressed as mean ± SE, (n=3) 
Concentration of 
Extracts (µg/mL) 
Percentage of Hydrogen peroxide Inhibition (%) 
 PR ̶ HE 
extract 
PR ̶ CE  
extract 
PR ̶ ME 
extract 
PR ̶ WE 
extract 
15.63 0.19±0.03 3.56±0.04 6.27±0.007 13.38±0.01 
31.25 0.28±0.07 8.05±0.009 18.71±0.02 20.58±0.02 
62.5 6.92±0.003 16.00±0.04 26.29±0.02 25.54±0.01 
125 12.82±0.005 19.27±0.04 41.25±0.02 32.65±0.02 
250 17.03±0.007 27.78±0.036 50.33±0.008 44.99±0.017 
 
   The percentage of inhibition of hydrogen peroxide radical scavenging 
activity of PR ̶ HE, PR ̶ CE, PR ̶ ME and PR ̶ WE extracts of P.rubra flowers increased 
with increasing concentration of the extracts. Among the four extracts, PR ̶ ME extract 
exhibited the highest percentage of hydrogen peroxide scavenging activity with 50.33 % 
inhibition at concentration of 250 µg/mL followed by PR ̶ WE, PR ̶ CE and PR ̶ HE 
extracts with 44.99 %, 27.78 % and 17.03 % at the same concentration, respectively. 
   Figure 4.9 illustrated the dose ̶ response curve of hydrogen peroxide 
radical scavenging activity of reference standard ascorbic acid, PR ̶ HE, PR ̶ CE, PR ̶ ME 
and PR ̶ WE extracts of P. rubra flower. 
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Figure 4.9. Hydrogen peroxide scavenging activity of P. rubra flower extracts and 
standard ascorbic acid. 
 
   In comparison with the positive reference standard ascorbic acid, PR ̶ ME 
extract of P. rubra flower showed lower percentage inhibition of hydrogen peroxide 
activity at all concentrations. The IC50 of PR ̶ ME extract is 248.38 µg/mL as shown while 
the IC50 standard ascorbic acid was 104.07 µg/mL as shown in Table 4.20. The IC50 of 
PR ̶ HE, PR ̶ CE and PR ̶ WE extracts could not be determined at the concentration 
evaluated due to inhibition percentage of hydrogen peroxide radical did not reach 50 % 
even at the highest concentration tested. Nevertheless, there are no significant difference 
(p< 0.05) of hydrogen peroxide scavenging activity between PR ̶ ME extract with the 
standard, ascorbic acid as well as with PR ̶ WE extract. The order of hydrogen peroxide 
scavenging activity of extracts from P.rubra flowers was ascorbic acid > PR ̶ ME> PR ̶ 
WE > PR ̶ CE > PR ̶ HE. 
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4.5.5 Nitric Oxide Radical Scavenging Activity Assay 
The purpose of nitric oxide scavenging assay is to evaluate the ability of P. rubra red 
flower extracts to scavenge the nitric oxide radical and compete with oxygen leading to 
reduced production of nitrite ions. Nitric oxide scavenging capacity is determined by the 
decrease in the absorbance at 546 nm. 
   Curcumin was used as the reference standard in the nitric oxide 
scavenging assay. Table 4.16 shows the percentage of inhibition of nitric oxide radical by 
standard curcumin at concentration of 15.63, 31.25, 62.5, 125 and 250 µg/mL. 
Table 4.16. The Percentage of inhibition nitric oxide radical by curcumin in nitric 
oxide radical scavenging assay. 
Concentration of Curcumin 
 (µg/mL) 
Percentage of Inhibition Nitric Oxide radical 
 (%) 
 
15.63 48.05 ±0.01 
31.25 62.99 ±0.01 
62.5 73.70 ±0.01 
125 82.47 ±0.01 
250 87.99 ±0.01 
 
  The percentage of inhibition of nitric oxide radical by curcumin increased with 
increasing concentrations. The strong scavenging activity was observed at highest 
concentration tested with 87.99 % chelating activity. The percentage of scavenging 
activity at concentration of 15.63, 31.25, 62.5 and 125 µg/mL were 48.05 %, 62.99 %, 
73.70 % and 82.47 %, respectively.  
   The result of nitric oxide radical scavenging activity assay for PR ̶ HE, PR ̶ 
CE, PR ̶ ME and PR ̶ WE extracts of P. rubra red flower are shown in Table 4.17 and 
were obtained at concentrations 15.63, 31.25, 62.5, 125 and 250 µg/mL. 
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Table 4.17. Nitric Oxide scavenging activities by hexane (PR ̶ HE), chloroform 
(PR ̶ CE), methanol (PR ̶ ME) and water (PR ̶ WE) extracts of P. rubra flower in 
nitric oxide scavenging assay. All percentage of inhibition (%) are expressed as 
mean ± SE, (n=3) 
Concentration 
of Extracts 
(µg/mL) 
Percentage Inhibition of nitric oxide radical (%) 
 PR-HE 
Extract 
PR-CE  
Extract 
 PR-ME 
Extract 
 PR-WE 
Extract 
15.63 17.53±0.02 25.65±0.01 30.20±0.003 28.90±0.01 
31.25 26.62±0.004 33.77±0.004 37.01±0.01 40.58±0.01 
62.5 31.49±0.004 38.31±0.004 50.33±0.01 42.86±0.01 
125 35.39±0.004 40.58±0.01 62.01±0.01 53.57±0.002 
250 37.99±0.004 44.16±0.003 69.48±0.01 55.52±0.01 
 
   The PR ̶ ME extract shown the highest scavenging activity against nitric 
oxide radical compared to other three extracts with percentage of inhibition of 69.48 %, 
62.01 %, 50.33 % and 37.01 % and 30.20 % at 250, 125, 62.5, 31.25 and 15.63 µg/mL, 
respectively. The PR ̶ WE extract exhibited moderate scavenging activity against nitric 
oxide radical with percentage of inhibition of 55.52 %, 53.57 %, 42.86 %, 40.58 % and 
28.90 % at 250, 125, 62.5, 31.25 and 15.63 µg/mL, respectively. The PR ̶ HE and PR ̶ CE 
extract exhibited the weak nitric oxide scavenging activity with only 37.99 % and 44.16 
% at concentration of 250 µg/mL, respectively. The nitric oxide scavenging activities of 
PR ̶ WE extract showed moderate activity with scavenging activity of 55.52 % at 
concentration of 250 µg/mL. 
   Figure 4.10 illustrated the dose ̶ response curves presenting the scavenging 
activities of all four extracts of P. rubra flower and curcumin as a positive standard 
against nitric oxide radical. 
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Figure 4.10. Nitric Oxide Scavenging activity of P. rubra flower extracts and 
standard Curcumin. 
 
   In comparison with the positive reference standard curcumin, PR ̶ ME 
extract of P. rubra flower showed lower percentage of nitric oxide inhibition at all 
concentrations. The IC50 of PR ̶ ME extract is 62.10 µg/mL as shown while the IC50 
standard curcumin was 24.81 µg/mL as shown in Table 4.20. Nevertheless, PR ̶ ME 
extract showed the significant higher of nitric oxide scavenging activity compared the 
other three extracts of flower from P. rubra (p<0.05). The PR ̶ WE extract showed 
moderate scavenging activity which was 116.67 µg/mL. The IC50 of PR ̶ HE and PR ̶ CE 
extract could not be determined at the concentration evaluated due to inhibition 
percentage of nitric oxide radical did not reach 50 % even at the highest concentration 
tested. The order of nitric oxide scavenging activity of extracts from P. rubra flowers was 
curcumin > PR ̶ ME > PR ̶ WE > PR ̶ CE > PR ̶ HE. 
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4.5.6 Superoxide Radical Scavenging Activity Assay 
The purpose of superoxide radical scavenging assay is to determine the capability of P. 
rubra red extracts to scavenge superoxide anion derived from dissolved oxygen by PMS ̶ 
NADH coupling reaction reduces NBT in this system. The inhibition of superoxide 
radicals was measured in absorbance at 570 nm. 
   Ascorbic acid and quercetin were used as the reference standard in the 
superoxide radical scavenging assay. Table 4.18 shows the percentage of inhibition of 
superoxide radical by standard quercetin and ascorbic acid at concentration of 15.63, 
31.25, 62.5, 125 and 250 µg/mL. 
Table 4.18. The Percentage of superoxide inhibition by quercetin and ascorbic acid 
in superoxide radical scavenging Assay 
Concentration of 
Quercetin 
(µg/mL) 
Percentage of 
Superoxide 
Inhibition 
 (%) 
Concentration of 
Ascorbic acid (µg/ml) 
Percentage of 
Superoxide Inhibition  
(%) 
 
15.63 23.41 ±0.01 15.63 27.13±0.01 
31.25 29.77 ±0.004 31.25 44.34±0.004 
62.5 49.61 ±0.01 62.5 61.86±0.01 
125 64.34 ±0.01 125 78.14±0.01 
250 74.88 ±0.003 250 82.48±0.004 
 
   The percentage of superoxide radical inhibition by ascorbic acid and 
quercetin increased with the increasing concentrations. As a standard, ascorbic acid 
exhibited better scavenging activity of superoxide anions compared with standard, 
quercetin. Ascorbic acid showed good percentage of superoxide radical scavenging 
activities with 82.48 % at highest concentration tested, 250 µg/mL.  However, quercetin 
only reached 74.88 % of superoxide anions scavenging activities at highest concentration 
tested. As depicted in Table 4.18, the percentage superoxide scavenging activity of 
ascorbic acid at concentration of 15.63, 31.25, 62.5 and 125 µg/mL of quercetin were 
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27.13 %, 44.34 %, 61.86 % and 78.14 %, respectively whereas quercetin at concentration 
of 15.63, 31.25, 62.5 and 125 µg/mL were 23.41 %, 29.77 %, 49.61 % and 64.34 %, 
   The result of superoxide radical scavenging assay for PR ̶ HE, PR ̶ CE, 
PR ̶ ME and PR ̶ WE extracts of P. rubra flower at concentration 15.63, 31.25, 62.5, 125 
and 250 µg/mL are shown in Table 4.19. 
Table 4.19. Superoxide radical scavenging activity of the hexane (PR ̶ HE), 
chloroform (PR ̶ CE), methanol (PR ̶ ME) and water (PR ̶ WE) extracts of P. rubra 
flower in superoxide radical scavenging assay. Percentage of inhibition (%) of 
extracts are expressed as mean ± SE, (n=3) 
Concentration of   
Extracts (µg/ml) 
Percentage of Superoxide Inhibition (%) 
 PR ̶ HE extract PR ̶ CE extract PR ̶ ME extract PR ̶ WE extract 
15.63 2.48 ±0.01 15.19±0.02 31.31±0.003 19.07±0.01 
31.25 8.06 ±0.01 21.55±0.002 48.06±0.01 27.44±0.003 
62.5 20.47 ±0.01 31.16±0.004 57.05±0.004 48.99±0.003 
125 26.82 ±0.0003 38.45±0.01 68.53±0.001 63.41±0.003 
250 36.74 ±0.001 50.08±0.01 79.54±0.01 70.85±0.004 
 
   From the Table 4.19, the percentage of superoxide radical scavenging 
activity of PR ̶ HE, PR ̶ CE, PR ̶ ME and PR ̶ WE extracts of P, rubra flowers increased 
with increasing concentration of the extracts. Among the four extracts, PR ̶ ME extract 
exhibited the highest scavenging activity of superoxide radical with 79.54 % inhibition at 
250 µg/mL followed by PR ̶ WE, PR ̶ CE and PR ̶ HE extracts with 70.85 %, 50.08 % 
and 36.74 % inhibition of superoxide scavenging activity at the same concentration, 
respectively. 
   Figure 4.11 illustrated the dose response curve of superoxide radical 
scavenging activity of both reference standards including quercetin and ascorbic acid, as 
well as sample extracts of P.rubra flower which are PR ̶ HE, PR ̶ CE, PR ̶ ME and PR ̶ 
WE. 
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Figure 4.11. Superoxide scavenging activity of P. rubra flower extracts and 
standard, quercetin and ascorbic acid. 
 
   In comparison with the positive reference standard ascorbic acid, PR ̶ ME 
extract of P. rubra flower showed lower percentage inhibition of superoxide radical at 
concentrations of 62.5, 125 and 250 µg/mL with 57.05 %, 68.53 % and 79.54 %, 
respectively whereas ascorbic acid presented 61.86 %, 78.14 %  and 82.48 %, inhibition 
of superoxide radicals at the same concentration, respectively. As depicted in Figure 4.11, 
PR ̶ ME extract presented slightly higher percentage of superoxide radical scavenging 
activity at the concentration of 15.53 µg/mL and 32.5 µg/mL with 31.32 % and 48.06 %, 
respectively compared to ascorbic acid showed percentage of superoxide scavenging 
activity with 27.13 % and 44.34 % at the same concentration, respectively. In addition, 
the IC50 of PR ̶ ME extract was 54.77 µg/mL while the IC50 standard ascorbic acid was 
50.52 µg/mL as shown in Table 4.20. Nevertheless, there are no significant difference of 
superoxide scavenging activity between the PR ̶ ME extract with the standard, ascorbic 
acid (p<0.05).  
   Surprisingly, PR ̶ ME extract exhibited significantly higher of superoxide 
scavenging activity compared to standard quercetin at all concentration tested (p<0.05). 
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Moreover, there are no significant difference of superoxide scavenging activity between 
PR ̶ WE extract and the standard quercetin. From the Figure 4.11, PR ̶ ME extract 
presented the percentage of superoxide scavenging activity with 79.54 % at the highest 
concentration tested, 250 µg/mL, whereas standard quercetin only reached percentage of 
superoxide scavenging activity with 74.88 % at the same concentration. According to 
Table 4.20, the IC50 of standard quercetin was 97.13 µg/mL compared to IC50 of PR ̶ ME 
extract was 54.773 µg/mL.  
   Among the four extracts, PR ̶ ME extract exhibited the significant highest 
scavenging activity of superoxide radical (p<0.05).The PR ̶ WE extract showed moderate 
scavenging activity of superoxide followed with PR ̶ CE extract at the highest 
concentration tested which showed 70.85 % and 50.08 %, respectively. The IC50 of PR ̶ 
WE was 98.563 µg/mL while the IC50 of PR ̶ CE extract was 249.611 µg/mL. The IC50 
of PR ̶ HE extract could not be determined at the concentration evaluated due to inhibition 
percentage of hydrogen peroxide radical did not reach 50 % even at the highest 
concentration tested. Therefore, the order of superoxide scavenging activity in present 
study was ascorbic acid > PR ̶ ME extract > quercetin > PR ̶ WE > PR ̶ CE extract> PR ̶ 
HE extract. 
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Table 4.20. IC50 and FRAP values of antioxidant activities of P. rubra flower 
extracts. Each value in the table is represented as mean ± SE (n = 3).The means 
with different lower case letters (a, b, c, and d) in the same column are significantly 
different at P < 0.05 (ANOVA, followed by Duncan’s multiple comparison 
test).ND: not detected. 
Extracts / 
Positive 
Control 
DPPH 
(IC50 
µg/mL) 
FRAP 
(mmol 
Fe2+ /g 
extract) 
Metal 
Chelating 
(IC50 
µg/mL) 
Hydrogen 
Peroxide 
(IC50 
µg/mL) 
Nitric 
Oxide 
(IC50 
µg/mL) 
Superoxide 
(IC50 
µg/mL) 
PR-HE ND 0.220 ± 
0.003 a 
ND ND ND ND 
PR-CE ND 0.973 ± 
0.004 b 
ND ND ND 249.61± 
0.01 c 
PR-ME 59.39± 
0.003 a 
4.95 ± 
0.004 c 
185.56 ± 
0.01 a 
248.38± 
0.004 a,b,c 
62.10 ± 
0.01 a 
54.77 ± 
0.004 a,d 
PR-WE 231.06 ± 
0.002 b, c 
3.5 ± 0.03 
d 
248.96 ± 
0.003 b 
ND 116.67± 
0.002 b 
98.56± 
0.004 b, e 
Ascorbic 
acid 
29.6 ± 
0.002  d 
_ _ 104.07 ± 
0.01 a, b, c 
_ 50.52 ± 
0.01 a, d 
EDTA _ _ 56.157± 
0.004 c 
_ _ _ 
Curcumin _ _ _ _ 24.81± 
0.01  c 
- 
Quercetin _ _ _ _ _ 97.14± 0.01 
b, e 
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4.6. Xanthine Oxidase Inhibitory Activity in in vitro Model 
The purpose of this study is to determine the capability of extracts from P. rubra red 
flowers to inhibit the activity of enzyme, xanthine oxidase (XO) in producing uric acid in 
in vitro model. XO inhibitory activity was assayed spectrophotometrically under aerobic 
conditions and the degree of enzyme inhibition was determined by measuring the increase 
in absorbance at 295 nm associated with uric acid formation. 
   Allopurinol, a known inhibitor of XO, was used as a positive reference 
standard due to prescription for many years of this drug to treat gout disease. Allopurinol 
has high capability to inhibit action of xanthine oxidase and catalyses the oxidation of 
xanthine and hypoxanthine into uric acid. Table 4.21 showed the percentage of inhibition 
of XO by standard allopurinol at concentration of 25, 50, 100 and 200 µg/mL. 
Table 4.21. The percentage of inhibition of XO by standard reference, allopurinol 
in in vitro Assay. All percentage of inhibition (%) are expressed as mean ± SE, 
(n=3) 
Concentration of allopurinol 
 (µg/mL) 
Percentage of XO inhibition 
 (%) 
 
25 77.15 ±0.71 
50 80.93 ±0.16 
100 86.63 ± 0.06  
200 90.81 ± 3.47 
 
   The XO inhibition activity of allopurinol showed strong inhibition activity 
and this activity was increased with increasing concentrations. The percentage of XO 
inhibition of allopurinol ranged between 77.15 % at 25 µg/mL to 90.81 % at 200 µg/mL. 
The percentage of XO inhibition of allopurinol at concentration 50 µg/mL and 100 µg/mL 
were 80.93 % and 86.63 %, respectively. 
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   The influenced of the P. rubra red flower extracts on XO activity 
evaluated by decreased production of uric acid, which was measured 
spectrophotometrically. The result of XO inhibitory activity assay for all extracts of P. 
rubra flower at concentration 25, 50, 100, and 200µg/mL are shown in Table 4.20. 
Table 4.22. XO Inhibition Activitity of hexane (PR ̶ HE), chloroform (PR ̶ CE), 
methanol (PR ̶ ME) and water (PR ̶ WE) extracts of P. rubra flower in vitro assay. 
All percentage of inhibition (%) are expressed as mean ± SE, (n=3) 
Concentration of  
Extracts (µg/mL) 
Percentage of XO Inhibition (%) 
 PR ̶ HE 
Extract 
PR ̶ CE  
Extract 
PR ̶ ME  
Extract 
PR ̶ WE   
Extract 
25 
50 
100 
200 
29.95 ± 2.67 
39.93± 3.35 
50.8± 1.23 
61.21± 2.26 
42.99 ± 1.83 
50.94± 5.28 
61.57 ± 3.2 
63.96± 2.76 
52.27 ± 2.00 
68.84 ± 1.69 
79.89 ± 0.60 
84.39 ± 1.12 
49.66 ± 3.15 
60.5 ± 2.00 
64.53± 4.29 
76.15 ± 2.69 
 
   Figure 4.12 illustrate the different effect of four different concentration of 
PR ̶ HE, PR ̶ CE, PR ̶ ME and PR ̶ WE extract of P. rubra flower compared to standard 
positive control, allopurinol in inhibition of xanthine oxidase enzyme. All the four 
extracts showed XO inhibitory activity in dose dependent manner. As shown in Figure 
4.12, all extracts were capable to inhibited XO ̶ induced superoxide formation at the 
highest concentration tested, 200 µg/mL. The order of XO inhibition activity in present 
study was allopurinol > PR ̶ ME extract > PR ̶ WE > PR ̶ CE extract> PR ̶ HE extract. 
From the Table 4.20, the percentage of inhibition of XO activity by PR ̶ HE, PR ̶ CE, PR ̶ 
ME and PR ̶ WE extracts of P. rubra flowers increased with increasing concentration of 
the extracts. Among the four extracts, PR ̶ ME extract exhibited the highest inhibition of 
XO activity with 52.27 % inhibition at concentration of 25 µg/mL followed by PR ̶ WE, 
PR ̶ CE and PR ̶ HE extracts with 49.66 %, 42.99 % and 29.95 % inhibition of XO activity 
at the same concentration, respectively. PR ̶ ME extract also appeared as the strongest 
XO inhibitor compared to other four extracts with highest percentage of XO inhibition in 
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all concentration tested which was 68.84 % at concentration of 50 µg/mL, 79.89 % at 
concentration of 100 µg/mL and 84.39 % at 200 µg/mL. 
 
Figure 4.12. Percentage xanthine oxidase (XO) inhibitory activity of different 
extracts which are various concentrations from P.rubra flower in vitro. Each value 
is represented as mean ± S.E. of three separate experiments in triplicate 
measurements. 
 
   The positive control, allopurinol, showed the best IC50 value which was 
16.20 µg/mL. As depicted in Figure 4.12, PR ̶ ME extract  exhibited the strongest XO 
inhibitory activity compared to other three extracts with the IC50 which was 23.91 µg/mL  
followed by PR ̶ WE extract produced the IC50 value which was 41.32 µg/mL as shown 
in Table 4.23. PR ̶ CE extract showed the moderate inhibition activity of XO enzyme 
which the IC50 value was 49.08 µg/mL (Table 4.23). The PR ̶ HE extract showed the 
lowest inhibition activity of XO enzyme which the IC50 value was 98.43 µg/mL as shown 
in Table 4.23. From the present result of XO inhibitory activity in in vitro, PR ̶ ME extract 
produced significantly highest inhibition activity than those other extracts. Thus, PR ̶ ME 
extract of P. rubra flower was selected for the screening of uric acid clearance via 
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hyperuricemic rat model in in vivo and also xanthine oxidase inhibitory activity in serum 
and liver in vivo.  
Table 4.23. IC50 value of crude extracts from P.rubra flowers and standard 
reference, allopurinol in inhibition activity of XO enzyme 
 Extracts IC50 (µg/mL) 
PR ̶ HE 98.43 ± 1.23 a 
PR ̶ CE 49.08 ± 5.28 b 
PR ̶ ME 23.91 ± 2 c 
PR ̶ WE 
Allopurinol 
41.32 ± 2 d 
16.20 ± 0.71 e 
 
 
4.7 Xanthine Oxidase Inhibitory Activity in in Vivo Model 
   Acute toxicity study revealed the non-toxic nature of the extracts. There 
was no lethality or any toxic behaviours found at single dose selected until the end of the 
study period. The PR ̶ ME extract of P. rubra red flower did not show any mortality and 
none of the orally administered rats in both sexes showed any visible symptoms of 
toxicity up to a dose of 4 g/kg body weight. In addition, at this single dose, there were no 
gross behavioral changes indicating high margins of safety. 
 
4.71 Effect PR ̶ ME Extract in Uric acid in in Vivo Model 
The purpose of this study is to determine the anti-hyperuricemic activity or uric-acid 
clearance of PR ̶ ME extract of P. rubra red flower in experimental rat model in in vivo 
study. The PR ̶ ME extract of P. rubra red flower had showed the beneficial result with 
the highest inhibition activity of XO enzyme in vitro assay.  
   Measurement of uric acid levels in in vivo study was determined using uric 
acid standard kit assay. The concentration of uric acid is determined by a coupled of 
enzyme reaction which give colorimetric result within 570 nm which proportional to the 
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uric acid present in standard. Figure 4.13 showed the linear regression of uric acid 
standard curved. Calculation of uric acid in serum was made according to formula 
provided by standard kit assay and expressed as mg/dl. 
 
Figure 4.13. Standard curve of uric acid  
 
   Effects of PR ̶ ME extract from P.rubra flowers and standard drug, 
allopurinol on uric acid levels in serum of hyperuricemic and normal rats are shown in 
Figure 4.14. As depicted from Figure 4.14, PR ̶ ME extract from P.rubra flower have 
shown dose ̶ dependent anti ̶ hyperuricemic effects on serum urate levels in the normal 
and hyperuricemic mice were determined after 7 day oral administration. Potassium 
oxonate (PO) act as an uricase inhibitor treatment caused hyperuricemia in rats, as 
indicated by drastic increases in serum uric acid levels and this increase was prolonged 
to 2 hour after the injection. The serum uric acid levels of PO ̶ hyperuricemic induced 
group (hyperuricemic gout-control group) were elevated significantly (p<0.05) to 13.65 
± 0.83 mg/dl compared to all group of control and treatment of induced hyperucemic rats 
at the end of the experiment.  
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   As shown in Figure 4.14, no statistical significant difference was observed 
in serum urate levels between groups in normal rats non ̶ induced with PO neither treated 
with test extract (baseline) which the concentration of uric acid was 3.96 ± 0.84 mg/dl 
with the high dose and low dose of PR ̶ ME extract of P. rubra flower control group which 
administered with 400 mg/kg and 200 mg/kg which the concentration of uric acid was 
3.82 ± 0.65 and 3.93 ±0.43  mg/dl, respectively, without PO ̶ induced, with as well as 
with 0.5 % CMC vehicle group and 3.97 ±0.87 mg/dl, respectively. In the hyperuricemic 
rats, after administration with PR ̶ ME extract of P. rubra flower at doses of 200 and 400 
mg/kg, serum and urate levels were significantly decreased in a dose ̶ dependent manner, 
compared to the gout control group. Likewise, the serum uric acid levels of hyperuricemic 
rats treated with high dose of  400 mg/kg PR ̶ ME extract from P. rubra flower were 
lowered significantly by 4.44 ± 0.44 mg/dl whereas low dose of 200 mg/kg also lowered 
significantly by 9.71 ± 0.44 mg/dl (p<0.05) compared to hyperuricemic gout control 
group. It can be seen that dose dependent effects of PR ̶ ME extract of P. rubra flower 
was detected in serum urate levels in rats from group of hyperuricemic induced PO group 
rather than control group (normal, CMC vehicle, high dose control, low dose control). In 
comparison to group of standard drug,allopurinol, which known as XO inhibitor has 
markedly reduced the level of serum urate of hyperuricemic rats to values even lower 
than that found in normal animals and also group from gout control rats with the 
concentration of serum urate level was 2.98 ± 0.589  mg/dl and 13.65 ± 0.83  mg/dl, 
respectively. 
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Figure 4.14 Effect of the PR ̶ ME extract of P.rubra red flower on serum urate level 
in PO ̶ induced hyperuricaemia in rats and control rats at 7 days. N: Rats without 
treated with PO, neither treated with P. rubra extract, CMC: Vehicle group of 
rats, HC: Rats administered with high dose, 400 mg/kg P.rubra extract, LC: Rats 
administered with low dose, 200 mg/kg P. rubra extract, GC: Gout control induced 
with PO, HT: Hyperuricemic rat dosed with high dose 400 mg/kg P. rubra extract, 
LT: Hyperuricemic rat dosed with low dose, 200 mg/kg P. rubra extract, AP: 
Hyperuricemic rat dosed with 10mg/kg allopurinol. The data are representative of 
6 animals and expressed as mean± S.E. with a p<0.05 significant when compared to 
normal (N) group, b p < 0.05 significant when compared to hyperuricemic gout 
control (GC) group, c p<0.05 significant when compared to allopurinol (AP) group. 
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4.7.2 Effect of PR-ME extract on XO Activity in in Vivo Model 
The purpose of this study is to determine the effect of PR ̶ ME extract from P. rubra red 
flower against the activity of XO enzyme in experimental rat model in vivo study which 
including serum and also in liver . The PR ̶ ME extract of P. rubra red flower had showed 
the beneficial result with the highest inhibition activity of XO enzyme in in vitro assay. 
   Measurement of XO activity in vivo study was determined using XO 
activity standard kit assay. The XO activity is determined by a coupled of enzyme reaction 
which give colorimetric result within 570 nm and proportional to the hydrogen peroxide 
generated. One unit of XO is defined as the amount of enzyme that catalyzes the oxidation 
of xanthine, yielding 1.0 mmole of uric acid and hydrogen peroxide per minute at 25 °C. 
Figure 4.15 showed the linear regression of standard curved,  of hydrogen peroxide 
standard provided by kit assay which gave the r2 value of 0.9755 and standard curve 
equation  of y= 0.2079x + 0.0783, where y is absorbance at 570 nm and x is concentration 
of standard hydrogen peroxide in nmole. Calculation of XO activity in serum and liver 
was made according to formula provided by standard kit assay and expressed as miliunit 
(mU)/mL. 
 
Figure 4.15 Standard Curve of hydrogen peroxide from XO standard kit assay 
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c.  XO Inhibitory Activity in serum 
   The levels of uric acid are depend to a XO ̶ catalyzed reaction. Thus, the 
activity of XO in serum were measured, since changes in XO activity might alter serum 
uric acid levels. The effect of PR ̶ ME extract of P. rubra flower in in vivo on serum with 
the other group of study were illustrate in Figure 4.16 whereas the percentage of XO 
enzyme was shown in Table 4.24. 
 
 
Figure 4.16 Effect of the PR ̶ ME extract of P. rubra red flower on XO activity in 
serum of PO ̶ induced hyperuricaemia in rat and normal control rat at 7 days. N: 
Rats without induced with PO neither treated with P. rubra extract and standard 
drug allopurinol, CMC: Vehicle group of rats, HC: Rats administered with high 
dose, 400 mg/kg P. rubra extract, LC: Rats administered with low dose, 200 mg/kg 
P. rubra extract, GC: Hyperuricemic gout control induced with PO (280 mg/kg), 
HT: Hyperuricemic rat dosed with high dose 400mg/kg P. rubra extract, LT: 
Hyperuricemic rat dosed with low dose, 200mg/kg P.rubra extract, AP: 
Hyperuricemic rat dosed with 10mg/kg Allopurinol. The data are representative of 
6 animals and expressed as mean± S.E. with a p<0.05 significant when compared to 
normal (N) group, b p < 0.05 significant when compared to hyperuricemic gout 
control (GC) group c p<0.05 significant when compared to allopurinol (AP) group. 
 
 
 117 
 
   As shown in Figure 4.16, dose dependent effects of high dose, 400 mg/kg 
and low dose, 200 mg/kg of PR ̶ ME extract from P.rubra flowers in serum can be seen 
only  PO – induced hyperuricemic rats. There were no statistically significant difference 
in serum XO activity (p<0.05) between group of normal untreated extract and non-
induced of PO (baseline) which the XO activity was 3.29 ± 0.38 mU/mL, 0.5 % CMC 
vehicle group which the XO activity was 3.15 ± 0.24 mU/mL, high control group (dose 
400 mg/kg) which the XO activity was 3.42 ± 0.2 mU/mL and positive control group, 
allopurinol which the XO activity was 2.74 ± 0.21 mU/mL Nevertheless, XO activity in 
low control group (200 mg/kg) was significantly increased to 6.01 ± 0.26 mU/mL 
compared to normal (baseline) group (p<0.05).  Refer to Table 4.22, administration of 
high dose, 400 mg/kg of PR ̶ ME extract of P. rubra flower among non ̶ induced of PO 
rats was able to cause weak inhibition of serum which was 3.95 %. Instead, low dose, 200 
mg/kg of PR ̶ ME extract of P. rubra flower not capable to inhibited the XO and in fact, 
increased the XO activity more than normal value. 
   It was noted that PO successfully play a role as competitive uricase 
inhibitor since the XO activity in hyperuricemic gout control group (GC) was 
significantly increased (p<0.05) and was the highest among the other seven groups of 
studies (12.77 ± 0.33 mU/mL). In hyperuricemic rats, after administration with PR ̶ ME 
extract of red flowers at doses of 200 and 400 mg/kg, XO activity were significantly 
decreased in a dose ̶ dependent manner, compared to the gout control group. As 
represented in Figure 4.16, the XO activity of hyperuricemic rats treated with high dose 
of 400 mg/kg PR ̶ ME extract from P. rubra flower were lowered significantly by 7.18 ± 
0.30 mU/mL with the percentage of XO inhibition was 43.77 % whereas low dose of 200 
mg/kg also lowered significantly by 8.73 ± 0.52 mU/mL (p<0.05) and showed percentage 
of XO inhibition was 31.64 % compared to gout control group. Interestingly, there was 
no statistical significant difference between the group hyperuricemic PO ̶ induced which 
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treated with high dose, 400 mg/kg PR ̶ ME extract of P. rubra flower with the group of 
normal rats that only given low dose, 200 mg/kg PR ̶ ME extract of P. rubra flower. 
However, standard drug, allopurinol which acted as positive control in this study 
exhibited the best inhibition of XO activity (Table 4.24) from those two different dose of 
PR ̶ ME extract of P. rubra flower which the XO activity of rats treated with allopurinol 
was nearly reached and no statistical different with the normal (baseline) rats. 
 
d. XO Inhibitory Activity in liver 
   The levels of uric acid are depend to a XO ̶ catalyzed reaction. Thus, the 
activity of XO in liver were measured, since changes in XO activity might alter serum 
uric acid levels. In fact, XO activity is present in significant level in liver. The effect of 
PR ̶ ME extract of P. rubra flower in in vivo model on liver with the other group of study 
were illustrate in Figure 4.17 whereas the percentage of XO enzyme was shown in Table 
4.24. 
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Figure 4.17 Effect of the PR ̶ ME extracts of P. rubra flower on XO activity in liver 
PO ̶ induced hyperuricaemia in rat and normal control rat at 7 days. N: Rats 
without treated with PO, neither treated with P. rubra extract, CMC: Vehicle 
group of rats, HC: Rats administered with high dose, 400 mg/kg P. rubra extract, 
LC: Rats administered with low dose, 200 mg/kg P. rubra extract, GC: 
Hyperuricemic gout control induced with PO, HT: Hyperuricemic rat dosed with 
high dose 400 mg/kg P. rubra extract, LT: Hyperuricemic rat dosed with low dose, 
200 mg/kg P. rubra extract, AP: Hyperuricemic rat dosed with 10mg/kg 
allopurinol. The data are representative of 6 animals and expressed as mean± S.E 
with a p<0.05 significant when compared to normal (N) group, b p< 0.05 significant 
when compared to hyperuricemic gout control (GC) group, c p<0.05 significant 
when compared to allopurinol (AP) group. 
 
   Figure 4.17 shows the dose dependent effects of both doses of PR ̶ ME 
extract of P. rubra flower, 400 mg/kg and 200 mg/kg only can be seen on XO activity in 
liver from PO ̶ induced hyperuricemic rats but not in normal rats after 7 days of oral 
administration. There were no statistically significant difference in liver XO activity 
(p<0.05) between group of normal untreated extract and non ̶ induced of PO (baseline) 
which the XO activity was 5.58 ± 0.249 mU/mL with the other four groups including 0.5 
% CMC vehicle group which the XO activity was 5.59 ± 0.224  mU/mL, high control 
group (dose 400 mg/kg) which the XO activity was 6.83 ±0.761 mU/mL, low control 
group (200 mg/kg) give the XO activity as 6.85± 0.530 mU/mL  and positive control 
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group, allopurinol which the XO activity was 4.96 ± 0.312 mU/mL when compared to 
normal without induced of PO and treatment of extract. Moreover, it was found that no 
statistical significant difference (p<0.05) between the high control group (dose 400 
mg/kg) with the low control group (dose 200 mg/kg) among non ̶ induced PO rats. 
Therefore, the administration of PR ̶ ME extract of P. rubra flower does not give any 
effect to XO activity of normal rats as these doses did not produced any inhibition of XO 
activity in liver (Table 4.24). Furthermore, PO played its role as uricase inhibitor as the 
gout control group exhibited the significantly increased the XO activity in liver compared 
which was  11.77± 0.232 mU/mL to other group of study but slightly less than XO activity 
in serum of the same group (12.77 ±  0.331 mU/mL). On the other hand, Figure 4.17 also 
demonstrated that XO activity in liver among hyperuricemic rats was significantly 
decreased in a dose ̶ dependent manner with oral administration of these two doses (200 
and 400 mg/kg) of PR ̶ ME extract from P. rubra flower after 7 day duration in  in vivo 
study when compared to the gout control group. As shown in Figure 4.17 and also in 
Table 4.24, the XO activity of hyperuricemic rats treated with high dose of 400 mg/kg 
PR ̶ ME extract from P. rubra flower were lowered significantly by 7.76± 0.381 mU/Ml 
with percentage of XO inhibition was 34.07 % whereas low dose of 200 mg/kg also 
lowered significantly by 9.88± 0.536 mU/mL (p<0.05) and showed percentage of XO 
inhibition was 16.06 % when compared to gout control group. Nevertheless, standard 
drug, allopurinol which acted as positive control in this study was assumed as most potent 
XO inhibitor since the XO activity of liver was reduced significantly (p<0.05) to 4.96 ± 
0.312 mU/mL when compared to gout control group, in spite of the percentage of XO 
inhibition activity of was lower (57.86 %) rather than in serum of the same group of rats 
(78.54 %). 
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Table 4.24. XO Activity and Percentage of XO inhibition of serum and liver from 
normal and hyperuricemic induced groups of rats after oral administration of PR ̶ 
ME extract of P.rubra flowers within 7 days. The data are representative of 6 
animals and expressed as mean ± S.E. with a p<0.05 significant when compared to 
normal (N) group, b p < 0.05 significant when compared to gout control (GC) 
group, c p<0.05 significant when compared to allopurinol (AP) group. 
Group of 
Treatment 
XO Activity (mU/mL) XO Inhibition (%) 
Serum  Liver Serum Liver 
Normal rats 
(Baseline) 
3.29 ± 0.38 b 5.58 ± 0.25 b  
- 
 
- 
Vehicle (CMC 
0.5 %) 
3.15 ± 0.24 b 5.59 ± 0.22 b - - 
High control (400 
mg/kg) 
3.42 ± 0.20 b 6.83 ±0.76 b 3.95 - 
Low control (200 
mg/kg) 
6.01 ± 0.26    
a, b, c 
6.85± 0.53  b, c - - 
Hyperuricemic  
Group Control 
12.77  ± 0.33 
a, c 
11.77± 0.23  a, c - - 
High treatment 
(400 mg/kg) 
7.18 ± 0.30    
a, b, c 
7.76± 0.38      
a, b, c 
43.77 34.07 
Low  treatment 
(200 mg/kg) 
8.73 ± 0.52    
a, b, c 
9.88± 0.54 
a, b, c 
31.64 16.06 
Allopurinol 
treatment 
2.74 ± 0.21 b 4.96 ±0.31 
b 
78.54 57.86 
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4.8 The Effect of PR-ME Extract on Body Weight 
   The effect of continuously consuming P. rubra red flower on health was 
examined by measuring body weights day 0, day 1, day 3, day 5 and day 7 as depicted in 
Table 4.25. Figure 4.18 showed the changes on body weight between normal and treated 
groups. The body weights of all the rats gradually increased throughout the experiment, 
regardless of their treatment group. Since there were no significant differences of body 
weight between the treatments groups, therefore, body weight of all rats was not 
influenced by extract of P. rubra flower. This indicated that the P. rubra flower extract 
is not toxic to the rats. 
   The data of changes in body weight were analyzed by one way ANOVA 
followed by Duncan and Dunnett’s post hoc multiple comparison test using SPSS 22.0 
software version. The values were considered statistical significant when p<0.05 level. 
All the results were expressed as mean ±S.E.   
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Table 4.25. Mean Body Weight of PR ̶ ME extract from P. rubra red flower on 
control groups and treated groups of animal. The data are representative of 6 
animals and expressed as mean ± S.E. 
Animal Group 
Mean Body weight (g) 
Day 0 Day 1 Day 3 Day 5 Day 7 
Normal 
(Baseline) 
212.30 
±0.23 
213.40 
±0.42 
215.10 
±0.46 
216.90 
±0.42 
218.10 
±0.32 
Vehicle 0.5 % 
CMC  
212.70 ± 
0.62 
213.80 ± 
0.65 
215 ± 0.68 
216.50 
±0.43 
218 ±  0.41 
High Control  
(400 mg/kg) 
212.20 ± 
0.48 
213.90 ± 
0.62 
215.20 
±0.70 
216.80 
±0.83 
218.20 
±0.83 
Low  Control  
(200 mg/Kg)  
212.70 ± 
0.83 
213.80 
±1.14 
215.20 
±1.39 
216.50 
±1.92 
217.60 
±2.03 
Hyperuricemic 
Control (PO) 
212.50 ± 
0.62 
214.20 
±0.61 
215.20 
±0.42 
216.30 
±0.41 
217.60 
±0.39 
High Treatment   
(PO+HPR) (400 
mg/kg) 
212.80  
±1.35 
214.50 
±1.57 
216.10 
±1.63 
216.90 
±1.65 
218.20 
±1.68 
Low Treatment 
(PO+LPR) (200 
mg/kg) 
212.70 
±0.79 
213.90 
±0.87 
215.40 ± 
0.94 
216.90 
±0.88 
218.40 
±1.03 
 Standard 
Allopurinol 
(PO+Allo) 
212.30 ±  
0.98 
213.50 ± 
1.06 
215.20 ± 
1.08 
216.80  
±1.01 
218.20 ± 
1.10 
  
 
 1
2
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Figure 4.18. Effect of PR-ME extract of P. rubra red flower on body weight of rats. N: Rats without treated with PO, P. rubra 
extract,  CMC Control: Vehicle group of rats, 0.5 % CMC, HC: Rats administered with high dose, 400 mg/kg P. rubra extract, LC: 
Rats administered with low dose, 200 mg/kg P. rubra extract, GC: Gout control induced with PO, HT: Hyperuricemic rat dosed 
with high dose 400 mg/kg P. rubra extract, LT: Hyperuricemic rat dosed with low dose, 200 mg/kg P. rubra extract, AP: 
Hyperuricemic rat dosed with 10 mg/kg allopurinol. The data are representative of 6 rats and expressed as mean± S.E. 
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CHAPTER 5  
DISCUSSIONS 
 
5.1 Thin Layer Chromatography (TLC) Profile of Plumeria rubra Flower Extracts 
    The thin layer chromatography profile of extracts from red flowers 
Plumeria rubra showed the presence of essential oils, phenols, flavonoids and terpenoids. 
The chemical reagents were carried out in order to detected the phytochemical 
compounds existed in the red flower P.rubra. The formation of blue spots with folin- 
ciocalteu reagent indicated the presence of phenols in the extracts of P.rubra flower. 
Besides, the presence of terpenoids was carried out using vanillin ̶ sulphuric acid reagent 
with the formation of purple spots while the formation of red spots or other colour 
indicated the presence of phenols and flavonoids. Furthermore, anisaldehyde ̶ sulphuric 
acid was another chemical reagent which detected the presence of essential oils with the 
formation of blue spot, whereas the flavonoid compound was detected with the formation 
of red spots. This finding was agreed with the previous research by Zaheer et al. (2010) 
which confirmed the presence of flavonoid compound in methanol extract of P.rubra 
flower through preliminary phytochemical screening.  
  Chloroform and methanol are both polar solvent which used to extract 
polar compound of lipids, phenolic compound (Hossain et al. 2011), and flavonoids 
(Bimakr et al. 2011). The higher polarity of methanol solvent compared to chloroform 
solvent showed the presence of terpenoids in methanol extract of thin layer 
chromatography profile (Iwalewa et al. 2003). Moreover, the best method for extraction 
of phenolic compounds was solvent extraction with water or methanol (Goli et al. 2005). 
On the other hands, hexane extract contain fewer compounds as compared to chloroform, 
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methanol and water extracts. The reason may be due to solvent hexane was non-polar 
solvent which not many chemical constituents could be extracted from this solvent 
resulted to slightly amount of phenols was detected through folin and vanilin reagent. 
Beside this, the observation of essential oil of hexane extract from flower of P. rubra is 
in agreement with research analyzed by Tohar et al. (2006) that the flower of genus 
Plumeria contain various of volatile component which benefit to fragrance and medicine 
industry. In addition, mostly lipids can be found in nonpolar phase of solvent system, and 
proteins, amino acids, and other hydrophilic molecules such as phenols and flavonoid 
remained in polar phase (Wanasundara & Shahidi, 1994). 
 From the result, the TLC profile indicated that no alkaloids within the 
flowers of P.rubra. This result could be explained that alkaloids tend to accumulate in 
very active tissues such roots, leaves, vascular sheath and latex (Robinson, 2012). 
 
5.2 Liquid Chromatography Mass Spectrometry (LCMS/MS) Analysis of P. rubra 
      Flower Extracts 
   The separations of the phytochemical compounds in extracts from P. 
rubra red flowers were carried out using Liquid Chromatography Mass Spectrometry 
tandem with mass spectrometry (LCMS/MS) in order to determine the phytochemical 
presence in flowers of P. rubra. Analysis with LCMS/MS in PR ̶ ME (methanol) extract 
from P.rubra flowers showed the presence of 3 ̶ caffeyolquinic acid , 5 ̶ caffeoquinic acid, 
chlorogenic acid, citric acid, kaempferol ̶ 3 ̶ O ̶ glucoside, kaempferol ̶ 3 ̶ rutinoside, 
kaempferol, quercetin 3 ̶ O ̶ α ̶ L ̶ arabinopyranoside , quercetin , quinic acid and rutin. 
Analysis with LCMS/MS in PR-WE (water) extract from P.rubra flowers showed the 
presence 1,3 ̶  Dicaffeoquinic acid , 3,3 ̶ di ̶ O ̶ methylellagic acid, 3 ̶ Caffeyolquinic acid, 
kaempferol ̶ 3 ̶ O ̶ glucoside, kaempferol ̶ 3 ̶ rutinoside, quercetin and quinic acid. It should 
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be noted that the phytochemical compounds which detected by LCMS/MS method in 
present study are difference compared from the phytochemical compounds that have been 
identified in flowers P.rubra as reported in previous study. Contrary to present study,  
phytochemical compounds including of myristic acid, linoleic acid, lauric acid and 
palmitic acid (Tohar et al. 2006), plumericidine (Ye et al. 2009), two anthocyanins which 
are cyanidine 3 ̶ O ̶ β ̶ (2’’ ̶ glucopyranosyl ̶ O ̶ β ̶ galactopyranoside) and 3 ̶ O ̶ β ̶ 
galactopyranoside (Byamukama et al. 2011), rubranoside (=7 ̶ O ̶ α ̶ L ̶ rhamnopyranosyl ̶ 
4’ ̶ O ̶ β ̶ D ̶ glucopyranosylnaringenin), rubrajaleelol, rubrajaleelic acid,1 ̶ α ̶ plumieride 
and plumieride  ̶ p ̶ z ̶ coumarate (Akhtar et al. 2013) were  identified  in red flowers of 
P.rubra. Nevertheless, these compounds was unable to be detected in the present study 
could be due to the low amount of compound presence and also different approach of 
extraction process in these research. 
 
5.3 Total Phenolic and Flavonoid Content of P .rubra Flower Extract 
 The total phenolic and flavonoids compounds were quantified since the 
phenolic and flavonoids has been qualitatively detected in extracts of P. rubra red 
flowers. Methanol extract (PR ̶ ME) showed the highest contents of both TPC and TFC 
followed by water extract (PR ̶ WE), chloroform extract (PR ̶ CE) and hexane extract (PR ̶ 
HE). The high TPC in PR ̶ ME of red flowers P.rubra flowers could be due to the presence 
of phenolic compounds which are 3 ̶ Caffeyolquinic acid, 5 ̶ Caffeoquinic acid, 
Chlorogenic acid and quinic acid. The total flavonoid contents in flowers from P. rubra 
was also highest in PR ̶ ME and the presence of kaempferol ̶ 3 ̶ O ̶ glucoside, kaempferol ̶ 
3 ̶ rutinoside, Kaempferol, Quercetin 3 ̶ O ̶ α ̶ L ̶ arabinopyranoside , quercetin and rutin 
in methanol extract of P. rubra flower might be contributing for high contents of 
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flavonoids. The result of TPC and TFC of flowers from P.rubra were varied among the 
four extracts. 
 Variation of result from different extract of P. rubra flowers could be due 
to the different amount of non-phenolic compound which was flavonoid has capable to 
formed complex with ion aluminium thus gave pink color reaction. In addition, methanol 
extract yielded highest phenolic and flavonoid content which are in agreement with Yao 
et al. (2004), reported that methanol is the best solvent in the extraction of phenolic 
compounds due to its ability to inhibit the reaction of polyphenol oxidase that causes the 
oxidation of phenolic and its ease of evaporation compared with water. Instead, the total 
phenolic contents and total flavonoid contents of PR ̶ HE extract were much lower, which 
are in agreement with Sahreen et al. (2010) and Medini et al. (2014) as both of these 
finding indicated the low content of phenols and flavonoids from the hexane extract. 
Beside this, the results also suggest that the extractability of polyphenols is influenced by 
the polarity and viscosity of the solvents used (Turkmen et al. 2006 and Hayouni et al. 
2007). This results are agreed the finding by Barreira et al. (2008) which revealed that P. 
rubra flower contained remarkable levels of phenols and flavonoids and the presence of 
these compounds are according to the polarity of solvent used. 
 
5.4 Antioxidant Activity Assays of P.rubra Flower Extracts 
 The antioxidant activities of red flowers from P. rubra extracts were 
evaluated with  2,2 ̶ diphenyl ̶ 1 ̶ picrylhydrazyl (DPPH) radical scavenging assay, Ferric 
Reducing Power Assay (FRAP), Metal Chelating Assay, Hydrogen peroxide radical 
scavenging assay, Nitric Oxide radical scavenging assay and Superoxide radical 
scavenging assay. On the other hand, the present study showed that the methanol extract 
of red flower from P.rubra  comprised of 3 ̶ caffeyolquinic acid , 5 ̶ caffeoquinic acid, 
 129 
 
chlorogenic acid,  kaempferol ̶ 3 ̶ O ̶ glucoside, kaempferol ̶ 3 ̶ rutinoside, kaempferol, 
quercetin 3 ̶ O ̶ α ̶ L ̶ arabinopyranoside , quercetin , quinic acid and rutin as detected by 
LCMS/MS analysis. These compounds are might attributed to all of six antioxidant assays 
in the current study and the antioxidant activity of these compounds from red flower of 
P.rubra were not reported yet in previous research. Besides, the result of all these 
antioxidant activities especially in PR ̶ ME might be due to synergistic effect of all 
detected compounds and several compounds contain in methanol extract had been 
reported from previous literatures. On the other hand, the types of chlorogenic acids 
presence in PR ̶ ME extract with different number of phenolic –OH would also affect the 
antioxidative activity. As of now, many literatures reported the antioxidant activity of 3 ̶ 
O ̶ caffeoylquinic acid rather than 5 ̶ O ̶ caffeoylquinic acid as both of them might 
contributed to antioxidant activity with different mechanism. 
 Some of the data of the antioxidant activity assays indicated the small 
range of SE. The reason is the present study had chose SE rather than SD in order to 
describe variation as SE gives the smallest of the error bars. In fairness, SEM is a perfectly 
legitimate descriptor of variation in research. 
 
5.4.1 DPPH (2, 2-diphenyl-1-picrylhydrazyl) Radical Scavenging Activity of P.rubra 
Flower Extracts 
 The DPPH scavenging activity was carried out to evaluate the ability of 
antioxidant to scavenge free radicals. DPPH is considered to be a model of a stable 
lipophilic radical. A chain reaction of lipophilic radicals is initiated by lipid auto-
oxidation. Antioxidants react with DPPH, reducing the number of DPPH free radicals to 
the number of their available hydroxyl groups (Khaliq et al. 2015). The more antioxidant 
compound in the extract, the more DPPH reduction will occur. The degree of 
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discoloration from violet colour of DPPH radical to pale yellow colour and adsorption 
intensity also decreased according to the number of electron captured and indicates the 
scavenging potentials of the antioxidant extract (Bastos et al. 2007). The higher intensity 
of DPPH reduction is related to high scavenging activity performed by particular 
compounds. In the present study, the scavenging activity of P. rubra flowers extracts 
were compared with ascorbic acid which is well known natural antioxidants. In general, 
the scavenging activity of P. rubra flower extracts was increased with increasing 
concentration. In this assay, the IC50 of standard ascorbic acid was 29.6 µg/mL. The 
weaker pattern of scavenging activity was observed for the PR ̶ CE compared to PR ̶ ME. 
PR ̶ HE was generally least reactive with lowest percentage of DPPH inhibition. The 
scavenging activities of PR ̶ HE was suited in most research that hexane extract showed 
hyperbolic curve. This observation is fairly common due to not many non ̶ polar 
compounds could act as potent antioxidant (Kulkarni et al. 2004).  
 The highest inhibition of DPPH radical in PR ̶ ME is due to the presence 
of flavonoids compound which are quercetin, kaempferol and rutin as well as phenolic 
acid which are 3 ̶ O ̶ Caffeyolquinic acid, 5 ̶ O ̶ Caffeoquinic acid, Chlorogenic acid and 
quinic acid that has been detected in LCMS/MS. Both the number and configuration of 
H ̶ donating hydroxyl groups are the main structural features that influence the antioxidant 
capacity of these flavonoids (Pannala et al., 2001). The quercetin and kaempferol 
structure contain of catechol arrangement which prerequisite to reinforce DPPH 
scavenging activity. Nevertheless, according to Wang et al. (2012), the glycosylation of 
flavonol as the detected phytochemical compounds in present study, kaempferol ̶ 3 ̶ 
glycoside, kaempferol ̶ 3 ̶ rutinoside and quercetin 3 ̶ O ̶ α ̶ L ̶ arabinopyranoside on both 
OCH3 and OH groups reduced the DPPH free radical scavenging potential. The result of 
PR-ME of the present study also show agreement with Yang et al. (2008) and Lue et al. 
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(2010) which extracts contain of rutin has capability to scavenge DPPH radicals. 
Moreover, the presence of ortho ̶ dihydroxyl group in the B ̶ ring of rutin as well as the 
sugars at the 3 position makes it strong free radical scavenging activity (Sintayehu, 2012). 
On the other hand, quinic acid presence in both PR ̶ ME and PR ̶ WE could act as ortho-
or para diphenolic group was also effective in free radical scavenging by electron transfer 
(Xu et al. 2008). In addition, the other study by Yuan et al. (2012) stated that the caffeoyl 
group in 3 ̶ O ̶ caffeolquinic acid is the key active site exhibiting antiradical activities in 
the separated phenolic compounds. The radical scavenging activities of tested phenolic 
compounds are slightly affected by the position of the caffeoyl group on quinic acid. 
Thus, the phenolic compounds including of 3 ̶ O ̶ Caffeoylquinic acid, 5 ̶ O ̶ caffeoylquinic 
acid, chlorogenic acid and quinic acid might play a role in order to scavenge DPPH radical 
in present study. 
5.4.2 Ferric Reducing Antioxidant Power (FRAP) assay of P.rubra Flower Extracts 
 The Ferric Reducing Antioxidant Power (FRAP) assay was carried out to 
evaluate the ability of extracts from P. rubra red flowers to reduce the ferum ion in 
relation to its antioxidant activity. The ferric reducing activity of all extracts of P.rubra 
flower were analyzed based on the reduction of ferric ̶ TPTZ (2, 4, 6 ̶  tri(2 ̶ pyridyl) ̶ 1,3,5 ̶  
triazine) to blue ferrous TPTZ. Antioxidant compounds which act as reducing agent exert 
their effect by donating hydrogen atom to ferric complex and thus break the radical chain 
reaction. The higher the absorbance is, the higher is the antioxidant activity which is 
indicated by the high FRAP value (Ghafar et al. 2010). The highest FRAP value was 
displayed from PR ̶ ME while the moderate polarity of solvent which was PR ̶ CE 
demonstrated the moderate reducing power and lowest FRAP value was displayed from 
PR ̶ HE. It was observed that PR ̶ ME and PR ̶ WE were able to donate electron, hence 
they should be able to donate electrons to free radicals in actual biological or food 
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systems, making the radicals stable and unreactive. The results obtained may have partly 
been contributed by the phenolics and flavonoids as detected in LCMS/MS in PR ̶ ME 
and PR ̶ WE such as 3 ̶ O ̶ caffeyolquinic acid, 5 ̶ O ̶ caffeoquinic acid, 1, 3 ̶ dicaffeoquinic 
acid, chlorogenic acid, 3, 3 ̶ di ̶ O ̶ methylellagic acid, kaempferol ̶ 3 ̶ O ̶ glucoside, 
kaempferol ̶ 3 ̶ rutinoside, kaempferol, quercetin 3 ̶ O ̶ arabinosyl glucoside, quercetin, 
quinic acid and rutin. Pu et al. (2015) stated that both quercetin and kaempferol are 
flavonoids which responsible to give high of FRAP value due to the number and position 
of hydroxyl groups and the different flavonoid skeletons. The other phytochemical 
compounds that reported to be acted as reducing agent of ferric ̶ TPTZ (2, 4, 6 ̶ tri(2 ̶ 
pyridyl) ̶ 1,3,5 ̶ triazine) are rutin (Firuzi et al. 2005) as well as chlorogenic acid, 3 ̶ O ̶ 
caffeoylquinic acid and 5 ̶ O ̶ caffeoylquinic acid (Shi et al. 2009). 
5.4.3 Metal Chelating Activity of P.rubra Flower Extract 
 In the metal chelating assay of red flowers of P. rubra extracts showed 
that PR ̶ ME produced the highest metal chelating activity. The present result was an 
agreement with Rohman et al. (2010) as the higher metal chelating activity was indicated 
by the smaller IC50 value. Ion Ferrous (Fe 2+) is an unstable form of iron which contributed 
to formation of ROS that cause lipid peroxidation, nucleic acid or protein damage whereas 
Ferric (Fe3+) is an inactive but more stable ion (Chvatalova et al. 2008). The complex 
formation of ferrozine with Fe2+ can be disturbed by chelating agents via inhibition of 
heavy metal. According to Gordon, (1990), the effective chelating agents able to form σ-
bonds with a metal as secondary antioxidants due to their capability to reduce the redox 
potential thus stabilizing the oxidized form of the metal ion.  
  The highest of metal chelation in PR ̶ ME might be contributed to 
phytochemical compounds that has been analyzed through LCMS/MS which are 3 ̶ O ̶ 
caffeoylquinic acid, 5 ̶ O ̶ caffeoylquinic acid, chlorogenic acid, quinic acid and quercetin. 
 133 
 
Polyphenols compound has been known to be attributed to antioxidant activity of plant 
by scavenging free radicals, iron chelating mechanism and changed the activity of 
enzymes by inhibiting oxidases (Melidou et al. 2005; Chvatalova et al. 2008). In addition, 
phenolic compounds interfered the oxidation of lipids and other molecules through rapid 
donation of a hydrogen atom to free radicals which this reaction leading to formation of 
stable substance phenoxy radical intermediates also act as terminators of propagation 
route by reacting with other free radicals (Dai & Mumper, 2010). Moreover, phenolic 
compounds such as 3 ̶ O ̶ caffeoylquinic acid and 5 ̶ O ̶ caffeoylquinic acid posses ideal 
structure chemistry for free radical scavenging activities because they have phenolic 
hydroxyl groups that are prone to donate a hydrogen atom or an electron to a free radical 
and also extended conjugated aromatic system to delocalize an unpaired electron. 
According to Luzia et al. (1998), 5 ̶ O ̶ caffeoylquinic acid could acts as metal chelator 
due to presence orthohydroxy in its chemical structure. In addition, chlorogenic acid 
revealed good metal chelating activity due to more complex structure of this phenolic 
acid which is a caffeic acid ester linked to quinic acid (Apati et al. 2003; Andjelkovic et 
al. 2006). The other phenolic compound, quinic acid also showed strong ability to chelate 
metal ions involved in the production of free radicals (Seabra et al. 2006). The fewer the 
number OH groups, the lower probability of hydrogen loss posed and the lower the 
probability of oxidation of the flavonoid and the reduction of the metal (Fernandez et al. 
2002). On the other hand, quercetin was known as iron chelating and iron stabilizing 
properties. The chemical structure of quercetin which contain catechol moiety in the B 
ring has been participated in metal chelation (Sestili et al. 1998; Prochazkova et al. 2011). 
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5.4.4 Hydrogen peroxide Radical Scavenging Activity of P. rubra Flowers Extracts 
 Hydrogen peroxide radical scavenging assay was carried out to estimate 
the ability of extracts from red flower of P.rubra to scavenge free radical, hydrogen 
peroxide. Hydrogen peroxide can be formed in in vivo by various oxidizing enzymes such 
as superoxide dismutase. It can permeate through biological membranes slowly oxidizing 
number of compounds. Hydrogen peroxide is used in the respiratory burst of activated 
phagocytes (Mac Donald et al. 2006). Although hydrogen peroxide itself is not very 
reactive (Namiki, 1990), together with the superoxide radical anion, can damage many 
cellular components thus, can be converted into other ROS, including hydroxyl radicals 
which is found to be main reason for toxicity associated with hydrogen peroxide (Ma et 
al. 2011). Moreover, hydrogen peroxide can deactivate few enzymes involved in cellular 
energy production such as glyceraldehyde ̶ 3 ̶ phosphate dehydrogenase found in 
glycolytic pathway (Hyslop et al. 1988) as well as aconitase and a-ketoglutarate 
dehydrogenase found in Krebs cycle (Tretter and Vizi, 2000) through oxidation of 
essential thiol ( ̶ SH) groups. Therefore, it biologically advantageous for hydrogen 
peroxide scavenger to control the amount of hydrogen peroxide that is allowed to 
accumulate.  
 In the hydrogen peroxide scavenging activity assay, the scavenging 
activity was found to increase with increasing concentration of P.rubra flower extracts. 
The present study exhibited the highest percentage of hydrogen peroxide scavenging 
activity in PR ̶ ME of P. rubra flower. Interestingly, the other extract of P. rubra flower, 
which are PR ̶ WE, PR ̶ CE and PR ̶ HE exhibited weaker pattern of hydrogen peroxide 
scavenging activity as their inhibition percentage of hydrogen peroxide radical did not 
reach 50 % even at the highest concentration tested. However, based on estimated IC50 
value the scavenging activity of PR ̶ ME extract was relatively lower than standard, 
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ascorbic acid. Therefore, the study indicates PR ̶ ME of P.rubra flower has demonstrated 
mild scavenging activity on hydrogen peroxide. The scavenging activity of hydrogen 
peroxide radical in PR ̶ ME are due to the presence of compounds which detected by 
LCMS/MS analysis including 3 ̶ O ̶ caffeoylquinic acid, kaempferol and quercetin. 
Scavenging of hydrogen peroxide by the plant extracts may be attributed to their phenolic 
contents, which donate electron to hydrogen peroxide, thus reducing it to water (Sharma 
et al. 2012). Furthermore, the other compound such as quercetin possessing all the 
structural requirement of a flavonol antioxidants which including 5 ̶ hydroxyl ̶ 4 ̶ keto 
substitution in the A ring, the 2, 3 – double bond promoting conjugation between the ring 
and 3, 4 dihyroxy catechol substitution in the B ring which these characteristics give 
quercetin as good antioxidant (Apak et al. 2007) and anti-radical activity (Seyoum et al. 
2006). Anti ̶ radical activity of bioactive compound are mainly correlated by the number 
of –OH group preferably in ortho position in one another bonded to aromatic ring (Sroka 
& Cisowki, 2003).  The mild scavenging activity on hydrogen peroxide radical was due 
to less bioactive compound which responsible to scavenge hydrogen peroxide radical. 
Meanwhile quercetin flavonoids also could be acted as pro-oxidant which exacerbate the 
oxidative stress derived from hydrogen peroxide (Prokazkova et al. 2011). Moreover, 
hydrogen peroxide is necessary to peroxidases catalyzed reactions and it scavenging 
could be the cause of a lower enzymatic oxidative process. 
 
 
 
 
 
 136 
 
5.4.5 Nitric Oxide Radical Scavenging Activity of P.rubra Flower Extracts 
 The nitric oxide (NO) radical scavenging activity was carried out to 
determine the ability of extracts from P.rubra red flowers to scavenge nitric oxide radical. 
NO is generates spontaneously from sodium nitroprusside in an aqueous solution at 
physiological pH, interacts with oxygen to produce nitrite ions which can be estimated 
using a griess reagent. Scavengers of nitric oxide act against oxygen, leading to reduced 
production of nitrite ions which can be monitored at 546 nm. Nitric oxide (NO) radical is 
involved in several pathological diseases, such as chronic inflammation, aut oimmune 
diseases and rheumatoid arthritis, were also proposed to be closely associated with its 
overproduction and inappropriate expression of cytokines (Szekanecz & Koch, 2007; 
Kobayashi, 2010; Hong et al. 2015). During inflammation, the level of nitric oxide 
increases and an overproduction can cause damage to cell macromolecules and therefore 
injuries to host tissue. Besides its own toxicity, this radical can further react with other 
species instigating even more toxic radicals, such as peroxynitrite, which results from its 
reaction with superoxide. (Royer et al. 2011:  Pereira et al. 2010).  
 The NO scavenging activity was found to increase with increasing 
concentration of P. rubra red flower extracts. The present study indicated that PR ̶ ME 
and PR ̶ WE could inhibited the nitrite formation by directly competing with oxygen in 
the reaction with nitric oxide. The high inhibition of red flowers PR ̶ ME and PR ̶ WE 
might be due to the presence of phenolics and flavonoids compound which including 
hydrocinnamic acid (3 ̶ O ̶ caffeolquinic acid, 5 ̶ O ̶ caffeolquinic acid), quinic acid, 
flavonoid (quercetin, and kaempferol). In fact, both 5 ̶ O ̶ caffeoylquinic acid, quercetin 
and kaempferol have already revealed antioxidant capacity, in several systems (Han et al. 
2004; Ferreres et al. 2008). Quercetin was claimed as most potent of flavonoids family 
as scavenger of ROS, including RNS like NO· (Vanacker et al. 1995; Haenen & Bast, 
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1999). As a result, several previous studies have shown that flavonoids which is quercetin 
able to inhibit NO production which in response to inflammatory stimuli. In fact, 
quercetin not only prevent the occurrence of oxidative stress but also help mitigate 
inflammation (MacNee, 2001; Rahman, 2002:  Nair et al. 2006).   Indeed, it has already 
been shown that quercetin and kaempferol were able to inhibit NO production to act 
against NOS isoforms boh by inhibition of induced NOS (iNOS) activity or down-
regulation of iNOS expression from different cell types (Rangan et al. 1999: Chen et al. 
2005; Hamalainen et al. 2007).  Furthermore, quercetin also inhibits ROS/RNS 
generation, inducible nitric oxide synthase expression and NF ̶ kB activation in IL ̶ 1b ̶ 
activated rat hepatocytes (Martınez-Flores et al. 2005). Hamalainen et al. 2007 stated that 
quercetin and kaempferol which able to inhibit the activation of NF ̶ kB and STAT ̶ 1 in 
activated macrophage are likely to down ̶ regulate production of an array of inflammatory 
mediators in addition to iNOS. In Chang Liver cells which the effect of quercetin and 
kaempferol were found inhibited the activation of NFkB that induced by a cytokine 
mixture (Garcıa Mediavilla et al. 2007; Hamalainen et al. 2007). Hejinen et al. (2001) 
reported that the optimal configuration for free radical scavenging scavenging activity of 
quercetin was derived from the presence of two antioxidant pharmacophores within the 
molecule which are catechol group in the B ring and the OH group at position 3 of the 
AC ring whereas kaempferol was due to AC ring with three OH groups. The presence of 
4 ̶ oxo ̶ 3 ̶ hydroxyl in kaempferol attributed in NO scavenging activity. On the other hand, 
there are reports of a variety of bioactivities of caffeoylquinic acids including antioxidant 
and anti ̶ inflammatory (Zhao et al. 2006; Hung et al. 2006). Phenolic compounds 
possessing catechol structures, such as 5 ̶ O ̶ caffeoylquinic acid, scavenge the nitric oxide 
ion and peroxynitrite ion by electron donation, generating the corresponding quinone 
(Choi et al. 2002; Rodrigues et al. 2014). Eventually, although the present result only 
revealed the ability of extracts from P.rubra flower to scavenge NO as the oxidative stress 
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in in vitro model but at least the potential of bioactive compound also been reported to be 
effective in inflammatory mediator in in vivo model. 
5.4.6 Superoxide Radical Scavenging Activity of P. rubra Flower Extracts 
 Superoxide anion itself is not considered as strong oxidant, however, it is 
responsible for the formations of other active reactive species such as hydrogen peroxide, 
peroxynitrite, and hydroxyl radicals (Stief, 2003). In this assay, superoxide radicals are 
generated in non-enzymatic system, PMS/NADH system, and acts as reducing agents of 
NBT. The superoxide radical scavenging assay evaluated the capability of extracts from 
red flowers of P. rubra to scavenge superoxide radicals as well as diminish the reduction 
of NBT. The reduction of NBT in presence of antioxidants was measured. The decrease 
of absorbance at 570 nm upon the addition of extracts as well as standard quercetin and 
ascorbic acid, is the indication of consumption of superoxide anion in the reaction 
mixture. Superoxide anion is a reduced form of molecular oxygen created by receiving 
one electron. Superoxide radicals have been observed to kill cells, inactivate enzymes, 
and degrade DNA, cell membranes and polysaccharides (Halliwell, 1996; Stief, 2003).  
 The superoxide scavenging activity of extracts from P. rubra red flowers 
was increased markedly with the increase in concentrations. The present study shows that 
all the extracts from P. rubra flowers are potentially act as superoxide scavenger except 
hexane extract. Moreover, good inhibitory effects of the PR-ME of P.rubra on superoxide 
anion formation noted herein possibly render it as a promising antioxidants. The standard 
ascorbic acid showed the most effective of scavenging activity against superoxide radical. 
The highest scavenging activity against superoxide radical in PR ̶ ME was due to the 
presence of phytochemical compounds which detected by LCMS/MS analysis. Several 
of these compounds has been reported from previous research as superoxide scavenger 
which including phenolic acids (3 ̶ O ̶ caffeoylquinic acid, 5 ̶ O ̶ caffeoylquinic acid, quinic 
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acid and also mixture of flavonoids compound such as quercetin, kaempferol and rutin. 
The hydroxyl group at C ̶ 3’ and C ̶ 4’of the B ring in rutin, kaempferol and quercetin 
should be contributed for superoxide radical scavenging activity due to hydrogen 
donation activity (Wang et al. 2010). Nevertheless, the efficiency of superoxide 
scavenging could be decreased by blocking of hydroxyl groups by sugar or alkoxyl 
substituents through glycosylation of quercetin and or kaempferol (Calderon-Montano et 
al. 2011).  Surprisingly, the present study indicated that PR ̶ ME was more efficient in 
scavenging of superoxide anion activity compared to standard quercetin which revealed 
the synergistic effect of superoxide scavenging activity from phenolic (3 ̶ O ̶ caffeoquinic 
acid, 5 ̶ O ̶ caffeoquinic acid, quinic acid) and flavonoid (quercetin, kaempferol, rutin) 
compounds. 
 
5.5 Xanthine Oxidase (XO) Inhibitory Activity of P.rubra Flower Extracts 
 The studies of XO inhibitory activity in extracts from P. rubra red flowers 
was evaluated in order to evaluated its effectiveness in reducing the production of uric 
acid. Allopurinol which was used as positive standard had been widely used as standard 
positive reference due to its excellent action in inhibiting activity of XO enzyme through 
in in vitro assay and also in in vivo experimental animal model (Umamaheswari et al. 
2007; Wang et al. 2008; Murugaiyah & Chan, 2009; Wang et al. 2010; Chen et al. 2011; 
Liu et al. 2014).  As the XO enzyme was inhibited, it reduced the XO activity and this 
would then eventually inhibit the catalyzation of hypoxanthine to xanthine, then xanthine 
to uric acid. Thus, the inhibition of XO enzyme will reduce the production of uric acid. 
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5.5.1 XO Inhibitory in In Vitro Model  
  The highest of XO inhibition in in vitro assay shown in PR-ME and this 
could be due to the presence of polyphenols such as 3 ̶ O ̶ caffeolquinic acid and 
chlorogenic acid while flavonoids such as quercetin, kaempferol and rutin as these 
phytochemicals has been detected by LCMS/MS. As reported by several researches, 
flavonoids such as rutin, kaempferol and quercetin has a high potential in order to inhibite 
the activity of XO enzyme (Cos et al. 1998, Nagao et al. 1999; Selloum et al. 2001; 
Ahmad et al. 2008; Matsuoka et al. 2012). Therefore, it can be concluded that the 
presence of these compounds in PR-ME could contributed to the inhibition of XO 
activity. On the other hand, Masuoka et al. (2012) described that XO inhibition activity 
of kaempferol 3 ̶ O glucosides was lower compared to flavonoid aglycone due to these 
flavonoids competitively bound a xanthine binding site in xanthine oxidase instead of the 
flavonoid glycosides.  In addition, Cos et al. (1998) stated that the chemical structure of 
flavonoids contain of hydroxyl groups at C5 and C7 and the double bond between C2 and 
C3 were essential for a high inhibitory activity on xanthine oxidase.  Later on, Nagao et 
al. (1999) stated hydroxyl group at C5 and C7 of flavonoid was essential for inhibition of 
xanthine oxidase activity but not a hydroxyl group at C3 of the flavone structure such as 
quercetin. Otherwise, quercetin which have hydroxyl group at C3’ and C4’ of the B ring 
showed slightly higher XO inhibition activity than kaempferol (3’ ̶ OH). Catechol 
structure in the B ring which gives the antioxidant potential to flavonoids was not related 
to the xanthine oxidase inhibition (Nagao et al. 1999). Recently, Wang et al. (2015) stated 
that the main inhibition mechanism of kaempferol on XO enzyme could be due to the 
insertion of kaempferol into the active site of XO occupying the catalytic center of the 
enzyme then avoid the entrance of the substrate and inducing conformational changes of 
XO. Furthermore, kaempferol also capable to inhibited XO activity and additional 
superoxide scavenging activity (Cos et al. 1998). In addition, the results showed that the 
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XO inhibition activity could be linked to the content and the nature of flavonoids and 
phenolic compounds contained in the extracts, and eventually to the presence of other 
types of molecules (Salem et al. 2011). In fact, the present result was an agreement with 
other researchers that possible synergy between polyphenols and other components 
present in methanol extracts might contributed to their overall antioxidant activity 
(Shahidi et al. 1994; Ordonez et al. 2006). 
 Generally, the present study indicated that PR ̶ ME of red flowers from 
P. rubra produced the highest activity on both XO inhibition activity and also superoxide 
radical scavenging assay. In fact, the inhibition activity of XO enzyme was higher 
compared to superoxide scavenging activity. Thus, the PR ̶ ME from P.rubra could be 
categorized as XO inhibitors with additional superoxide scavenging activity as reported 
by Cos et al. (1998). On the other hand, Matsuoka et al. (2012) had summarized the three 
possible mechanism pathway in order to be an antioxidant to superoxide radicals and 
inhibited XO activity.  These include (A) with the inhibition of XO enzyme, antioxidants 
inhibit uric acid formation and this inhibition suppresses both superoxide generation and 
also hydrogen peroxide formation. Apart from that, with the reduction reaction of XO 
(B), antioxidants act as a reducing reagent of XO. The reduced XO enzyme only catalyses 
the hydrogen peroxide formation. Antioxidants also function by means of the superoxide 
scavenging activity (C) and the activity could be monitored by using the PMS ̶ NADH 
system. 
 PR ̶ ME showed strongest XO inhibition activity in in vitro model and this 
is strongly correlate with its ethnomedicinal used the trearment of inflammatory disorder 
and rheumatic disease (Dubois & Rezzonico, 2007; Kumar et al. 2009), and it was 
furthered investigated for its capability to reducing uric acid in serum of induced 
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hyperuricemic rats as well as evaluated the XO inhibition activity in serum and liver of 
induced hyperuricemic rats. 
5.5.2 XO Inhibitory Activity in In Vivo Model 
 Acute toxicity study indicated the non-toxic nature of the P.rubra extracts. 
There was no lethality or any toxic reactions found at both doses selected, 2000 mg/kg 
and 4000 mg/kg body weight of PR ̶ ME extract until the end of the study period. 
 In animal study, the anti ̶ hyperuricemic activity and XO inhibitory activity 
of PR ̶ ME of red flower from P. rubra were evaluated in in vivo model with the doses of 
200 mg/kg and 400 mg/kg body weight. The allopurinol is used as standard and the results 
showed that body weight of treatment group fed with dose of 10 mg/kg body weight 
showed no significant different to all groups of study. Furthermore, XO inhibition activity 
were determined in both within serum and liver of PR ̶ ME and these were also carried 
out in in vivo with the doses of 200mg/kg and 400mg/kg body weight. The body weights 
of eight groups increased gradually through 7 days treatment, and no significant 
differences (p < 0.05) in body weights among eight groups were observed. In addition, 
the rats in each group had lustrous body hair, normal water consumption, diet 
consumption, and urine volume and were in good mental state during the experimental 
period, indicating that PR ̶ ME of P. rubra flowers did not exhibited any side effects on 
the rats. The allopurinol was used as standard and the result showed that body weight of 
group 8, which  group of rats were induced intraperitoneally with PO then fed with 
allopurinol showed no significant differences with untreated normal group as well as 
treated group of both doses, 200 mg/kg and 400 mg/kg. 
 Result demonstrated that PR ̶ ME was significantly exert serum urate 
levels in hyperuricemic induced rat but not in normal rats after 7 days of treatment. Both 
doses of PR ̶ ME (400 mg/kg and 200 mg/kg) shown to elicit a dose-dependent decrease 
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in serum uric acid levels only in hyperuricaemic induced rats. This finding was similar to 
the previous research by that most of medicinal plant extract exhibited less inhibitory 
effects on serum uric acid levels in normal mice compared with those animals preinduced 
with PO (Kong et al., 2004; Wang et al., 2004; Zhu et al., 2004; Zhao et al., 2006). Thus, 
the detected phytochemical compounds in methanol extract by LCMS/MS analysis did 
not exhibited significant reduction on uric acid levels in normal rats within 7 days of 
administration. In addition, result from normal rats indicated that PR ̶ ME from P. rubra 
flower was safe as XO inhibitor compared than allopurinol in treatment of hyperuricemia. 
Moreover, the clinical use of both dose PR ̶ ME from P. rubra flower in the treatment of 
gout and hyperuricemia might be safer than that of allopurinol. Despite Nuki (2006) has 
found that the elevated levels of uric acid in the circulation could give rise to gout and 
possibly other pathological conditions, Stinefelt (2005) has gave the different theory 
whereby the antioxidant action of uric acid, particularly its ability to inhibit DNA damage, 
is also well proven. Thus, excessive lowering of the uric acid level in the circulation 
beyond that of the normal range might even be counterproductive (Wang et al. 2004).  
  The serum urate level of hyperuricemic induced rats with doses of 200 and 
400 mg/kg of PR ̶ ME of P. rubra flower were decreased significantly in a dose dependent 
manner. The uric acid lowering effect of group 6, which was hyperuricemic induced rats 
treated with high dose of 400 mg/kg PR ̶ ME and group 7 which was hyperuricemic 
induced rats treated with low dose of 200 mg/kg PR ̶ ME indicated that the PR ̶ ME of P. 
rubra flower has the potential to attenuate hyperuricemia. As compared to standard, 
allopurinol, known as a protective role in XO inhibitor showed most effective 
hypouricemic action in in vivo study with 78.2 % of uric acid lowering effect even in a 
dose only 10 mg/kg. The decreasing of uric acid levels in serum could be due to the 
presence of compounds which including quercetin, kaempferol and rutin which contaim 
in PR ̶ ME of P.rubra flowers as detected in LCMS analysis. In fact, kaempferol, 
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quercetin and rutin were capable of reducing the accumulation of purine metabolites in 
blood following PO ̶ induction rats as reported by several literatures (Zhu et al. 2004; 
Rashidi et al. 2008; Chen et al. 2011; Mathew et al. 2015). 
 The XO inhibition activity of PR ̶ ME from P.rubra flower was carried 
out in in vivo model with the doses of 200 mg/kg and 400 mg/kg body weight. It should 
be noted that the activity of XO enzyme in serum and liver at normal mechanism was not 
influenced with this form of dose (400 mg/kg). Thus, this high dose (400 mg/kg) did not 
have allopurinol ̶ like hypouricemic effects influencing uric acid levels in the normal 
purine metabolic system. In the contrast low dose (200 mg/kg) has a different effect that 
increased the activity of XO enzyme in serum but not in liver. For this reason, 200 mg/kg 
of this extract was not suggested dose to be administered when hyperuricemia was not 
triggered. The varies result of XO activity in normal rats could be due to different effect 
of reaction from different phytochemical compounds presence in PR ̶ ME which 
comprising of phenols such as 3 ̶ O ̶ caffeoylquinic acid and chlorogenic acid while 
flavonoids such as quercetin, kaempferol and rutin and flavonoid as detected from 
LCMS/MS. Despite that previous literature reported that the good natural products 
previously indicated alteration in uric acid levels and XO activity occurs only in the 
hyperuriceamic mice, but not in the normal mice, the capability of PR ̶ ME extract cannot 
be excluded. 
 The inhibition effects of XO activity was more dominants in groups of 
hyperuricemia ̶ induced rats compared to their effects on normal rats. Moreover, the XO 
enzyme activity in serum was correlated with XO enzyme activity in liver within 
hyperuricemic –induced rats. According to Yoshisue et al. (2000), XO is well known of 
inducible enzyme, thus, PR ̶ ME was found exert the inhibitory action on induced XO in 
both serum and liver of hyperuricemic-induced rats in a dose ̶ dependent manner. 
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Accordingly, it could be possible that the presence of phenols and flavonoids which 
including 3 ̶ O ̶ caffeolquinic acid, 5 ̶ O ̶ caffeoylquinic acid, chlorogenic acid, kaempferol, 
quercetin and rutin may partly contribute to the beneficial effects of PR ̶ ME extract on 
the inhibition of XO enzyme activities. In addition, Zhu et al. (2004) described that 
quercetin and rutin were capable to inhibit XO enzyme in in vitro and in vivo model. 
Thus, the hypouricemic effect produced by PR ̶ ME extract of P. rubra might be 
contributing from the phytochemical compound such as quercetin, rutin. Moreover, 
kaempferol seem to be partly mediated by the inhibition XO activities and was better 
inhibitor of xanthine/xanthine oxidase than the two glycosides (Wang et al. 2015; Haidari 
et al. 2011). Nevertheless, the standard XO inhibitor, allopurinol at dose of 10 mg/kg 
produced stronger inhibition effect of XO enzyme in both of serum and liver, as reported 
as several researches (Zhu et al. 2004; Wang et al.2008; Chen et al.,2011; Huang et al. 
2011; Haidari et al. 2011; Lima et al. 2015).  
 The present results indicated that the PR ̶ ME of red flowers from P. rubra 
possess good antioxidant activity via different mechanisms including hydrogen atom 
donation, ability in reducing ferric ions, metal chelating effect, hydrogen peroxide 
scavenging ability, nitric oxide scavenging ability and superoxide anion scavenging 
ability. These antioxidant properties of the PR ̶ ME were attributed to the presence of 
phenolics and flavonoids compound as detected in LCMS/MS. Moreover, the PR ̶ ME 
showed potential of XO inhibitory activity in in vitro assay as well as in in vivo in both 
serum and liver of PO ̶ induced hyperuricemic rats. Furthermore, reducing effects of 
serum urate levels from PO ̶ induced hyperuricemic was mediated to XO inhibitory 
activity of PR ̶ ME. Besides, there are relation between oxidative stress and gout disease, 
as XO enzyme contributed to production of uric acid by catalyzing hypoxanthine to 
xanthine, with concomitant production of superoxide and hydrogen peroxide radicals 
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(Dalbeth & Haskard, 2005; Umamaheswari et al. 2007; Kong et al. 2000).  Thus, the 
results of this research has shown that the bioactive compounds detected in the PR ̶ ME 
from P. rubra flowers capable to inhibited the activity of XO enzyme as play direct role 
to hyperuricemia and disease such as gout, endothelial dysfunction, atherosclerosis as 
well as indirect role as a source of ROS. 
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CHAPTER 6 
CONCLUSION 
 
   The phytochemical bioactive compounds of Plumeria rubra Linn red 
flowers was detected using Thin Layer Chromatography (TLC) and displayed the 
presence of flavonoids, phenols, terpenoids and  essential oils while detected with 
chemical reagents. The analysis of the methanol (PR ̶ ME) and water (PR ̶ WE) extract of 
P.rubra with Liquid Chromatography Mass Spectrometer tandem mass spectrometer 
(LCMS/MS) indicated that the presence contains 3 ̶ caffeoylquinic acid, 5 ̶ caffeoylquinic 
acid, 1, 3 ̶ dicaffeoquinic acid, chlorogenic acid, citric acid, 3,3 ̶ di ̶ O methylellagic acid, 
kaempferol ̶ 3 ̶ O ̶ glucoside, kaempferol ̶ 3 ̶ rutinoside, kaempferol, quercetin 3 ̶ O ̶ α ̶ L ̶ 
arabinopyranoside, quercetin, quinic acid and rutin. Both of the contents of TPC and TFC 
showed the PR ̶ ME extract from red flowers of P. rubra contained the highest phenols 
and flavonoids content. The PR ̶ ME extract of red flower from P. rubra has the highest 
XO inhibitory activity in in vitro, and therefore it was selected for further in in vivo model. 
The oral acute toxicity test revealed that the PR ̶ ME extract of P. rubra red flower was 
nontoxic nature at the dose of 4000 mg/kg, and no lethality or any toxic effects was 
observed during 14 days of monitoring. Furthermore, PR ̶ ME extract of P. rubra red 
flower could reduced serum uric acid level in dose dependent manner in hyperuricemic 
rats induced by PO but not in the normal rats within 7 days experiment. Along with the 
good XO inhibitory activity in in vitro assay, the PR ̶ ME extract of P. rubra red flower 
also exhibited inhibition activity against XO enzyme in serum and liver in a dose ̶ 
dependent manner within 7 days experiment. Moreover, no significant difference of body 
weight between treated rats and normal rats within 7 days of extract administration. The 
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antihyperuricemic activity of the PR ̶ ME extract from P. rubra red flowers seems to be 
mediated by XO inhibition. In the six differents of antioxidant activity assay, PR ̶ ME 
extract of P. rubra red flowers demonstrated highest in DPPH scavenging activity, ferric 
reducing power, chelating activity, hydrogen peroxide radical scavenging activity, nitric 
oxide radical scavenging activity and also superoxide radicals scavenging activity. 
Apparently, the inhibition activity of XO enzyme in in vitro and in in vivo model, 
antihyperuricemic in serum and antioxidant properties of red flowers from P. rubra were 
due to presence of phytochemical compounds that has been detected and identified by in 
TLC and LCMS/MS methods. Thus, this study indicate that red flower of P. rubra is 
useful for new therapeutic option of management of gout or other XO ̶   induced diseases.  
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